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Background: The National Institute for Health and Care Excellence (NICE) 2009 guidelines for persistent
low back pain (LBP) do not recommend the injection of therapeutic substances into the back as a
treatment for LBP because of the absence of evidence for their effectiveness. This feasibility study aimed to
provide a stable platform that could be used to evaluate a randomised controlled trial (RCT) on the clinical
effectiveness and cost-effectiveness of intra-articular facet joint injections (FJIs) when added to normal care.
Objectives: To explore the feasibility of running a RCT to test the hypothesis that, for people with
suspected facet joint back pain, adding the option of intra-articular FJIs (local anaesthetic and
corticosteroids) to best usual non-invasive care is clinically effective and cost-effective.
Design: The trial was a mixed design. The RCT pilot protocol development involved literature reviews
and a consensus conference followed by a randomised pilot study with an embedded mixed-methods
process evaluation.
Setting: Five NHS acute trusts in England.
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Participants: Participants were patients aged ≥ 18 years with moderately troublesome LBP present
(> 6 months), who had failed previous conservative treatment and who had suspected facet joint pain.
The study aimed to recruit 150 participants (approximately 30 per site). Participants were randomised
sequentially by a remote service to FJIs combined with ‘best usual care’ (BUC) or BUC alone.
Interventions: All participants were to receive six sessions of a bespoke BUC rehabilitation package.
Those randomised into the intervention arm were, in addition, given FJIs with local anaesthetic and steroids
(at up to six injection sites). Randomisation occurred at the end of the first BUC session.
Main outcome measures: Process and clinical outcomes. Clinical outcomes included a measurement of
level of pain on a scale from 0 to 10, which was collected daily and then weekly via text messaging
(or through a written diary). Questionnaire follow-up was at 3 months.
Results: Fifty-two stakeholders attended the consensus meeting. Agreement informed several statistical
questions and three design considerations: diagnosis, the process of FJI and the BUC package and
informing the design for the randomised pilot study. Recruitment started on 26 June 2015 and was
terminated by the funder (as a result of poor recruitment) on 11 December 2015. In total, 26 participants
were randomised. Process data illuminate some of the reasons for recruitment problems but also show that
trial processes after enrolment ran smoothly. No between-group analysis was carried out. All pain-related
outcomes show the expected improvement between baseline and follow-up. The mean total cost of the
overall treatment package (injection £419.22 and BUC £264.00) was estimated at £683.22 per participant.
This is similar to a NHS tariff cost for a course of FJIs of £686.84.
Limitations: Poor recruitment was a limiting factor.
Conclusions: This feasibility study achieved consensus on the main challenges in a trial of FJIs for people
with persistent non-specific low back pain.
Future work: Further work is needed to test recruitment from alternative clinical situations.
Trial registration: EudraCT 2014-000682-50 and Current Controlled Trials ISRCTN93184143.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 30.
See the NIHR Journals Library website for further project information.
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PI principal investigator
PPI patient and public involvement
PROM patient-reported outcome measure
PSEQ Pain Self-Efficacy Questionnaire
PSSRU Personal Social Services Research
Unit
QALY quality-adjusted life-year
R&D research and development
RCT randomised controlled trial
RMDQ Roland–Morris Disability
Questionnaire
SD standard deviation
SF-12v2 Short Form questionnaire-12 items
version 2
UNTRAP University/User Teaching and
Research Action Partnership
VAS visual analogue scale
WCTU Warwick Clinical Trials Unit
WEMWEBS Warwick–Edinburgh Mental
Well-Being Scale
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Plain English summary
Injections of drugs into joints in the back is a treatment option for some people with low back pain (LBP).We do not know how well these work. Before a large-scale randomised controlled trial could be carried
out, there was a need to explore if a trial is possible.
At a gathering of health professionals, pain experts, academics and lay people, agreement was reached on
how to diagnose possible facet joint pain, how and what to inject into the joints and what the best
physiotherapy treatment was. Here we ran a feasibility trial exploring if it is possible to run a larger trial to
test if the addition of injections into the back to a custom-made physiotherapy treatment reduces LBP.
Patients who had suspected facet joint pain from five NHS pain services were invited to take part.
They received a first physiotherapist session. At the end of this, they were randomly allocated to receive either
an injection and five additional physiotherapy sessions or only the five additional sessions. We aimed to
recruit 150 people in total over a 6-month recruitment period. During the study we examined all of the trial
processes, for example exploring the recruitment of participants, and monitored patients’ pathways through
the trial. We also carried out interviews with study staff and patients to explore their experiences of the study.
Recruitment was very difficult, and only 26 people had been recruited when the trial was terminated by
the funder. We understand why there were difficulties in recruitment and we were also able to identify
that, once patients were recruited, there were no problems with patient care. We cannot make any
suggestions about the effects of the interventions. Overall, pain was reduced and the interventions were
inexpensive in terms of costs to the NHS.
With slight changes, it would be feasible to deliver a larger trial exploring the use of these injections.
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Scientific summary
Background
Low back pain (LBP) is ranked as highest in the Global Burden of Disease in terms of years lived with
disability. The National Institute for Health and Care Excellence (NICE)’s 2009 guidelines for the management
of non-specific LBP lasting between 6 weeks and 1 year recommended against the injection of therapeutic
substances into the back. However, facet joint injections (FJIs) continue to be used. In 2014/15, 81,963 FJI
procedures were performed in England for the NHS, an increase from 62,671 in 2012/13.
That pain can arise from facet joints has been proven. Drawing on data from other parts of the musculoskeletal
system, it is a reasonable hypothesis that intra-articular injection of corticosteroids could produce at least
short-term pain relief in a synovial joint, such as a facet joint, that is causing pain. The current randomised
controlled trial (RCT) evidence on the use of intra-articular FJIs is sparse, of generally poor quality and too
heterogeneous for any firm conclusions to be drawn regarding efficacy or effectiveness.
There is a clear need for a trial to test the effectiveness of adding FJIs to best usual care (BUC) for the treatment
of persistent LBP. There are methodological challenges to setting up and running such a trial. Our feasibility
study addressed these methodological issues and tested trial processes and recruitment in an external pilot.
A different team has been funded to test the feasibility of a more explanatory trial comparing active
intra-articular injection with a sham control in people who have a positive diagnostic medial branch nerve
block (Health Technology Assessment 11/31/02). The two studies will produce complementary data that
will inform decisions on the merit of offering therapeutic intra-articular FJIs to selected people with LBP.
Objectives
In this study we explored the feasibility of running a RCT to test the hypothesis that for people who have
suspected facet joint pain contributing to persistent LBP the addition of the option of intra-articular FJIs,
with local anaesthetic and corticosteroids, to best usual non-invasive care available from the NHS is
clinically effective and cost-effective. Our objectives were to:
1. develop, and evaluate, agreed criteria for identifying people with suspected facet joint pain
2. develop an agreed protocol for the injection of facet joints in a consistent manner
3. develop, and evaluate, a standardised control treatment deliverable in the NHS and congruent with
NICE guidance
4. develop and test systems for collecting short-term and long-term pain outcomes, including measures
required for economic evaluation
5. demonstrate that recruitment to the main trial is feasible
6. collect the recruitment and outcome data required to inform sample size and number of sites needed
for the main study
7. conduct a between-group analysis to inform the decision on the need for a full trial
8. carry out a process evaluation of patient experience within the trial.
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Methods
Before starting the randomised pilot, we addressed the key uncertainties that needed resolving to ensure
a robust trial design (objectives 1–3 and part of 4). Subsequently, we ran a randomised pilot study
(objectives 5–8 and part of 4).
Consensus meeting
A four-stage process was adopted to ensure that the Facet Injection Study (FIS) was robust and informed
by current evidence, that it was acceptable to the academic community and practising clinicians and that it
reflected NHS practice. First, we identified key design considerations that are of vital importance for the
production of robust and acceptable evidence on an implementable FJI programme. Second, an evidence
review of each design consideration was conducted using systematic methodology. Third, an evidence
document was prepared that contextualised the pragmatic FIS, outlined the methodological challenges of
designing a credible pragmatic trial and presented the outputs from the evidence reviews. Fourth, using
the evidence document as a delegate pack, the FIS design considerations were discussed by a consensus
conference of clinicians, experts, academics and lay representatives. Attendees were asked to agree on
how to diagnose suspected facet joint pain, a protocol for the injection of facet joints and for the BUC
package and what effect size is clinically important, and to suggest any potential subgroups that may
respond better to FJIs.
Feasibility randomised controlled trial
The primary objective of this trial was to explore the feasibility of running a RCT to test the hypothesis that
for people with suspected facet joint pain contributing to persistent LBP the addition of the option of FJIs
to best usual non-invasive care available from the NHS is clinically effective and cost-effective.
Research methods
The study ran in five NHS acute trusts in England.
Patients who were referred to a trust for the treatment of LBP that had been present for at least 6 months,
after failure of conservative treatment, were considered as potential participants. We aimed to recruit
150 patients. We expected up to 40 participants to be recruited at each participating centre. Recruitment
was planned to be primarily from pain clinic services.
We recruited people aged ≥ 18 years who had at least moderately troublesome LBP present for at least
6 months, who had undergone registered health professional delivered treatment for LBP in the 2 years
prior to study entry and who had suspected facet joint pain.
All participants received the best usual conservative care package agreed in our consensus exercise.
This consisted of one initial session and five follow-up sessions. Those randomised to FJIs had these within
2 weeks of randomisation. Up to six facet joints (L3/L4, L4/L5 and L5/S1) bilaterally in each participant
were injected at the discretion of the treating clinician. We randomised participants at the end of the first
treatment session to ensure that baseline pain data were collected close to intervention and that all
participants received some conservative care.
Participant identification
At each site we actively identified referrals to secondary care for patients with LBP.
Potential participants had a diagnostic assessment for suspected facet joint pain by a study physiotherapist.
Baseline data were collected, and consent was obtained, for eligible participants at the time of this
appointment. Randomisation was performed centrally by Warwick Clinical Trials Unit using a remote
telephone randomisation system.
SCIENTIFIC SUMMARY
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Outcome assessment
As a feasibility study, the main outcomes were process related. Data included quantitative data collected as
part of recording trial activity (e.g. attendance rates, compliance) and qualitative data from interviews and
small group discussions with patients, research therapists and staff.
The primary clinical outcome was an 11-point numerical rating scale for pain collected via text messaging
over 3 months following randomisation. For those participants unable or unwilling to use a text messaging
system, we used a paper-based system.
Our second primary outcome was back pain related disability [measured by the Roland–Morris Disability
Questionnaire (RMDQ)] at 3 months.
Statistical considerations
If the desired standardised mean difference indicative of a minimally clinically important difference is in the
range of 0.3–0.4, then if we recruited around 150 participants, after allowing for 20% loss to follow-up,
the probability of proceeding to a full trial is around 50% if the true effect is zero.
The resulting 75 patients in the active injection group would have allowed us to estimate the proportion
who had ‘true’ facet joint pain, based on achieving immediate pain relief, with a precision of 11% if the
true proportion was 62%.
Our proposed primary analysis for pain was the difference in the area under the curve values from our pain
measurements over 3 months. We specified RMDQ at 3 months as a second primary outcome. If there
was not a positive signal suggesting an early reduction in pain, then we would not proceed to a full trial.
Poor recruitment meant that between-group analyses were not possible. The analyses therefore focus on
trial process measures, presenting overall descriptive data on study participants, assessing performance of
outcome measures and estimating acquisition costs of study interventions.
Results
Consensus
Fifty-two people attended the consensus meeting: 19 pain consultants/physicians, six anaesthetists,
12 physiotherapists/physical specialists, four academics, three psychologists, two radiographers and six
lay representatives.
Agreement was reached at the consensus meeting on the effect size and choice of subgroups. Some further
clarifications were needed for three of the design considerations: diagnosis, the process of FJI and the BUC
package. The final agreements from this process were taken forward in the design of the randomised pilot study.
Feasibility trial
Recruitment started on 26 June 2015 and, after 26 participants had been randomised, the trial was
terminated by the funder on 11 December 2015 because of poor recruitment.
Process evaluation
It was found that approval delays, which were outside the control of the research team, delayed the start
of recruitment. Sites were ready to begin the trial at the planned starting point, but the long delay meant
that staff were not available at the sites when approvals were in place. It was specified in the funding brief
that the study was to recruit participants from pain clinics and we had evidence that a large proportion of
patients in pain clinics have back pain. However, during the screening process there were limited numbers
of patients who met our criteria. Many of the patients approached had undergone multiple treatments.
It was also difficult to identify patients with back pain when screening referrals.
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Outcome data
Although there were missing data in the text message responses for pain, these were largely replaced by
the results of a written pain diary. We achieved usable outcome data on 23 out of 26 (88%) participants
for the primary outcome. All pain-related outcomes show the expected improvement between baseline
and follow-up.
The mean total cost of performing a FJI was estimated at £419.22 per patient. The mean total cost of the
full course of physiotherapy treatment was estimated to be £264 per participant. The mean total cost of
the overall treatment package (comprising one injection and six physiotherapy sessions) was estimated at
£683.22 per participant. This is similar to a NHS tariff cost for a course of FJIs of £686.84.
EuroQol-5 Dimensions (EQ-5D) diary scores indicate marked fluctuations in health-related quality of life in
the first few weeks after randomisation. In particular, there is a substantial short-lived improvement in the
first few days after the initial treatment.
Study interventions
Both the BUC package and the procedures for FJIs were acceptable to participants and ran smoothly.
Discussion
Our overall aim was to explore the feasibility of running a RCT to test the hypothesis that, for people with
suspected facet joint pain contributing to persistent LBP, adding the option of FJIs, with local anaesthetic and
corticosteroids, to best usual non-invasive care available from the NHS is clinically effective and cost-effective.
In the first part of the study we considered the main clinical and scientific challenges that needed to be
addressed before the start of the trial. Specifically, we developed an agreed standardised approach to the
injection of facet joints and we achieved consensus on which patients to consider for FJIs and what a
package of BUC should consist of.
An important outcome from this study is the finding that pain clinics are not the most appropriate place to
recruit participants. The people attending these clinics were, on the whole, less likely to be suitable for the
study than those who had not yet been referred. There were also substantial operational issues with the
clinics, which were unfamiliar with recruiting to RCTs, meaning that, even after approvals had been
obtained, the start of recruitment was delayed. Nevertheless, at the time the study was terminated we had
explored alternative recruitment areas and there were some indicators that recruitment was improving.
Strengths and weaknesses
All of the key uncertainties that needed to be considered before a main trial have been addressed. That we
have achieved consensus on describing the population of interest, the control and the active intervention is
a real strength of this project. Furthermore, we have demonstrated that participants are able to comply with
the recruitment process for the study and provide initial data for us to assess our non-standard approaches
to clinical data collection: the Patient Generated Index.
The key weakness of this study was the failure to achieve our expected recruitment targets and the consequent
termination by the funder. There had been very substantial organisational barriers to the set-up of the trials.
A 10-month delay between the first application for research ethics approval and the green light to start
recruitment at the first site meant that adequate recruitment was a challenge. Although the funding brief
specified that recruitment should be sought from pain clinics, it became apparent in the course of this study
that this was insufficient.
SCIENTIFIC SUMMARY
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Is a main study still needed?
It has been argued that the question of the effectiveness of intra-articular FJIs is no longer relevant, as
this approach has been superseded by radiofrequency denervation of the medial branch of relevant lumbar
nerves. New NICE guidance for LBP and sciatica that was published in 2016 recommends radiofrequency
denervation in selected patients who have had a positive diagnostic block. It also suggests that research
into the long-term effectiveness and cost-effectiveness of radiofrequency denervation is a key research
recommendation. There remains a need for robust studies of both the efficacy and the effectiveness of
invasive procedures, such as intra-articular FJIs or radiofrequency denervation, for people with suspected
facet joint pain.
Conclusions
The procedures and paperwork for the study require only minor improvements but the title of the study
should be reconsidered to avoid raising patients’ expectations of receiving an injection.
In undertaking this process evaluation we aimed to identify aspects of the study design that have the
potential to threaten the success of a full trial. Although our data were limited in scope, particularly from
patients, they sufficiently identified major threats.
All key uncertainties that needed to be considered to run the main trial have been addressed. We demonstrated
in the randomised pilot that eligible patients who were invited to join the trial were interested in the study and
could comply with the study procedures. We also successfully collected frequent short-term outcomes, which
has allowed us to identify relevant short-term harms and benefits.
We have shown that it is feasible to run such a trial, but any future trial would need to learn lessons from
this with regard to recruitment.
Trial registration
This trial is registered as EudraCT 2014-000682-50 and Current Controlled Trials ISRCTN93184143.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Low back pain
A global problem
Low back pain (LBP) is ranked as highest in the Global Burden of Disease in terms of years lived with disability.1
The most recent UK ‘cost-of-illness’ study was in 1998.2 At that time, the direct health-care costs of LBP were
£1067M for the UK NHS and £565M for private health care, resulting in a cost of £28 per head of population.
A 1998 US study3 estimated direct health-care costs as US$90,601M and a cost of US$335 per person. Much
has changed since then. In the USA, there has been a 2.4-fold increase in spinal fusions and a massive increase
in facet joint interventions, both of which are still increasing.4,5 In response to this problem, the National
Institute for Health and Care Excellence (NICE) commissioned guidelines for the management of non-specific
LBP lasting between 6 weeks and 1 year.6 The excluded treatment approaches included the injection of
therapeutic substances into the back. Deep divisions in the scientific and clinical communities have become
clear since the publication of the 2009 NICE guidelines and the 2009 American Pain Society guidelines for
LBP,7 which also indicated that there was insufficient evidence to support the injection of therapeutic
substances into the back.8 Although the methodological approach used by the American Pain Society has
been challenged, the American Society of Interventional Pain Physicians also concluded that the evidence
for therapeutic intra-articular facet joint injections (FJIs) was limited.9,10 A new NICE guideline for LBP and
sciatica,11 published in 2016, did not support the use of intra-articular FJIs (www.nice.org.uk/guidance/
conditions-and-diseases/musculoskeletal-conditions/low-back-pain). It does, however, in contrast to the
2009 guidance, support the use of radiofrequency denervation in people who have had a positive
diagnostic medial nerve branch block.
There is a variety of different interpretations of the available evidence from randomised controlled trials
(RCTs) and observational studies on the effectiveness of intra-articular FJIs.12–18 Controversy surrounding
this issue remains in the USA, and in the UK there has been new research evaluating lumbar facet joint
interventions.9,19,20 However, the outcome of all this work was that, at the outset of this study, the data
were not a robust evidence base on which to inform decisions about the use of therapeutic intra-articular
FJIs. Notwithstanding current NICE guidance and insufficient evidence to justify the use of FJIs, Hospital
Episode Statistics21 record that, in 2014/15, 81,963 FJI procedures were performed in England for the NHS,
an increase from 62,671 in 2012/13. Although there may be some inaccuracies in the coding of different
facet joint-related procedures, this still represents a 30% increase in activity over 2 years.
Thus, there was a clear need for a trial to test the effectiveness of adding intra-articular FJIs to usual care
for the treatment of persistent LBP when usual care as recommended by NICE or the American Pain
Society has been ineffective. It is important that the proposed trial provides data that all parties can agree
on. If the trial has positive results, then reinvestment in this treatment will be justified. If the trial has
negative results, its conclusions need to be sufficiently robust that all parties to the debate on current
guidance are satisfied that the evidence does not support the use of therapeutic intra-articular FJIs.
The UK National Institute for Health Research, via a specific call, funded two feasibility studies in preparation
for trials of therapeutic intra-articular FJIs. We were funded to carry out one of these studies. Our proposed
main study will test the addition of a therapeutic intra-articular FJI to best usual care (BUC) [Health Technology
Assessment (HTA) programme reference number 11/31/01].22 A different team is funded to test the feasibility
of a more explanatory trial comparing active intra-articular injection with a sham control in people with
a positive diagnostic medial branch nerve block (HTA 11/31/02).23 These two studies will produce
complementary data that will inform decisions on the merit of offering therapeutic intra-articular FJIs to
selected people with LBP.
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Diagnosis of low back pain
Low back pain is pain or discomfort felt in the back between the bottom of the rib cage and the buttock
creases. Once medically serious causes of LBP have been excluded (infection, fracture, malignancy,
inflammatory disorders such as ankylosing spondylitis), LBP is labelled as being non-specific. None of the
early treatment options recommended in the 2009 NICE guidance requires any further diagnostic work-up.
Unless there is a concern that there is a serious medical cause for the pain, imaging of the lumbar spine is
not indicated. This approach recognises the difficulty of reliably identifying subgroups of people who may
respond better to any particular treatment approach.24,25 Notwithstanding this overall approach to the
diagnosis of LBP, it is possible that there are subgroups of individuals who would benefit from one or more
specific approaches to the treatment of their LBP. One subgroup who may benefit from a more specific
back treatment is patients whose pain wholly, or partially, arises from the facet joints. This notion is
supported by the 2016 NICE back pain guideline, which recommends the use of diagnostic medial branch
nerve blocks before considering radiofrequency denervation in people with suspected facet joint pain.
The clinical assessment of suspected facet joint pain suggested in NICE 2016 guidance is based on work
described later in this report.26
Facet joint pain
The facet joints are paired structures between the superior and inferior articular processes of adjacent
vertebrae that, in the lumbar spine, allow flexion and a degree of rotation of the spine. They are synovial
joints whose capsule is richly innervated. With increasing age, progressively more people develop
radiological osteoarthritis of the facet joints. A systematic review estimated the prevalence of facet joint
degeneration increased from 4% for those in their twenties through 32% for those in their fifties to 83%
for those in their eighties.27 There is not, however, an association observed between radiological change in
facet joints and the presence of back pain.28 If pain arising from the facet joint is suspected clinically, it
may be abolished temporarily by the injection of local anaesthetic, which may be used as a diagnostic test.
A depot preparation of steroid added to the injection may prolong the analgesic benefit. The relief or
reduction of pain may facilitate compliance with a programme of exercise designed to improve lumbar
range of movement and muscular stability.
Clinical features of facet joint pain
There are few good epidemiological data on the prevalence of facet joint pain in different populations or on
how to diagnose suspected facet joint pain clinically. In some studies, 5–15% of people with chronic LBP are
believed to have disease of one or more facet joints that is contributing to their pain.29 The gold-standard
test for the presence of facet joint pain is pain relief after the injection of affected joints with a local
anaesthetic. There is considerable diagnostic uncertainty about how to identify people with pain of facet
joint origin among the wider chronic LBP population.
Revel et al.30 in 1998 found that people with pain of facet joint origin were characterised by:
l being aged > 65 years
l pain that is well relieved by recumbency
l absence of pain exacerbation
¢ by coughing
¢ by forward flexion
¢ when rising from flexion
¢ by hyperextension
¢ by extension rotation.
All predicted a benefit from injection of anaesthetic into facet joints. The presence of five of these characteristics,
including pain on recumbency, correctly identified 92% of responders and 80% of non-responders.30 Others,
however, were unable to replicate their findings.31 Subsequent reviews suggest that 62% of those with these
clinical features of facet joint pain obtained immediate relief from FJIs; one-third of these were false positives.32,33
BACKGROUND
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Laslett et al.34 in 2006 found that seven factors were predictive of facet joint pain:
1. age ≥ 50 years
2. pain is best when walking
3. pain is best when sitting
4. onset of pain is paraspinal
5. modified somatic perceptions questionnaire score exceeding 13 (suggesting a somatisation disorder)
6. positive extension/rotation test
7. absence of centralisation during repeated movement testing.
They found that presence of three or more factors of age ≥ 50 years, pain is best when walking, pain is best
when sitting, onset of pain is paraspinal and positive extension/rotation test was 85% sensitive and 91%
specific for facet joint pain.34 In a 2007 systematic review, Hancock et al.35 did not find evidence for a robust
diagnostic test for facet joint pain. In an initial scoping review in preparation for this work, we found one
additional relevant article. In a retrospective chart review (n = 170), DePalma et al.36 found that the presence
of isolated paramidline LBP increased the probability of facet or sacroiliac joint dysfunction and slightly
reduced the likelihood of lumbar disc degeneration. The sensitivity of reporting paramidline pain if the
patient has facet joint pain was 96% [95% confidence interval (CI) 83% to 99.4%] for sacroiliac pain and
67% for internal disc disruption. This supports other work indicating that paraspinal or paramidline pain
is a clinical indicator of possible facet joint involvement. Similarly, although not empirically proven, lumbar
segmental motion may also be useful in identifying the level of facet joint involvement.37 A 2007 consensus
study38 identified clinical features thought to be associated with facet joint pain, such as:
l localised unilateral LBP
l lack of radicular features
l pain eased in flexion
l pain, if referred, is above the knee
l palpation: local unilateral passive movement shows reduced range of motion or increased stiffness on
the side of pain
l unilateral muscle spasm over the affected facet joint
l pain in extension
l pain in extension, lateral flexion or rotation to the ipsilateral side.
In a prospective cohort study of medial branch blocks for suspected lumbar or cervical facet pain, Wasan
et al.39 used selection criteria including a history of axial pain with radiation in an established facet joint
referral pattern and tests for facet joint loading signs (extension, side bending and rotation). Although they
acknowledged that their study was not designed to confirm diagnosis, Wasan et al.39 concluded that the
selection criteria reduced the likelihood of radicular pain due to nerve root involvement or non-specific LBP.
In the 2011 protocol for a trial of specific physiotherapy compared with advice, Hahne et al.40 argued that
if three or more of the following factors are present then there is facet joint dysfunction:
l unilateral LBP
l pain reproduced with lumbar extension and ipsilateral lateral-flexion movements
l pain on ipsilateral passive postero-anterior accessory movement applied through the transverse process
or zygapophyseal joint at one or two segments
l improvement in pain or range of movement following a ‘mini-treatment’ of manual therapy directed at
the zygapophyseal joint.
The choices of Hahne et al. are grounded in the Maitland’s clinical reasoning approach to identifying a
group who would respond to manual therapy.41 The use of such phenotypically defined subgroups,
grounded on clinical reasoning, may be the most appropriate approach to subgroup identification in LBP.42
This approach has not been tested empirically and may not be directly relevant to identifying people likely
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to respond to FJIs. It does, however, represent current best practice to identify people likely to respond to
the physical component of our proposed control intervention. Interestingly, this trial is restricted to people
aged < 65 years, even though others have found increasing age to be a feature predicting the presence of
facet joint pain. Nevertheless, 20% of recruits were identified clinically as having facet joint dysfunction.
Diagnoses were not confirmed using diagnostic injections.
During the early stage of this study we identified a further study, published as a conference abstract,43 that
identified combined movements as a predictor of pain relief from a diagnostic lumbar medial branch block.
Why might injecting facet joints be helpful?
The use of corticosteroid injection has been shown to be effective in producing, at least in the short term
(1–4 weeks), benefits for a range of musculoskeletal disorders including frozen shoulder and osteoarthritis
of the knee and hip.44–46 Analgesic benefits of intra-articular injection of corticosteroids in rheumatoid
arthritis may be more sustained (up to 3 months).47 Drawing on these data from other parts of the
musculoskeletal system, it is a reasonable hypothesis that intra-articular injection of corticosteroids could
produce at least short-term pain relief in a different synovial joint that is causing pain. The focus of this
study is on intra-articular FJIs.
Evidence on the safety of facet joint injections
Robust evidence on the complications from FJIs is very sparse. Manchikanti et al.,15 however, in an
observational study of facet joint nerve blocks (3162 LBP episodes with 15,654 lumbar nerve blocks) found
no major complications. However, 73% of encounters had local bleeding, 10% had oozing, 4% had
intravascular injection and 0.4% had profuse bleeding. These figures may be indicative of minor adverse
event rates from FJIs. The number of people with a short-term increase in pain was not reported.
Evidence for treatment of facet joints
That pain can arise from facet joints has been proven. There are several good double-blind studies that
show, in selected patients, that immediate pain relief can be obtained from injecting local anaesthetic into
facet joints that is not obtained from injecting saline.48 Indeed, demonstrating such pain relief is the
gold-standard test for diagnosing facet joint pain.
Observational studies
There is a body of observational data suggesting that FJIs are an effective treatment for lumbar facet
joint pain. Boswell et al.49 identified six prospective studies (n = 253) of FJIs. All but one of these studies
found positive short- and long-term effects. There are, of course, substantial limitations to using such
uncontrolled observational data to inform practice because of the natural history of LBP. There is substantial
improvement even in the usual-care arms in nearly all trials of chronic LBP.50
Placebo-controlled trials
At the time this research started, there were five recent reviews of the RCT evidence for FJIs compared
with a placebo or sham procedure. NICE7 and Boswell et al.51 each identified one trial (Carette et al.52);
Chou et al.53 and Henschke et al.54 each identified two trials (Carette et al.,52 n = 97; Lilius et al.,55 n = 86).54
Datta et al.56 identified both of these studies but excluded them: Carette et al.,52 unusually, because
they had not excluded placebo responders, and Lilius et al.55 because theirs was considered to be an
observational study. Neither of these trials was reported by the original authors as showing a positive result.
The National Institute for Health and Care Excellence, in both 20096 and 2016,11 and Chou et al.7 concluded
that the evidence did not support the use of FJIs. Henschke et al.54 concluded, based on very low-quality
evidence, that there was no difference between FJIs with placebo and corticosteroids. Datta et al.56
concluded that, because of the lack of evidence, there could be only a very weak positive recommendation
or a recommendation not to provide FJIs. Boswell et al.,49 on the other hand, felt that there was evidence
for a positive effect from FJIs. This was based on categorising one study (Carette et al.52) as a positive trial.
This was because, although there was not a positive effect at 3 months, there was a strong positive effect in
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the 6-month analysis. Both Carette et al.52 and Chou et al.53 discounted this observation because the patients
who gained a benefit at 6 months were not the same as those who had gained a benefit at 1 month and
because of the large number of cointerventions in the steroid arm of the trial. Neither group felt it to be
biologically plausible that a steroid injection would be effective at 6 months if it had not been effective at
1 month. Notwithstanding differences in interpretation, and the absence of statistical significance at
3 months, the point estimates for benefit from FJIs in the Carette et al.52 study are competitive with currently
recommended treatments.57 The proportion of patients who reported substantial improvement was 42%
versus 33% (95% CI –11% to 28%) and 46% versus 15% (95% CI 14% to 48%) at 3 and 6 months,
respectively. These equate to numbers needed to treat (NNTs) of 11 and 5, respectively. If such NNTs were
reproduced in a definitive trial, then FJIs could be an attractive addition to recommended treatments for
selected people with LBP. These results, however, were obtained in participants who had already had a
diagnostic FJI, suggesting that this study was carried out in patients who were most likely to benefit. Not
excluding those with a placebo response to the diagnostic injections might also have reduced the apparent
effect size. Carette et al.52 also did not include those who found the diagnostic injections too painful; 7 out
of 110 participants (6%) with a positive result from diagnostic injections did not want therapeutic injections
because they found the process too painful.
Facet joint injections compared with other treatments
At the start of this study there were two reviews of FJIs compared with other treatments. Henschke identified
five studies (n= 420) of FJIs with corticosteroids compared with other interventions.13,16–18,58 Marks et al.18 found
that FJIs gave superior pain relief to facet nerve blocks (both used corticosteroid and lignocaine) at 1 month
but not at immediate follow-up or at 3 months (n= 86). Mayer et al.58 found no benefit from adding a FJI with
local anaesthetic and corticosteroid to a home stretching exercise programme (n= 70). Fuchs et al.13 found no
significant differences between FJIs with steroid and sodium hyaluronate (n = 60). Manchikanti et al.16 found
no difference when comparing multiple medial facet nerve blocks with local anaesthetic with or without
steroids (n= 84). Manchikanti et al.17 found no differences between medial branch blocks with and without
corticosteroid (n= 120). Datta et al.56 identified two of the same trials of facet joint blocks.16,17 and concluded
that there was strong evidence for facet joint nerve blocks because of the good outcome in both groups. Celik
et al.12 reported a positive effect from FJIs in a subsequent trial (n= 80) comparing FJIs with a combination of
bed rest, a non-steroidal anti-inflammatory and a muscle relaxant. In a subsequent trial (n= 100) comparing
FJIs with facet joint radiofrequency denervation, Civelek et al.59 found better immediate results from injection
and better long-term results from denervation.
Cost-effectiveness
Our scoping reviews did not identify any studies of the cost-effectiveness of FJIs. FJIs require specialist
facilities and experienced operators but the potential benefit observed in observational studies may well
outweigh these costs.
Conclusion of initial scoping literature review
In our own 2016 review,60 we identified six relevant randomised placebo/sham-controlled trials of intra-articular
FJIs.12,52,55,58,61,62 Two studies (Lilius et al.,55 n= 109; Carette et al.,52 n= 97) used placebo injections into the
facet joints as the control treatment, one study (Ribeiro et al.,62 n= 60) used intramuscular corticosteroid as
the control treatment, two studies (Mayer et al.,58 n= 70; Kawu et al.,61 n= 18) used exercise as the control
treatment and one (Celik et al.,12 n= 80) used bed rest plus analgesia and non-steroidal anti-inflammatory
drugs as the control treatment. Four studies made a clinical diagnosis of facet joint pain,12,55,61 one study62
used clinical and radiographic features to make the diagnosis and two studies52,58 used diagnostic blocks. We
considered the study populations, and the comparisons made, to be too heterogeneous for any robust
conclusions to be drawn.60
The quality of reporting of these trials of FJIs is generally poor and it is not a robust evidence base to
inform decisions about the use of FJIs.
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Measurement of outcome
The measurement of outcome in LBP trials is problematic.63–65 Although there are well-established standard
packages of outcome measures, endorsed by expert groups, the theoretical underpinning of these is poor
and they may not capture those outcomes that are important to individuals.63,66 It is of note that neither of
these consensus exercises included input from patients and the decision about which outcomes should be
measured in LBP trials was from a consensus of clinicians and researchers.67 More recent recommendations
from the expert advisory group, the Initiative on Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT), do include patient group consultations to explore the relevance and acceptability of
outcomes used to determine recovery.68
Studies of patients suggest that other domains, not included in current recommendations, may be of
similar or even greater importance. For example, domains such as enjoyment of life and fatigue were
rated most highly in a patient survey.69 A review of outcomes measured in RCTs of LBP found that 5 out of
19 outcomes rated as important by respondents to the patient survey were never reported and a further
eight measured only rarely.70 There is a need to broaden the pool of outcome measures used beyond the
established package to include measures that more effectively capture the patient perspective.
Where might facet joint injections fit in the care pathway?
For people with acute or subacute LBP or early persistent LBP, the prognosis is generally very good and
there is little need for invasive treatments. Low-intensity, low-risk and therapist-delivered interventions,
as recommended by NICE, are sufficient. Although there are some differences between the 2009 NICE
guidance6 and the 2016 guidance,11 both support the use of therapist-delivered interventions as the first
treatment approach after advice and analgesics. Those with substantial problems persisting after such
interventions (typically ≥ 6 months from onset) require more intensive treatment. Persistent LBP is a
complex biopsychosocial phenomenon. In those people with pain persisting beyond 6 months, in spite of
good conservative care, a syndrome of chronic pain and disability will already be present. For this reason,
one would not expect FJIs, on their own, to resolve the problem. Rather, pain relief obtained from a FJI
may give the person with back pain the confidence and a window of opportunity to engage more fully
with a rehabilitation programme.
There is a clear need for a trial to test the effectiveness of adding FJIs to usual care as recommended by
NICE for the treatment of persistent LBP. It is important for this trial that it provides conclusive results.
If the trial has positive results then this will be a justification for investment in this area. On the other hand,
if the trial is negative then its conclusions need to be sufficiently robust that all parties to the debate on
the role of therapeutic intra-articular FJIs are satisfied that the evidence does not support their use. There
are methodological challenges to setting up and running such a trial; principally, these centre on the
identification of people with LBP that is, at least in part, from facet joints. Our feasibility study addressed
these methodological issues, tested trial processes and recruitment in an external pilot, conducted an
interim analysis and identified sites to conduct the main study.
For the NHS to consider reinstating FJIs for people with otherwise non-specific LBP, a package of care
including FJIs, for selected patients, needs to be an effective and cost-effective addition to BUC. This is true
regardless of the result of any placebo-controlled trial of the efficacy of FJIs. The components of any overall
effect (positive or negative) of FJIs will be the non-specific effects of attending for the injection (including
any advice from the treating clinician), any local effects from injecting fluid into the facet joint and the
specific effects of the drug/s injected. A positive efficacy study in a tightly controlled population will not
necessarily transfer to a treatment that is effective in real life. Conversely, failure to show a positive effect
in an efficacy study using a placebo or sham injection would not necessarily exclude the possibility that the
overall package of care is effective. Furthermore, such an efficacy study will not be able to answer a
question on the cost-effectiveness of adding the intervention to usual care.
The situation here is perhaps analogous to interpreting the evidence on the use of acupuncture, a treatment
with a much weaker theoretical base than FJIs. There is a substantial body of evidence that acupuncture is
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superior to usual care for a range of common disorders, with meaningful effect sizes. The evidence that
verum acupuncture is superior to a sham control is, however, much weaker, with very small apparent effect
sizes. Nevertheless, acupuncture was recommended by NICE for LBP in 2009,6 although not in 2016
guidance,11 and for headaches in 2012.71 For these reasons we propose a two-arm study testing the effect of
adding FJIs to a BUC package.
Aims and objectives
The aim of the study was to carry out a feasibility study for a trial to assess the clinical effective and
cost-effectiveness of intra-articular FJIs for selected patients with chronic LBP.
In this feasibility study we explored the feasibility of running a RCT to test the hypothesis that, for people
with suspected facet joint pain contributing to persistent LBP, the addition of the option of FJIs, with local
anaesthetic and corticosteroids, to best usual non-invasive care available from the NHS is clinically effective
and cost-effective.
The specific objectives for this feasibility study were to:
1. develop, and evaluate, agreed criteria for identifying people with suspected facet joint pain
2. develop an agreed protocol for the injection of facet joints in a consistent manner
3. develop, and evaluate, a standardised control treatment deliverable in the NHS and congruent with
NICE guidance (BUC)
4. develop and test systems for collecting short-term and long-term pain outcomes, including measures
required for economic evaluation
5. demonstrate that recruitment to the main trial is feasible
6. collect the recruitment and outcome data required to inform sample size and number of sites needed
for the main study
7. conduct a between-group trial to inform the decision on the need for a full trial
8. do a process evaluation of patient experience within the trial.
Overview of the Facet Injection Study
This report is split into a number of key sections. The Facet Injection Study (FIS) includes a considerable
body of development work to inform the study processes, the diagnoses and the feasibility study’s control,
intervention and injection technique as well as the pilot trial. The feasibility trial was terminated by the
funder because of poor recruitment.
First, we present this development work, which was mostly informed by a consensus conference. We
summarise the methodologies used and the outcomes that informed the development of the trial protocol,
a diagnostic manual, a ‘BUC manual’ and an injection manual. Reports of the full consensus methods,
results and conclusions are available elsewhere as online resources.72–76 Second, we report the experience of
running the feasibility RCT research methods, including the process evaluation, and the outcome/results of
the study. The final section, the discussion and conclusion, is a synthesis of all of the results and outcomes.
Patient and public involvement
We are not able to report on patient and public involvement (PPI) in the framing of the original
commissioning brief from the HTA programme. Throughout the development of this proposal, in response
to the HTA brief, and subsequent conduct of the study there has been input from PPI representatives and
groups. All of the project’s development work and interpretation of the results have had input from
PPI representatives.
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l Two very active co-applicant PPI representatives on the studies trial management group played an
important part in the development of study material and intervention development at the consensus
conference, and one provided a reflection of their experience working on the trial (see Appendix 1).
l One PPI representative on the trial steering committee who gave clear guidance throughout.
l Six lay representatives participated in our consensus meeting.74,76
We also acknowledge the help and support provided by University/User Teaching and Research Action
Partnership (UNTRAP) at the University of Warwick, which provides training and support to ensure
effective PPI.
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Chapter 2 Consensus: developing the study
protocols
A four-stage process was adopted to ensure that the FIS protocol was robust and informed by currentevidence and expert opinion, was acceptable to the academic community and practising clinicians and
reflected NHS practice. First, the FIS team identified key design considerations that are of vital importance
for the production of robust and acceptable evidence on an implementable FJI programme. Second, an
evidence review of each design consideration was conducted using systematic methodology. Third, an
evidence document was prepared that contextualised the pragmatic FIS, outlined the methodological
challenges of designing a credible pragmatic trial and presented the outputs from the evidence reviews.
Fourth, using the evidence document as a delegate pack, the FIS design considerations were considered by
a consensus conference of clinicians, experts, academics and lay representatives.
Methods
Before the conference
The three stages of the study are presented in Figure 1: (1) scoping review and identification of key design
considerations, (2) evidence reviews and (3) consensus conference.
Scoping reviews and formulation of key design considerations
Our study team includes pain clinicians, physical therapists, radiologist and lay representatives, as well as
research methodologists. Based on scoping reviews of clinical practice guidelines, empirical studies and
related literature and team discussion, five design considerations for the proposed trial were identified and
questions posed, as follows.
l Diagnosis: what is the best choice of clinical assessment to identify patients with facet joint pain?
l Injection technique: what is the agreed technique for the therapeutic intra-articular injection of facet joints?
l BUC: what is the optimal conservative management/rehabilitation for patients with LBP for whom facet
joints have been identified as a contributing source of symptoms?
l Between-group differences: what is the difference in magnitude of response between treatment and
control groups that should be considered large enough to establish the scientific or therapeutic
importance of the results?
l A priori subgroup analyses: which variable(s) should be used for a priori subgroup analyses in the main trial?
Evidence reviews
To provide evidence on each design consideration, reviews were undertaken informed by the Cochrane
and Centre for Reviews and Dissemination guidelines.77,78 The complete evidence document is available as
an online resource.76
The consensus conference
Potential conference participants were invited through relevant professional and lay organisations (Box 1).
We sought participation from experts from across the UK. By expert, we mean that participants were
professionals or lay people with an interest in, or experience of, back pain, its treatment and, in particular, its
treatment with therapeutic intra-articular FJIs. The invitation was to a 1-day conference with no attendance
charge and travel expenses were reimbursed. This was held at the University of Warwick on 27 June 2014.
Approximately 1 week before the consensus conference, a document consisting of the design
considerations and related evidence was sent to all those registered to attend.
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We used nominal group technique to gain consensus. This allows for discussion, while avoiding individuals
or groups dominating the consensus process, and allows participants to draw on available evidence and
expertise.79 We started the conference with a brief reminder of the key design considerations and evidence.
We then held 15 small group consensus sessions, each lasting 1 hour, with five groups meeting in parallel
at any one time (Figure 2). Small group results were fed back to a plenary session, in which final consensus
was reached. With participant consent, all sessions were audio-recorded for reference during analysis.
Participants were randomly assigned to small group sessions stratified by profession (approximately
10–12 per group) with each participant discussing three different design considerations. Each small group
had a trained facilitator, a scribe and a subject expert from our team. The subject expert did not participate
in the discussions but answered questions about technical issues when invited to by the facilitator.
Preliminary FIS design discussions:
pain clinicians, physical therapists, lay participants
The determination of the FIS design considerations
Evidence document
Systematic evidence reviews
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Final FIS design discussions
Formulation of FIS protocol
Initial scoping reviews:
clinical practice guidelines, empirical studies 
and related literature
FIS design considerations
(operationalisation)
1: Diagnosis
2: Facet joint injection
3: Best usual care
FIS design considerations
(evaluation)
4: Minimal important 
    change/difference
5: Subgroup analysis
Post-conference follow-up and 
data analysis/synthesis
FIGURE 1 Facet Injection Study protocol development process. Adapted with permission from Mars et al.26
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Discussions centred on the particular design consideration, with the suggested ‘protocol’ as a starting point
when appropriate. Nominal group technique was adapted to the design consideration under discussion as
described in Figure 2. Each participant confidentially ranked the acceptable approaches identified by the
group. Results were collated by the scribes.
In the sections following, we outline the five design considerations and how the discussions on these were
conducted during the consensus conference day. More detailed information is provided in three documents:
1. the evidence reviews76
2. the consensus final report74
3. a publication based on the consensus day.26
BOX 1 Organisations through which invitations to the consensus conference were distributed
l Professors/consultants in pain management via Binley mailing services (www.binleys.com) (accessed
22 February 2014).
l British Association of Spinal Surgeons (www.spinesurgeons.ac.uk) (accessed 3 March 2014).
l Association of British Neurologists (www.theabn.org) (accessed 3 March 2014).
l British Society of Skeletal Radiologists (www.bssr.org.uk) (accessed 3 March 2014).
l British Society of Interventional Radiologists (www.bsir.org) (accessed 5 March 2014).
l Primary Care Rheumatology Society (www.pcrsociety.org) (accessed 19 March 2014).
l Council for Allied Health Professions Research (www.csp.org.uk/professional-union/research/networking-
support/council-allied-health-professions-research) (accessed 28 March 2014).
l Midlands Health Psychology Network (www.mhpn.co.uk) (accessed 19 March 2014).
l Back Care – a lay advocacy and support organisation (www.backcare.org.uk) (accessed 14 March 2014).
l UNTRAP is a partnership between users of health and social care services and carers, the University of Warwick
and the NHS (www2.warwick.ac.uk/fac/cross_fac/healthatwarwick/untrap) (accessed 10 March 2014).
Adapted with permission from Mars et al.26
Collation of ranking
Discussion
group 1
Discussion
group 2
Discussion
group 3
Discussion
group 4
Discussion
group 5
Small group discussions,
identification of items 
for ranking and ranking 
using NGT
Plenary discussion and 
where no consensus from 
groups, ranking using NGT
Checks made on all 
rankings and where error 
identified, ranking 
completed by e-mail
Plenary
Collation of ranking
Consensus
FIGURE 2 A diagrammatic representation of the consensus process. Adapted with permission from Mars et al.26
NGT, nominal group technique.
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
11
Diagnosis: assessment for facet joint pain
Participants were presented with summaries of the information about diagnosis from the evidence reviews
and asked to suggest components of clinical assessment (Box 2). These were then discussed to identify any
that were similar and then grouped as sets forming complete clinical assessments. Participants then ranked
the clinical assessments.
Injection technique
Participants were presented with summaries of the information about injection technique from the
evidence reviews (Box 3).
A potential protocol was presented to them to aid with discussions (Box 4). This included 14 different
aspects of the process of injection. For each aspect a proposal was made for the technique to be used.
Group members first identified which of these they considered acceptable. After collation of these results,
the facilitator invited discussion in turn on each of the aspects for which there was not agreement on
acceptability. For each of these, alternative processes were identified and then ranked.
BOX 2 Diagnosis: evidence and implications
What the evidence suggests
l Current empirical evidence on the clinical diagnosis of facet joint pain is limited.
l Some signs/symptoms or aggravating factors have been suggested to be indicative of facet joint pain but
their use is not supported by the research evidence.
l Small-scale and provisional research suggests that a regular compression pattern when testing combined
movements may have some validity for identifying facet joint pain.
Implication for the Facet Injection Study
l The ability to identify patients where the facet joints are a suspected source of pain is important as it is one
of the entry criteria for enrolment in the study.
l Being able to accurately identify a relatively homogenous group of back pain patients with facet joint pain
will allow a true evaluation of the potential benefits of FJIs.
BOX 3 Injection: evidence and implications
What the evidence suggests
l Key educational/instructional texts for FJI describe details of each author’s technique. A broad methodology
emerges that varies in detail within a narrow range of options.
Implications for the Facet Injection Study
l For this study we need to achieve a single detailed process for therapeutic injection of lumbar facet joints
that is acceptable to the professional community and can be applied consistently across all participating
study centres.
CONSENSUS: DEVELOPING THE STUDY PROTOCOLS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
BOX 4 Proposed protocol for injection procedure (before consensus)
When they attend for injection the operator will make a brief clinical assessment to satisfy themselves that FJIs are
appropriate. Consent for the procedure will be obtained and the current pre-injection risk management procedures
of the participating study centres will be adhered to. The operator will then inject the facet joint(s). We expect to
inject up to six facet joints in each individual (L3/L4, L4/L5 and L5/S1) bilaterally. However, when, on clinical
assessment, there is unilateral pain or involvement of only some levels the operator may choose to do unilateral
injection or be selective on levels injected. We expect that everyone should receive at least two injections. This
pragmatic approach reflects what actually happens in NHS practice. This approach is consistent with that used in
trials of other complex interventions for LBP, for example manual therapy or a cognitive–behavioural approach,
where practitioners choose from a limited range of options based on their clinical assessment of the patient.
Procedure to position the needle
l We do not expect to use intravenous sedation.
l Prone position with pillow under abdomen to flatten lumbar lordosis.
l Intravenous access, resuscitation equipment available.
l Skin cleansing with 0.5% or 2% chlorhexidine in alcohol, sterile drapes. (Some clinicians think that 2%
chlorhexidine is neurotoxic and like to use 0.5% as skin cleansing before nerve blocks. On the other hand,
2% chlorhexidine is recommended by the control of infection experts as optimum skin cleansing before
intravenous cannulation and may be preferred in some trusts.)
l Radiography (C-arm fluoroscopy) oblique view to visualise joint.
l The dose of radiation used will be adequate to visualise the joint while minimising X-ray exposure.
l Skin weal at needle entry point: 1% lidocaine via a 25-gauge hypodermic needle.
l 22-gauge × 3.5-in (0.7 × 90 mm) needle with Quincke type point: guide needle to joint cleft.
l Entry to the joint cleft may be indicated by radiograph appearance: observation of the needle tip on the
joint line with medial/lateral movement of the X-ray beam to cause parallax shift.
l If entry to the joint has not been achieved after repositioning the needle twice, the needle will be
positioned on the joint line without further attempts at capsular puncture.
l Aspiration should be negative for blood or cerebrospinal fluid.
l We do not expect to use contrast medium because of the restriction of available joint volume and the risk
of serious allergic reactions.
l The immediate post-injection advice will be in accordance with the current procedures of the participating
study centre.
Injection
l Pre-filled syringes containing 7.5 mg of bupivacaine and 20 mg of methyl prednisolone in total volume; 2 ml
will be used for each joint.
l The full volume, 2 ml, will be injected through the spinal needle placed into each joint. Some facet joints
may not be sufficiently large to take this volume of injectate meaning in practice that the injections will be
intra- and periarticular. This reflects what we believe to be current practice in the UK.
l Resistance to injection may occur because of abutment of the needle bevel to a surface or because of filling
of the intra-articular space:
¢ Force should not be used.
¢ The needle should first be rotated 90° and a further attempt at injection made.
¢ If, after two further 90° rotations resistance to injection persists or if, after successful injection of a
part-volume resistance develops, gentle pressure should be maintained on the plunger and the needle
withdrawn gradually until resistance to injection falls.
l After completion of the injection, the needle is removed and a sterile dressing applied.
Adapted with permission from Mars et al.26
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Best usual care
Group participants were asked to suggest what treatment approaches should be included in the package
from which a therapist could pick and tailor treatment for each patient. This could include manual therapy,
home exercises and cognitive approaches. The content of the initial assessment and the number and
duration of individual treatment sessions was also discussed. A basic outline and protocol was presented to
the groups to aid in the discussions (Box 5). Group participants identified which aspects of the proposed
BUC they considered acceptable. After collation of these results, the facilitator invited discussion in turn on
each of the treatment approaches for which there was no agreement on acceptability. The group voted on
inclusion/exclusion of treatment approaches from the ‘toolbox’ and assessment session content. They
ranked alternatives for the number/duration of individual treatment sessions.
BOX 5 Proposed content and structure of control intervention (before consensus)
Initial assessment
Initial assessment of 60 minutes. Assessment includes discussion of expectations, fear avoidance and self-efficacy
to assess any perceived challenges and barriers that patients feel may be preventing them from engaging in
self-management of chronic pain and to allow subsequent treatment sessions to be tailored to individual need. For the
intervention group, the FJIs are given in the period between this first assessment and the first follow-up appointment.
Individual sessions
Five further sessions each of 30 minutes incorporating elements of manual therapy, pacing, motor control
retraining, therapeutic exercise, soft tissue stretches/release, postural and general advice, goal-setting and
challenging negative thoughts associated with physical activity and chronic LBP, as appropriate.
Manual therapy intervention may include
l Passive accessory intervertebral movements: either central or unilateral applied to either the symptomatic
level or the level adjacent depending on the severity and irritability.
l Soft tissue release/trigger point release/muscle energy techniques: as indicated in order to facilitate motor
control retraining and effectiveness of manual therapy.
l Manipulation treatment: as indicated.
l Active exercise: to increase mobility, improved motor control and core stability, improve overall strength
and stretch any tight muscle groups.
l Mobility techniques: such as flexion in lying, pelvic tilt, side glides in standing and gym ball exercises.
l Motor control retraining exercises (depending on individual assessments): this may include all muscles involved in
core stabilising of the spine and also reducing activity in more superficial muscles that have been shown to
become overactive in the presence of LBP. Treatment focuses on retraining the ‘coactivation’ pattern of stabilising
muscles such as transversus abdominus and lumbar multifidus. This includes retraining of lumbar multifidus, as it
is innervated by the medial branch and becomes inhibited ipsilateral to the pain in chronic back pain conditions.
There is also evidence that specific retraining of ‘core muscles’ can improve pain and disability in some back
pain patients.
l Passive stretches: muscle groups identified during assessment as tight or overactive may be stretched within
the therapy sessions in order to allow for improved spinal mobility and facilitate motor control retraining.
Stretches are taught as part of the home exercise regime.
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Between-group difference
Participants were asked to consider each of the questions based on the evidence with which they were
provided. These were quite technical questions, and the ‘expert’ in the room provided much needed
support and clarification. Participants provided suggestions that were then voted on and/or rank-ordered.
This particular topic is discussed in more detail in Chapter 3.
Subgroups for analysis
Participants were presented with a list of potential moderators from the evidence reviews. These were
discussed and edited by either the addition of new items or the removal of an item (through agreement
within the group). Items were ranked in order of preference/importance.
The results from all the small group sessions were collated and presented to the plenary session. When
small group results were consistent, no further discussion took place. When there were inconsistencies
between small group results, these were discussed and further ranking undertaken, collated and reported
to the plenary session. We discussed and reranked issues until one option was clearly the preferred option
and there was no objection to its adoption from conference delegates. We considered consensus to have
been reached when there was 75% agreement.
Post conference
All results were checked and verified from all small group sessions and the plenary session. A small number
of errors were found in the collation of rankings. The team therefore contacted participants with relevant
expertise via e-mail to clarify and reach a consensus on these items.
Home exercises and advice may include
l Bespoke exercise programme to complement face-to-face sessions: prescription to include frequency, dose,
repetitions and progressions.
l Advice on positions of ease, strategies to use in event of a ‘flare-up’ and strategies to reduce increasing
pain: for example use of pelvic tilt prior to standing after prolonged sitting.
Cognitive approaches may include
l Pacing: including discussion of what is meant by pacing, relevance of pacing and methods to incorporate
pacing into daily activities such as pacing by time, pacing by numbers or pacing by grading activities.
l Goal-setting: including discussion of setting mutually agreed goals related to functional activities as well as
general daily goals and long-term goals. Goals agreed between the physiotherapist and patient participant.
In line with a cognitive–behavioural approach, goals may be based on Specific, Measurable, Achievable,
Realistic and have a Time frame (a date for competition) (SMART) principles.
l Challenging negative automatic thoughts (cognitive restructuring): including working with patients to
identify particular negative thoughts they may have in relation to physical activity, fear avoidance and
helping patients challenge their thoughts and adapt positive coping strategies.
Homework tasks between each session tailored to each individual and what is discussed during the session. For
example, using pacing on a particular activity identified by the patient, keeping a diary of negative automatic
thoughts that may trigger anxieties about movement or exercise and pain.
Adapted with permission from Mars et al.26
BOX 5 Proposed content and structure of control intervention (before consensus) (continued)
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Results
Fifty-seven people confirmed their attendance, of whom 52 attended on the day. Table 1 summarises their
professional or lay roles. Of the 52 attendees, three asked not to be associated with the final consensus
document: one was not happy with the way the day was organised and with the involvement of laypersons,
one did not agree with having a physiotherapist-led BUC package and one noted no conflict but stated that
they felt unable to contribute as they were not statistically minded. All other attendees agreed to being
identified as part of the consensus group.
Evidence reviews
A full evidence document was produced for each delegate, which was distributed electronically before
the day and provided in hard copy on the day.76 This included tabulated results of the searches, brief
summaries and, in several cases, suggested ‘protocols’.
Consensus conference
We present a brief summary of the results from the consensus conference for each of the five design
considerations. Full data are available.74 Results related to the first three of these design considerations
(diagnosis, injection technique and BUC) have been published elsewhere and data and a number of tables
have been reproduced here with the full permission of the editors.
Diagnosis
The four ‘diagnosis’ group sessions all approached the problem in different ways. In three of the groups
lists were generated and items were then ranked, with the top-ranked items going forward to the plenary
discussions. However, in one group there was considerable discussion and the group agreed/proposed
a diagnostic pathway. This was taken forward to the plenary session. Key components of diagnostic
assessment that were discussed in all groups included increased pain on extension/rotation and extension/
lateral flexion and no pain on rising from flexion. In addition, the following were considered: no radicular
symptoms, no sacroiliac joint pain on pain provocation testing and flexion less painful than extension.
Consensus was not reached on the day.
Injection technique: the process of therapeutic intra-articular facet joint injection
There were 14 aspects of the injection process for the groups to consider. In each group a number
of these were considered acceptable without discussion, although these varied between the groups.
All 14 aspects were brought to the plenary session, but 10 were discussed very briefly before consensus
was reached. The following items prompted considerable discussion and were ranked: administration of
local anaesthetic and its composition, confirmation of needle position, injectate volume and injectate
TABLE 1 Number of consensus conference attendees categorised by professional/lay role
Specialty/role Number of attendees
Pain consultants and physicians 19
Anaesthetists 6
Physiotherapist or physical specialists 12
Academics 4
Psychologists 3
Radiographers 2
Lay representatives 6
Adapted with permission from Mars et al.26
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composition. Owing to errors in ranking identified, we undertook post-conference ranking of injectate
volume and composition among participants with experience of injecting.
Best usual care
All four of the BUC group discussions followed a similar format. First, the group discussed and voted on
agreement/disagreement with the suggested protocol items. The groups then proposed and voted on new
items for inclusion. Comprehensive packages were proposed in all groups and these were taken forward to the
afternoon plenary session. Although a consensus was reached regarding the key components to be included,
some clarification was sought after the conference with participants who had experience of treatment delivery.
Size of signal
Table 2 summarises the results of the consensus meeting discussions on the size of the signal. There was
considerable discussion in these groups and some questions were not covered because of time constraints.
TABLE 2 Summary of results from the morning small group discussions that related to ‘what is the difference in
magnitude of response between treatment and control groups that should be considered large enough to
establish the scientific or therapeutic importance of the results?’
Question Group 1 (total votes) Group 2 (total votes)
1.1: at 3 months, should we be seeking a mean between-group difference in change scores that is smaller/the
same/or larger than that observed for the trials of manual therapy?
A Smaller 1 0
B Larger 6 9
C Same 2 2
1.1a: additional question asked in group 1 – should we be asking for the number who got better/the difference
in benefit?
A Smaller 2 N/A
B Larger 4 N/A
C Same 3 N/A
1.2: informed by the MID units calculated for the trials of manual therapy (supporting evidence), at 3 months
should we be seeking a small (< 0.5), medium (0.5–1.0) or large (> 1.0) MID unit as proof of important difference?
A Small (< 0.5) 8 2
B Medium (0.5–1.0) 1 5
C Larger (> 1.0) 0 1
1.3: what magnitude of reduction in pain after
the injection constitutes immediate pain relief? Group 1 (ranking)a
A 80% 2 N/A
B > 50% 4 N/A
C 0% 3 N/A
D 60% 1 N/A
MID, minimally important difference; N/A, not applicable.
a Group 1 discussions generated the four suggestions. They then ranked them in order of preference.
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The results from the morning sessions were taken forward to the afternoon plenary session, in which there
was a considerable amount of discussion about this topic. As there was a difference of opinion from the
morning session for question 1.2, the whole group were asked to vote on the two items, (A) small (< 0.5)
and (B) medium (0.5–1.0). There were 48 out of 49 valid votes, with the outcome of eight votes for small
(< 0.5) and 40 votes for medium.
An additional question was posed: ‘What difference in those who achieve minimally important change (MIC)
is good?’. The group was asked to vote on three options: larger, the same and smaller. In total, 44 out of
49 ballots were valid, with the result of 22 votes for larger, nine votes for the same and 13 votes for smaller.
During discussion, the question of measuring pain relief at 1 hour in the study was raised. A vote was
therefore held that asked participants ‘should we assess pain at 1 hour?’. The result was inconclusive, with
a total of 46 out of 49 valid votes: 22 said yes and 24 said no.
Finally, the group revisited question 1.3: ‘What magnitude of reduction in pain after the injection constitutes
immediate pain relief?’. Four options were suggested (some extracted from the morning session) and 46 out
of 48 valid votes were included. There were four votes for 30%, 22 votes for 50%, 12 votes for 60% and
eight votes for 80%.
Subgroup analysis
There was only one group discussion on this topic. The participants were presented with current evidence
and asked to consider the variables that they felt were important. Lists were generated and items collapsed
into categories. This resulted in a list of 10 variables, which were then ranked in order of importance.
Table 3 summarises the result from this group (concerning subgroup analysis).
The top five ranked items were presented to the plenary session as the adopted items (see Table 3).
Post conference
Clarifications were needed for three of the design considerations (diagnosis, the process of FJI and the
BUC package).
TABLE 3 Showing the final variables and order after ranking
Final rank Identifier Variables
1 A Severity
2 D Anxiety/depression
3 M Do you think you need an injection to get better
4 E Treatment expectations
5 H Back beliefs
6 G Quality of life
7 B Age
8 F Self-efficacy
= 9 L Forward flexion pain (yes/no)
= 9 N Does the therapist think the treatment is effective
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Diagnosis
In order to confirm the diagnostic criteria for the study, 45 of the professional delegates were e-mailed to
ask the following question:
We would like you to review the following text and confirm if the suggested clinical diagnostic criteria
proposed for the study is ‘acceptable’? Stating ‘YES’ or ’NO’.
Increased pain unilaterally or bilaterally, on lumbar paraspinal palpation. AND. Increased LBP on one or
more of the following; Extension (more than flexion), Rotation, extension/side flexion, extension/
rotation. AND. No radicular symptoms (defined as pain radiating below the knee). AND No sacroiliac
joint pain elicited using a pain provocation tests.
Responses received: acceptable, n = 23; yes, n = 22, no, n = 1.
Box 6 outlines the diagnostic criteria that emerged from the consensus and which went on to be used in
the study.
BOX 6 Diagnosis of facet joint pain (brief outline of protocol after consensus)
There is considerable diagnostic uncertainty about how to identify people with pain of facet joint origin among
the wider chronic LBP population. Therefore, the diagnostic criteria used in this trial have been drawn from the
available evidence base and following consensus gained from a range of experts and clinicians.
Diagnostic criteria for trial
A summary of the diagnostic criteria is shown below. Criteria 1 and 2 cover the issue of presence of pain on
palpation or symptom reproduction on movement testing. The second two criteria relate to the absence of
symptoms, namely radicular symptoms and sacroiliac pain.
1. Increased pain unilaterally or bilaterally, on lumbar paraspinal palpation.
AND
2. Increased LBP on one or more of the following;
i. extension (more than flexion)
ii. rotation
iii. extension/side flexiona
iv. extension/rotation.a
AND
3. No radicular symptoms (defined as pain radiating below the knee or objective neurological signs above
the kneeb).
AND
4. No sacroiliac joint pain elicited using a pain provocation test.
a Both tests representative of regular compression patterns.80
b Using a ‘contracted’ neurological examination.81
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
19
The process of facet joint injection
Following the consensus conference there was uncertainty about the injectate to be used in the study.
Six options were sent, via e-mail, to 27 pain consultants, anaesthetists or professionals (delegates) who
indicated that they were responsible for injection. We received 11 responses; the results can be seen in
Table 4. Box 7 provides a summary of the final agreed injection protocol.
Best usual-care package
Confirmation of the number and duration of sessions was sought post conference. We e-mailed
15 delegates who were physiotherapists, extended scope practitioners or clinical/health psychologists.
Two alternatives, (1) and (2), were sent and delegates were asked to state a preferred option and to also
say if they felt that it was acceptable or not.
There were 12 responses:
1. one session of 60 minutes plus five sessions of 30 minutes (nine preferred, seven yes, zero no)
2. up to six sessions of 45 minutes each (three preferred, six yes, one no).
Among the 12 responses reported, two responders answered that both options were acceptable, one
responder provided only a preference and did not state whether the options were acceptable and two
responders preferred option (1) and thought that this was the acceptable option. Box 8 summarises the
agreed BUC package agreed.
Summary/conclusions
We have established consensus from health professionals concerned with the treatment of facet joint pain
in the UK on the assessment of facet joint pain, injection of facet joints, BUC, minimal important difference
and subgroup analysis for use in a feasibility study for a proposed clinical trial of FJIs. The process was
evidence based and open to all those with a professional interest in this topic. It included lay participants
and was undertaken in a transparent way. The use or not of FJI is controversial internationally and,
therefore, consensus and transparency is essential for the design of the proposed trial of FJIs to ensure that
the results are acceptable to the whole pain treatment community. The results of the consensus process
have provided much-needed clarity into key components of the study and have shaped the protocol for the
subsequent feasibility RCT.
TABLE 4 Post-conference clarification process: number of respondents indicating a preferred option and acceptable
option for injectate showing preferred option and acceptability (yes or no)
Injectate options Preferred option
Acceptable
Yes No
Triamcinolone (10 mg/ml)/Levobupivacaine (2.5 mg/ml) 4 5 2
Triamcinolone (10 mg/ml)/levobupivacaine (5.0 mg/ml) 4 5 0
Triamcinolone (10 mg/ml)/levobupivacaine (7.5 mg/ml) 1 6 3
Triamcinolone (20 mg/ml)/levobupivacaine (3.75 mg/ml) 1 3 5
Triamcinolone (20 mg/ml)/levobupivacaine (7.5 mg/ml) 0 4 4
Triamcinolone (20-mg/ml)/levobupivacaine (11.25-mg/ml) 0 2 6
One responder did not answer acceptable, yes or no. One responder answered ‘yes’ acceptable to triamcinolone (10 mg/ml)/
levobupivacaine (7.5 mg/ml) ‘if using 0.75% levobupivacaine’. One responder answered same injectate option as preferred
and acceptable. One responder gave only an ‘acceptable’ option.
Adapted with permission from Mars et al.26
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BOX 7 Brief outline of intra-articular injection procedure post consensus
Pre-injection procedures
Prior to the study injection procedure, following normal local trust clinical practice, the investigator will obtain
informed consent for the injection from the participant prior to injecting the facet joints . . .
Skin cleansing with chlorhexidine 0.5% or 2% in alcohol sterile drapes are recommended to be used.
No intravenous sedation is required.
Prone position with measures to reduce the lumbar lordosis, for example a pillow under the abdomen.
Intravenous access
Radiography (C-arm fluoroscopy or other suitable equipment) for visualisation of the joint.
The dose of radiation will be adequate to visualise the joint while minimising X-ray exposure.
Entry to the joint cleft may be indicated by radiograph appearance. Medial/lateral movement of the X-ray beam
with intermittent screening to cause parallax shift may be used . . .
For the FIS, contrast will not be administered.
Injection
Local anaesthesia at needle entry point: 1% lidocaine via 25-gauge hypodermic needle . . .
. . . The investigator responsible for the injection will prepare the injection syringe to contain 1ml of Levobupivacaine
(5 mg/ml) and 1ml of Triamcinolone (10mg/ml) in total volume; 2ml will be used for each joint . . .
. . . Up to six facet joints (L3/L4, L4/L5 and L5/S1) bilaterally in each participant will be injected. However, when
on clinical assessment there is unilateral pain or involvement of only some levels, the investigator may choose
to do unilateral injection or be selective on levels injected.
The full volume, 2 ml, will be injected through the spinal needle placed into each joint. Some facet joints may
not be sufficiently large to take this volume of injectate, meaning, in practice, that the injections will be
intra- and periarticular. This reflects what we believe to be current practice in the UK.
If there is resistance to injection may occur because of abutment of the needle bevel to a surface or because of
filling of the intra-articular space. Force should not be used.
The needle should first be rotated 90° and a further attempt at injection made.
If, after two further 90° rotations, resistance to injection persists or if, after successful injection of a part-volume
resistance develops, gentle pressure should be maintained on the plunger and the needle withdrawn gradually
until resistance to injection falls.
After completion of the injection the needle is removed and a sterile dressing applied.
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BOX 8 Brief outline of the BUC package after consensus
Structure of best usual care
Session 1: assessment and planning (1 hour)
Patients initially undergo a thorough physical assessment based on the principles of Maitland manual therapy
assessment and clinical reasoning.
Sessions 2–6 (30 minutes each)
The aim of BUC for this trial is to provide a fully integrated psychological and physical rehabilitation. It is
important therefore to integrate the two elements of care as far as possible so that participants do not see
them as ‘stand alone’.
Treatment should be directed at pain arising from the facet joint. Physiotherapists should use their full range of
skills and knowledge in constructing a personalised rehabilitation programme using the comprehensive ‘tool
kit’ provided.
The section below outlines component parts of the ‘tool kit’. The BUC manual provides full instructions and
examples for the physiotherapists to use.
Acceptance (session 1), goal-setting (session 1 or 2), pacing (session 1 or 2) and challenging negative
thoughts and mindfulness
Manual therapy
Kaltenborn.
McKenzie.
Maitland.
Cyriax.
Osteopathic techniques.
Mulligans.
(Natural apophyseal glides/ sustained natural apophyseal glides/movement valued manual therapies.)
Other.
Soft tissue
Myofascial.
Trigger point.
Soft tissue massage.
Manipulation.
Soft tissue release.
Other.
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Exercises (session 1 or 2)
Specific.
Motor control retraining/core stability.
Cardiovascular.
Strength.
Stretches.
Other.
Advice
Pain terminology, mechanisms and pathways.
Activities of daily living.
Work and ergonomics.
Lifestyle changes.
Management of flare ups and changing.
Symptoms.
Paced home exercises.
Other.
BOX 8 Brief outline of the BUC package after consensus (continued)
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Chapter 3 Interpreting treatment effects: ‘What is
the minimal between-group difference in change
scores necessary for facet joint injection to be
considered worthwhile?’
Background
The important aspects of LBP and how it impacts individuals’ ability to live their life can be assessed using
well-developed patient-reported outcome measures (PROMs).63,82 Increasingly, such measures, for example the
Roland–Morris Disability Questionnaire (RMDQ)83 and the Pain Numerical Rating Scale (Pain-NRS),84 are used
as primary or secondary outcomes in clinical trials of LBP management.57,85,86 However, the effect size even in
positive effectiveness trials comparing physiotherapist-delivered interventions with ‘usual care’ are typically
modest. These may be expressed either as natural units of measures such as the RMDQ (typically 1–2 points on
a 24-point scale) or as a standardised mean difference [between-groups difference/baseline standard deviation
(SD), typically 0.2–0.4 points in trials with positive results]. By way of benchmarking, there is consensus that
a 5-point change, or a 30% improvement from baseline, in the RMDQ represents a worthwhile benefit to
an individual patient.87 Although determination of the clinical relevance or meaningfulness of these scores
is crucial to determining if treatment is worthwhile,88 interpretation guidance is largely unavailable.89
Moreover, the lack of interpretation guidance is often a barrier to appropriate utilisation of trial data.90
There are two aspects of score interpretation relevant to clinical trials: (1) between-groups difference or
the ‘minimally important difference’ (MID) and (2) the within-individual change (‘MIC’) or ‘responder
definition’.91,92 International consensus for the reporting of continuous patient-reported outcomes in LBP
trials supports the reporting of:
i. between-group differences, with guidance for MID when available
ii. a responder analysis that adopts an empirically derived MIC within patients, reporting both proportion
improved and deteriorated according to a predefined responder definition
iii. a calculation of the NNTs.89 However, the authors acknowledge that guidance for MID is often lacking
and is difficult to estimate empirically.
The MID compares the average change from baseline across all patients in treatment and control groups92,93
and has been defined as the difference in magnitude of response between treatment and control groups that
should be considered large enough to establish scientific or therapeutic importance of the results. It is usually
reported through the comparison of summary measures (e.g. mean between-group differences for continuous
measures).91 Although it is common to declare that there is a single MID for an outcome measure, in reality
one might expect that the MID for an invasive procedure would be larger than that for a low-risk educational
intervention. Analytical approaches that report statistical significance of score change fail to convey the clinical
value or the patient perspective on the value of the difference.88,94,95 An alternative approach that takes into
consideration meaningful individual-level change is afforded by the calculation of the MID unit.96,97 The MID
unit divides the between-group difference found in a trial by the established MIC for the outcome of interest:
estimates of < 0.5 MID units suggest that it is increasingly less likely that an appreciable number of patients
will achieve important benefits from treatment, whereas values between 0.5 and 1.0 suggest that treatment
may benefit an appreciable number of patients. This approach, increasingly used within meta-analyses of trial
evidence,96,97 grounds the calculation in clinical reality (a within-person individual change) while tailoring the
MID to the nature of the intervention. Interpretation provides an evaluation of whether or not an appreciable
number of patients achieve clinically important benefits, with MID units of < 1 reflecting increasingly lower
likelihood of benefit.
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Minimally important difference units have been applied in meta-analyses supporting new treatment
guidelines for knee osteoarthritis.98 The authors concluded that for MID units < 0.5 there was a low
likelihood that an appreciable number of patients achieved clinically important benefits. Although MIC
guidance for several legacy measures in LBP exists,87 the application of MID units that incorporate
individual MIC values has not been described. Informed by calculation of the MID unit, we sought to
provide guidance for the minimal between-group difference in change scores (MID) for the RMDQ and/or
the Pain-NRS necessary for FJI to be considered worthwhile.
Methods
There were three stages of this work package:
1. meta-analysis of published data from large trials of physiotherapist-delivered interventions for
chronic LBP
2. calculation of the between-group differences of change scores and the MID unit from a large UK trial
[the UK Back pain Exercise And Manipulation (BEAM) trial]86
3. consensus meeting – score interpretation.
Meta-analysis of data from large trials of physiotherapist-delivered interventions for
chronic low back pain
To gain an indication of the likely magnitude of MID unit differences that may be expected in a positive
study of an intervention to treat LBP, we conducted a meta-analysis using published data from large trials
with which we were already familiar. We selected studies that we had previously included in a database of
individual patient data from RCTs of physiotherapist-delivered interventions for back pain.25 Studies were
included if they included data on ≥ 300 participants and had used the RMDQ.25 Our original intention was
to also include a meta-analysis of Pain-NRSs; however, none of the studies in our sampling frame included
both a RMDQ and useable Pain-NRS data. The purpose of this analysis was to obtain illustrative data for
the consensus meeting rather than to systematically report all studies meeting these criteria. For this
reason, we made the pragmatic decision to include only those studies that we had assessed as part of this
previous project.
Full-text versions of the included studies were retrieved. Two reviewers extracted study-level information
from the included articles: a standardised data extraction list included study-specific information (authors
and trial population) and outcome-specific information [primary and secondary outcomes, mean (SD)
between-group differences in scores at baseline and follow-up and MIC if calculated].
The mean between-group differences in change scores for the RMDQ and across treatment groups and
at different time points were reported for each trial. Each value was compared with the known MIC for
the RMDQ.87
For all included studies, MID units were calculated using published MIC guidance. MID units were calculated
per trial and as an overall value (all trials combined) at 3 and 12 months. As two MIC values are recommended
for the RMDQ, two forms of MID unit were calculated, reflecting the MIC score change and MIC 30%
improvement from baseline.87
Calculation of the between-group differences of change scores and the minimally
important difference unit from a large UK trial (UK Back pain Exercise And
Manipulation trial)
We carried out a further analysis of data from a large UK trial of therapist-delivered interventions
(n = 1169) (the UK BEAM trial86). Using individual patient data, we were able to obtain Pain-NRS data for
pain today as a single item extracted from the Modified Von Korff pain grade scale.86,99 For this analysis,
all three active treatments in UK BEAM trial were pooled for comparison with the control intervention.
WHAT IS THE MINIMAL BETWEEN-GROUP DIFFERENCE IN CHANGE SCORES NECESSARY?
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Scores for the RMDQ and Pain-NRS were adjusted for sex, age and scores at baseline. Mean between-group
differences of change in RMDQ and Pain-NRS scores and MID units (30% and score change) at 4 weeks,
3 months and 12 months were calculated.
Consensus meeting: score interpretation
Finally, a consensus meeting was held.76 The results from the two previous stages were used to inform a
1-day consensus meeting of clinical and academic experts and lay representatives who sought to determine
and make recommendations for between-group score interpretation. All participants received an evidence
synthesis in advance of the meeting. A nominal group technique was adopted to gain consensus. Following
a brief reminder of key evaluation considerations and evidence, delegates were randomly assigned to small
group sessions that were stratified by profession (approximately 10–12 per group). Discussions lasted up
to 1 hour. Each group had a trained facilitator, a scribe and a subject expert. Participants were invited to
consider the following overall question: what is the difference in magnitude of response between treatment
and control groups that should be considered large enough to establish the scientific or therapeutic
importance of the results?
Specific subquestions, pertaining to the RMDQ and/or Pain-NRS, included:
l At 3 months should we be seeking a mean between-group difference in change scores that is smaller
than/the same/or larger than that observed for the trials of physiotherapy?
l Informed by the MID units calculated for the trials of physiotherapy, at 3 months should we be seeking
a small (< 0.5), medium (0.5–1.0) or large (> 1.0) MID unit as proof of important difference?
The results from all small group sessions were collated and presented during the final plenary session, in
which there was considerable discussion on this topic. When there were inconsistencies between small
groups, these were discussed and further ranking undertaken. Final consensus was sought for all questions.
Results
Meta-analysis of data from large trials of physiotherapist-delivered interventions for
chronic low back pain
Following application of our inclusion criteria, three out of five shortlisted large trials were included in the
analysis (Table 5).
TABLE 5 Details of trials included in MID difference meta-analysis
Author (year) Treatment
Number at
randomisation
Age (years),
mean (SD)
Female,
n (%) RMDQ Pain (Pain-NRS)
Lamb et al. (2010)100 Control 233 54 (14.9) 142 (61) Yes No (Von Korff)99
Advice plus cognitive–
behavioural therapy
468 53 (14.6) 278 (59)
UK BEAM trial
(2004)86
Control 338 43 (10.6) 178 (53) Yes No (Von Korff)99
BUC and exercise 310 44 (11.0) 170 (55)
BUC and manipulation 353 43 (11.4) 212 (60)
BUC, manipulation and
exercise
333 43 (11.9) 189 (57)
Hay et al. (2005)101 Manual physiotherapy 201 41 (11.6) 110 (55) Yes No (VAS)
Brief pain management
programme
201 40 (12.0) 100 (50)
VAS, visual analogue scale.
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Mean between-group differences for the Roland–Morris Disability Questionnaire
The trial data suggest that differences in mean functional ability between control or ‘best care’ groups
and a range of physical modalities, such as cognitive–behavioural therapy (CBT) with advice, exercise,
manipulation, manipulation followed by exercise and physical therapy, following 3 months of treatment/
follow-up were small and ranged between 0.8 and 1.87 points in the RMDQ (Table 6).89,101
Following 12 months of follow-up the mean between-group difference in RMDQ scores ranged from 0.8101
to 1.30 points (see Table 6).85,89,100
It is noteworthy that the between-group score differences are considerably lower than the suggested
within-individual change or MIC for the RMDQ (5 points or 30% improvement from baseline).
Meta-analysis and calculation of the minimally important difference units for the
Roland–Morris Disability Questionnaire
We calculated MID units per trial and as an overall score for the three trials (trials combined) at 3 and
12 months (Table 7). Larger MID units were calculated when the 30% MIC was used than for the score
change of 5 points, ranging between 0.20 and 0.69 points at 3 months (combined-trials MID unit 0.49 points,
95% CI 0.37 to 0.61 points). At 12 months, MID units were smaller, ranging from 0.14 to 0.49 points
(combined-trials MID unit 0.34 points, 95% CI 0.21 to 0.48 points).
The use of the MIC 30% change from baseline score as a denominator produced consistently larger MID
units than the use of the MIC raw score change.
Calculation of the between-group differences of change scores and the minimally
important difference unit from a large UK trial (UK Back pain Exercise And
Manipulation trial): Roland–Morris Disability Questionnaire and Pain Numerical
Rating Scale
The two suggested MIC values for the RMDQ and Pain-NRS were used to inform calculation of the MID
unit: (1) a score change of 5 points (RMDQ) or 2 points (Pain-NRS) and (2) 30% score improvement.
Minimally important difference units (mean change/minimal important change
score change)
Small MID units were calculated for the RMDQ at 4 weeks, 3 months and 12 months ranging from 0.20
points (0.09–0.30 points) at 4 weeks to 0.31 points (0.12–0.43 points) at 3 months. Small to moderate MID
units for the Pain-NRS were calculated at 4 weeks (0.22 points, 0.06–0.37 points), 3 months (0.41 points,
0.22–0.59 points) and 12 months (0.25 points, 0.06–0.43 points) (see Table 7).
Minimally important difference units (mean change/minimal important
change 30% improvement)
The use of the 30% MIC produced larger MID units for the RMDQ at all time points: the MID units were
moderate at 4 weeks (0.42 points, 0.20–0.64 points) and at 1 year (0.48 points, 0.20–0.75 points) and
large at 3 months (0.68 points, 0.43–0.93 points). Use of the MIC 30% produced small to moderate
MID units for the Pain-NRS, ranging from 0.13 points (–0.15 to 0.42 points) at 4 weeks to 0.54 points
(0.22–0.86 points) at 3 months and 0.41 points (0.06–0.75 points) at 12 months.
Interpretation of minimally important difference units
In general, larger MID units were calculated for both the RMDQ and Pain-NRS when applying the 30%
MIC in comparison to the MIC score change (see Table 7). The larger MID units for the RMDQ suggest
that treatment may result in the improvement in function in an appreciable number of patients at all time
points (all MID units greater than 0.4 points) but particularly at 3 months (MID unit 0.68 points).
WHAT IS THE MINIMAL BETWEEN-GROUP DIFFERENCE IN CHANGE SCORES NECESSARY?
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Interpretation suggests that few people will achieve important benefits from treatment at 4 weeks and
12 months (MID units > 0.5 points) with regard to an improvement in their pain experience. However, an
appreciable number of patients may experience a reduction in pain at 3 months (MID unit 0.54 points).
Consensus meeting: score interpretation
These data were presented at the consensus meeting. The outcome of the meeting was that any trial of
FJIs should show a larger effect size than that typically seen in trials of physical interventions and that a
medium MID unit difference of 0.5–1.0 points should be sought. The largest effect size seen on the RMDQ
at 3 months in the example trials was 1.87 points (UK BEAM trial combined treatment). This is a MID
unit difference of 0.37 using an absolute difference of 5 points, or a MID unit difference of 0.69 based on
a 30% reduction from baseline. Delegates were also keen that results should be presented as responder
criteria and that they would expect any trial of FJIs to have a greater number of responders compared with
usual care than a trial of physiotherapy.
Discussion
The findings from the meta-analysis and secondary analysis demonstrated that the largest MID units (range
0.2–0.69 points) were consistently reported at the 3-month follow-up: this suggests that physiotherapist-
delivered interventions might result in an improvement in functional ability (RMDQ) and reduction in pain
(Pain-NRS) in an appreciable number of patients at 3 months and to a lesser extent at 12 months. However,
fewer people will achieve important benefits from treatment at 4 weeks.
Participants in the consensus meeting agreed that if FJIs resulted in an additional improvement similar to
that achieved in trials of therapist-delivered interventions, it would be a worthwhile intervention. A MID unit
score of 0.5–1.0 points was therefore recommended. By way of illustration, if the baseline value of the
RMDQ is 10.0 points, this would equate to a MIC (30% improvement) of 3 points; accepting a MID unit of
0.5–1.0 points would result in a between-group difference of 1.5–3.0 points. The alternative approach
based on absolute RMDQ scores (score change of 5), a worthwhile between-group difference of interest
would be 2.5 points regardless of baseline values. Similarly, if the mean baseline Pain-NRS is 7.5 points this
would equate to a MIC (30% improvement) of 2.25 points; accepting a MID unit of 0.5–1.0 points would
imply, therefore, that a worthwhile benefit would be a between-group difference of 1.125–2.25 points.
The purpose of this work was to inform the decision regarding progression to a main trial, for example
based on the estimated difference and CI calculated for these two measures, a main trial would be
considered to be appropriate if the upper limit of the 95% CI, for either assessment, exceeded the minimal
worthwhile effect. Conservatively, for the RMDQ we suggest use of the smaller of the two values estimated
for the RMDQ. If the limit of the 95% CI does not exceed this value, this indicates that it would not be
worthwhile proceeding to a main trial. As the pilot study closed prematurely and no between-group
comparisons were carried out, we cannot use this finding to inform a decision to progress to a main study;
it will, however, inform the sample size estimate for any main study.
The suggestion that responder criteria were used has many attractions. Previous work has shown that the
NNT within the UK BEAM trial data set for an improvement on the RMDQ at 3 months is 5.2 patients
(95% CI 3.7 to 8.8 patients) for a 5-point improvement and 5.4 patients (95% CI 3.8 to 9.9 patients) for a
30% improvement. At 12 months the NNTs are 8.4 patients (95% CI 5.0 to 28.6 patients) for a 5-point
improvement and 8.0 patients (95% CI 4.9 to 24.3 patients) for a 30% improvement.57 These previous
analyses could also serve to inform sample size calculations, however, they do not take into account any
effects on deteriorations prevented by treatment or indeed deteriorations as a consequence of treatment.
The previous work did consider these but was limited in its analysis by the absence of consensus on what
represents a deterioration. This may be particularly pertinent in the context of this study, in which any
deterioration as a consequence of the intervention is likely to be in the short term and may not be
measured at the same time point used for any responder analyses. Thus, although we think that this
approach is important for presentation, we do not think that it should be used to estimate sample size.89
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Chapter 4 Feasibility randomised controlled trial
In Chapter 3 we outlined the FIS consensus conference. Data from this event have played a considerablerole in shaping key methodological components of our protocol, including the diagnosis of patients
with suspected facet joint pain, the technique/protocol for injecting the facet joints and a package of BUC
combining both physical and psychological components for the treatment of patients with suspected facet
joint pain. In this chapter we bring these together into the methods used to carry out the feasibility RCT.
Trial summary
The FIS was a mixed-methods randomised multicentre feasibility trial to test the addition of FJIs to a
bespoke BUC package. The trial was conducted in the UK only. We planned to randomise up to
150 participants into two equal groups stratified by trust, participant age and severity. Recruitment was
expected to take around 6 months.
The randomised pilot trial was planned to be conducted in up to six NHS acute trusts. Patients referred for
treatment of LBP present for at least 6 months, after failure of conservative treatment, were considered as
potential participants. Potential participants were sent a trial screening information sheet and screening
questionnaire for completion and return with their contact details on an expression of interest form. The
screening questionnaire assessed preliminary eligibility for enrolment into the trial. If the potential participant
appeared eligible and interested, an appointment with a research physiotherapist was made during which
a diagnostic assessment was undertaken to determine if facet joint pain was probable. If the potential
participant was deemed to be unsuitable for the trial, his or her standard treatment of care continued
as normal. In the event that the assessing physiotherapist had concerns that a potential participant having a
specific cause of back pain (malignancy, fracture, infection or possible ankylosing spondylitis), cauda equina
compression or radicular pain suitable for surgery, the assessing physiotherapist, as appropriate, expedited a
specialist assessment or referred the potential participant back to their general practitioner (GP). If the potential
participant was confirmed to have suspected facet joint pain, he or she was considered for enrolment. If the
potential participant was able and willing to attend on specified dates for the scheduled intervention, written
informed consent was obtained and the participant was considered enrolled into the trial.
For this study we wished to test a pragmatic approach in which those with suspected facet joint pain
receive a therapeutic intra-articular injection. This is congruent with how any such service would be
delivered in the NHS. Outside a research environment, performing an initial diagnostic intra-injection or
medial branch block to confirm the diagnosis would be unnecessarily resource intensive. The resources
necessary to carry out a therapeutic injection are almost identical to those needed to carry out a
diagnostic procedure.
Randomisation was performed centrally by Warwick Clinical Trials Unit (WCTU) using randomised
permuted blocks, stratified by trust, participant age and troublesomeness of LBP. Participants were
randomised to receive either FJI with BUC or BUC only. Pain outcomes were collected, immediately before
and after injection (intervention only), daily for up to 7 days before first physiotherapy treatment session
until 28 days after randomisation (including 7 days after the notional injection date; all injections should
have taken place within 21 days of randomisation) and weekly for 3 months after the intervention. Health
utility data [EuroQol-5 Dimensions, five-level version (EQ-5D-5L)] were collected daily for 8 days from
around the notional injection date and then weekly until 3 months after randomisation.
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Aims and objectives
Primary objective
The primary objective of this trial was to explore the feasibility of running a RCT to test the hypothesis that
for people with suspected facet joint pain contributing to persistent LBP, adding the option of FJIs to best
usual non-invasive care available from the NHS is clinically effective and cost-effective.
Secondary objectives
l To evaluate a standardised control treatment deliverable in the NHS and congruent with NICE
guidance (BUC).
l To develop and test systems for collecting short-term and long-term pain outcomes, including measures
required for economic evaluation.
l To demonstrate that recruitment to the main trial is feasible.
l To collect the recruitment and outcome data required to inform sample size and number of sites
needed for the main trial.
l To conduct a between-group analysis to inform the decision on the need for a full trial.
l To undertake a process evaluation of patient experience within the trial data from exploratory work,
data from the pilot trial and data from both exploratory work and the pilot trial.
Research methods
A protocol paper has been published for this part of the study.102
Study design
The FIS was a mixed-methods randomised multicentre feasibility trial to compare FJIs with BUC.
Setting
The feasibility RCT was conducted in five NHS acute trusts in the centres based in England. These were:
1. University Hospitals Coventry and Warwickshire NHS Trust
2. Kidderminster Hospital and Treatment Centre, Worcestershire Acute Hospital NHS Trust
3. King’s Mill Hospital, Sherwood Forest Hospitals NHS Foundation Trust
4. The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust
5. Warwick Hospital, South Warwickshire NHS Foundation Trust.
In each hospital we were working with the clinicians providing pain services for patients. One further trust,
Hull and East Yorkshire Hospitals NHS Trust, was preparing to join the study at the time recruitment stopped.
Participants
Patients referred to the trust for treatment of LBP present for at least 6 months, after failure of conservative
treatment, were considered as potential participants. We aimed to recruit 150 patients. We expected up
to 40 participants to be recruited at each participating centre, with up to 20 participants randomised to
each group at each site. Recruitment was planned to be primarily from pain clinic services, which was an
approach that was congruent with the commissioning brief.
Inclusion criteria
1. Was able and willing to comply with the trial procedures and signed and dated informed consent
was obtained.
2. Was aged ≥ 18 years with at least moderately troublesome LBP present for at least 6 months.103
3. Had LBP as their predominant musculoskeletal pain.
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4. Had undergone registered health professional delivered treatment for LBP in the 2 years prior to
study entry.
5. Met clinical criteria for possible facet joint pain when there is no radicular symptoms (defined as pain
radiating below the knee) and no sacroiliac joint pain elicited using a pain provocation test and
increased pain unilaterally, bilaterally on lumbar paraspinal palpation and increased LBP on one or more
of the following: extension (more than flexion), rotation, extension/side flexion or extension/rotation.
6. Was able to manage text messaging, or an alternative means of daily data collection (paper-based diary).
7. Was fluent in written and spoken English.
Exclusion criteria
1. Was unable to attend for randomised treatment, other circumstances that would significantly decrease
the chance of obtaining reliable data, achieving trial objectives or completing the trial and follow-up
assessments or was considered unsuitable to participate in the trial by an investigator.
2. Was unable/unwilling to undergo injections.
3. Had used oral corticosteroids or had a corticosteroid injection in the preceding 3 months.
4. Had an underlying serious psychiatric or psychological disorder that precludes participation in
either intervention.
5. Had previously undergone spinal injections.
6. Had previously undergone spinal surgery.
7. Had a contraindication to FJIs, for example a serious comorbidity (e.g. severe chronic obstructive
pulmonary disease, poorly controlled diabetes), such as malignancy, infection, inflammatory disorder
or fracture, or was taking anticoagulant medications.
8. Had a known allergy to the constituents of the planned injections.
9. Pregnancy or suspected pregnancy.
10. Was previously randomised in this trial.
11. Was currently participating in another clinical trial (with an unregistered medicinal product) or
< 90 days had passed since completing participation in such a trial.
Study treatments
Facet joint injection with ‘best usual care’
Participants received detailed information (verbal and written) about the procedure prior to and during the
diagnostic physiotherapy assessment. When the participant attended for injection, the clinician (consultant)
responsible for injection made a clinical assessment to ensure FJI remained appropriate. Briefly, the clinical
assessment, as per normal clinical practice, included a review of the medical history and an assessment of
the participant’s suitability for FJIs. There was a particular emphasis on ensuring that the participant had no
important comorbidities such as malignancy, inflammatory disease, severe chronic obstructive pulmonary
disease, poorly controlled diabetes, fracture or infection (trial exclusions). The clinician could also ‘postpone’
a treatment session if the patient presented with a short-term ailment (e.g. influenza). Following normal local
trust clinical practice, the clinician obtained informed consent for the injection procedure from participants
prior to injecting the facet joints. If during the assessment the clinician identified significant pathologies that
had not been identified previously that excluded a potential participant, they ‘flagged’ these in the patient
notes or to a local investigator site clinician or a GP, whichever was the most appropriate. Participants were
fully informed that they may not receive the injection at this consultation. If it was determined that the
injection was not appropriate, the participant would continue to receive the ‘BUC’ physiotherapy package.
Up to six facet joints (L3/L4, L4/L5 and L5/S1) bilaterally in each participant were injected. However, when,
on clinical assessment, there was unilateral pain or involvement of only some levels, the operator may have
chosen to carry out a unilateral injection or to be selective on levels injected. This pragmatic approach
reflects current clinical practice within the NHS and was informed by the earlier consensus meeting.
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This approach is consistent with that used in trials of other complex interventions for LBP, for example a
manual therapy or a cognitive–behavioural approach, in which practitioners choose from a limited range of
options based on their clinical assessment of the patient.13,14
Control treatment: ‘best usual-care’ package (standardised treatment
deliverable in the NHS and congruent with 2009 National Institute for
Health and Care Excellence guidance)
A study ‘physiotherapist and cognitive–behavioural treatment manual’ was prepared to ensure that all sites
adhere to the same procedures when delivering the ‘BUC’ package. Prior to commencement of the trial,
physiotherapists within the investigator site team were trained in the delivery of the package and its
processes. Below we outline the principles and theoretical underpinnings of our ‘BUC’ package. This builds
on previous work showing that physiotherapists can deliver an effective cognitive intervention but has an
additional emphasis on a physical approach to treating facet joint dysfunction.104 Informed by the Medical
Research Council framework for complex interventions, we developed a best practice intervention that is
congruent with NICE.105 Consensus agreement ensured that the ‘BUC’ package was deliverable within the
NHS at a reasonable cost, that is, for much less than 100 hours of contact time recommended by NICE at
the time this study took place.106
Fundamentally, treatment followed guidance from NICE but tailored to individual patients. Participants
underwent a thorough initial physical assessment (60 minutes) based on the principles of Maitland manual
therapy.107 The assessment included discussion of patient expectations, fear avoidance and perceived self-efficacy.
Participants randomised to the injection arm had their FJIs between their first and second physiotherapy
treatment sessions and within no more than 3 weeks. They then had four further sessions, of 30 minutes
each, which incorporated manual therapy, active and motor control exercises, soft tissue stretches and a
cognitive–behavioural approach. This included cognitive restructuring, challenging unhelpful thoughts
associated with physical activity and chronic LBP, pacing and goal-setting. The sessions were delivered
in a participant-centred manner, with each session tailored to the participant’s needs.
The ‘BUC’ intervention was piloted with five participants recruited from participating trusts before the trial
went into the randomised phase.
Procedures
Procedures for screening
A member of the local principal investigator (PI)’s site trial team actively identified referrals to secondary care for
patients with LBP. We expected that most of these patients, having been referred after failure of conservative
treatment, would already have a diagnosis of non-specific LBP. The referring GP would have referred the
patient based on their knowledge and the patient’s history of chronic back pain and previous treatments.
Those patients in whom the GP suspected a specific cause for their back pain would typically have been
referred in through a different pathway, such as the 2-week wait pathway for suspected cancer. Any patients
for whom the referral from the GP queried a specific cause of back pain were not approached for the study.
As the entry criteria for this study required participants to have chronic pain, to have been assessed by their
GP and to have already had a course of conservative treatment, it is extremely unlikely that any patients with
malignancy, infection or inflammatory disorders were approached. We were, however, aware that the 2009
NICE guidance6 for the management of non-specific LBP recommends keeping the diagnosis under review. As
originally planned, we recruited from secondary care pain services. It was here that we perceived the question
on the effectiveness of intra-articular FJIs to be of greatest importance. Recruitment in this environment was
challenging. At the time the study closed because of poor recruitment, we were working towards being able to
recruit from neurosurgery, rheumatology and orthopaedic clinics. We were also setting up a GP and community
physiotherapy referral system into a secondary care physiotherapist-led research clinic. Posters were placed in
GP and community clinics. Interested patients could contact local research nurses in their participating trusts.
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A member of the investigator’s trial team based at the local site (e.g. a research nurse or physiotherapist)
sent a brief screening information sheet, a screening questionnaire and an expression of interest form
to potential participants, for whom there were no concerns about a specific cause of LBP, to assess
preliminarily their eligibility for enrolment into the trial. At this time, the brief screening information sheet
was sent to potential participants to provide them with sufficient information to make an informed
judgement about whether or not they might be interested in finding out more about the study. At some
sites, patients with LBP who were attending clinics were approached by their treating clinician (e.g. the local
PI or team) to assess their possible participation in the trial. In these cases, the treating clinician gave the
patient a trial information pack containing a brief screening information sheet, a screening questionnaire
and an expression of interest form. The potential participant was invited to return the completed screening
questionnaire and expression of interest form to the PI’s trial team at the local site using an envelope
provided. From review of the questionnaire, if the potential participant appeared eligible and interested,
a member of the local site trial team sent out the full participant information sheet regarding the trial.
Specifically, the full participant information sheet informed the patient about the eligibility assessment they
were being invited to attend, which helped to determine their possible inclusion in the trial, and clearly
explained that it was only at this assessment that their eligibility would be confirmed. They were invited to
attend an appointment for their clinical/physical (diagnostic) assessment at a nominated research clinic. Each
site was required to maintain an anonymised trial screening log (see Appendix 2) monitoring the number of
screening packs sent out, returned and recruited, noting reasons for ineligibility (Figure 3).
Clinical diagnosis of suspected facet joint pain (visit A)
A study-trained physiotherapist met with potential participants who had agreed to attend the assessment
appointment. On arrival the physiotherapist carried out the FIS diagnostic assessment.
Based on the agreement from the consensus conference, suspected facet joint pain was considered to be
present when there was:
1. no radicular symptoms (defined as pain radiating below the knee)
2. no sacroiliac joint pain elicited using a pain provocation test
3. increased pain, unilaterally or bilaterally, on lumbar paraspinal palpation
4. increased LBP on one or more of the following:
¢ extension (more than flexion)
¢ rotation
¢ extension/side flexion
¢ extension/rotation.
Note that both extension/side flexion and extension/rotation were representative of regular compression
patterns.49
A manual was developed for the diagnostic assessment to aid the physiotherapist.72
After it had been confirmed that the patient met all of the inclusion criteria and none of the exclusion criteria,
and was deemed ‘eligible’ following the diagnostic assessment, their written informed consent to participate
in the trial was obtained by suitably trained physiotherapists or research nurses, or by the PI as a delegated
responsibility.
If potential participants were considered not to have facet joint pain, the physiotherapist informed them
that they would not be included in the trial and that their standard treatment/management care plan
would continue as referred.
The outcome of the eligibility assessment for suspected facet joint pain was documented for all potential
participants. Those potential participants who were considered not eligible based on eligibility assessment
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Hospital site identifies potential patients After identifying eligible patient, site 
sends cover letter enclosing screening 
patient information sheet, screening 
questionnaire and expression of interest, 
along with pre-paid envelope. Complete 
screening spreadsheet
For all patients screened, provided or sent 
questionnaire – complete screening log 
(spreadsheet preferable or paper available)
Screening: if eligible, sends full patient 
information sheet and appointment letter 
confirming date of diagnostic assessment
Screening: if not eligible, site sends patient 
a thank you letter, confirming not eligible, 
and encloses back book. Patient continues 
in system/on referral
Diagnostic assessment: if eligible, complete
consent process, written informed consent 
obtained. Enrolment form completed, 
patient contact details form completed.
Patient completes baseline questionnaire.
Letter sent to GP. Appointment letter 
confirming first BUC treatment session and
‘provisional’ injection date.
(Appointments are scheduled by 
physiotherapist/nursing staff locally.) 
Patient taken out of original referral 
system as now enrolled in the study
If patient is not eligible or is eligible but 
does not wish to take part, request to use
data collected so far. If patient agreeable, 
patient completes consent form – Eligibility
Assessment Data. Site gives thank you letter 
and gives back book. Patient continues in 
system/on referral
At first physiotherapy treatment the 
lead physiotherapist contacts randomisation 
service at WCTU at end of the treatment 
session or at the latest within 72 hours 
for allocation of treatment – lead 
physiotherapist completes randomisation 
form
Site contacts the patient and sends out 
letter to patient to confirm allocation arm 
and confirms appointments of treatment 
arm. If allocated to control arm, the 
provisional injection appointment is to 
be cancelled
Patient continues to complete daily pain
scores for 35 days starting 7 days prior to 
randomisation, and EQ-5D scale daily for 
8 days and then weekly until 3 months 
after randomisation (text and paper-based 
diary).
WCTU sends out postal questionnaires to 
patients at 3, 6 and 12 months
On return, check against inclusion and 
exclusion criteria. If eligible, pass details to
assessment physiotherapist
Physiotherapist carries out 
diagnostic assessment
Hospital site sends
screening documents to 
potentially eligible patient; 
return envelope to site
Patient sent information
sheet and diagnostic 
assessment appointment 
is confirmed
If eligible: patient consented.
Baseline questionnaire completed by 
patient at end of diagnostic assessment.
Diaries (× 3) provided to patient (with 
Freepost envelope for return to WCTU).
First BUC and provisional injection
appointments booked.
Contact form, enrolment form completed; 
unique ID number obtained from WCTU 
via telephone
Diagnostic assessment
Visit A
Physiotherapist
appointment
Visit B
Screening
All consented patients attend first
physiotherapist appointment (B1)
Randomisation: treating physiotherapist contacts lead, who
contacts the randomisation service, and patient is allocated 
to either control or injection arm
Patient completes pain diary each day for 35 days starting
7 days prior to randomisation, and EQ-5D scale daily for 
8 days and then weekly until 3 months after randomisation. 
Patient completes 3-, 6- and 12-month postal questionnaires
Not eligible
Not eligible
Intervention arm
FJI and BUC: five further 
BUC appointments (visits B2–6) 
and injection appointment (visit C)
Control arm
BUC: five further 
appointments 
(visits B2–6)
Case report form
FIGURE 3 Participant pathway and procedures. EQ-5D, EuroQol-5 Dimensions.
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were asked to consent to the use of the data generated from their assessment. This was documented in
each person’s clinical record.
After giving written informed consent, the participant was scheduled to attend a 1-hour preliminary ‘BUC’
physiotherapy session delivered by a specially trained physiotherapist.
First ‘best usual-care’ session (visit B1)
Participants initially underwent a thorough physical assessment based on the principles of Maitland manual
therapy assessment and clinical reasoning,107 in which symptomatic levels are identified, and the severity
and nature of the symptoms recorded and used to direct treatment.
Assessment included discussions of acceptance, goal-setting and pacing as well as general discussion of
patient expectations, fear avoidance and self-efficacy to assess any perceived challenges and barriers that
patients felt may be preventing them from engaging in self-management of chronic pain and to allow
subsequent treatment sessions to be tailored to individual need. A manual was developed for the ‘BUC’
intervention to aid the physiotherapist.73
Once the first trial physiotherapy session was completed, the participant was randomised to receive FJI
with BUC package or BUC package only. The treating physiotherapist, within 1 working day, informed the
investigator trial team that the first treatment session has been completed. The investigator trial team then
completed the randomisation process and informed the participant whether or not they needed to attend
for an injection.
This approached ensured that all participants had received the introductory physiotherapy session and that
we were testing the addition of intra-articular FJIs to BUC physiotherapy package rather than comparing
FJIs with physiotherapy. Our concern here was that those allocated to injections might have elected not to
attend for physiotherapy assessment if they expected a substantial benefit from injections.
At this visit we also collected an immediate pre-treatment pain score that would be important for any
analysis of short-term benefits, or harms, from treatment. This is pertinent because there would inevitably
be a delay between consent and arranging treatment sessions.
If a patient was randomised to receive FJI, the injection was scheduled between the preliminary and
secondary physiotherapy treatment session. This took place within 3 weeks of randomisation.
Facet joint injections (visit C)
For those participants who were randomised to undergo FJI, the injection took place between the first and
second BUC sessions. The treating clinician at this time made their own assessment of the participant’s
suitability for FJI and obtained consent for the procedure following normal practice in each participating
trust. The treating clinician could postpone injection in the presence of short-term illness (e.g. influenza).
If significant comorbidity was identified at this time that contraindicated the injection, this was ‘flagged’
in the patient notes or to the local investigator, site clinician or GP, whoever was most appropriate. The
participant would continue to receive the control intervention. A manual was developed for the clinician,
which gave clear instructions on how the injection(s) should be carried out.75
‘Best usual-care package’ (visits B2–B6)
It was expected that all 150 participants would have up to a total of six ‘BUC’ physiotherapy sessions
(including the first treatment session immediately prior to randomisation). The five remaining sessions
were to last approximately 30 minutes. All participants (those in the intervention and those in the control
arms) were encouraged to attend all of these sessions. The package was a series of one-to-one sessions
with a study physiotherapist who would use the BUC manual informed by consensus to help them tailor
the treatment to the participant’s needs.26 Sessions were a bespoke package of physical and behavioural
rehabilitation. All treatment sessions were to be completed within 12 weeks of randomisation.
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Follow-up
Follow-up was conducted at 3 months after randomisation using self-administered questionnaires.
The majority of questionnaires were completed in postal format. Response was tracked carefully by the
trial office and a reminder questionnaire was sent after 2 weeks if a follow-up questionnaire had not
been returned. If the questionnaire had still not been returned after a further 2 weeks, participants were
telephoned to check that they were receiving the questionnaires and to arrange for another to be sent if
needed. A core data set was requested via the telephone, at a time convenient to the participant, if a
participant had still not responded.
The case report form (CRF) was stamped with the date and initialled on receipt at the WCTU office. It was
checked for correctness and completeness and coded for data entry. Any queries were checked with the
statistician. Missing data were clarified with participants when possible.
The baseline and follow-up data were entered into the study database and a random sample check of
10% was undertaken to ensure accuracy.
Outcome assessment
Table 8 outlines the outcome measures and delivery time points.
Demography and baseline assessment
Appendix 3 includes an example of the CRF listing the demographic and clinical data that were collected
at pre-enrolment and pre-randomisation stages. This includes the baseline assessments that are carried out
during visit ‘A’ at the time of enrolment.
Clinical outcomes
For the randomised pilot trial we used a package of outcome measures consistent with consensus
recommendations for outcome assessment in back pain trials. These included pain measurement, physical
function, emotional function, back-related function, generic well-being, disability (social role), satisfaction
with care, patient rating of improvement and satisfaction with treatment, symptoms (pain), adverse events,
participant disposition and a modified form of the Patient Generated Index (PGI).67,108 In this feasibility
trial we assessed performance of these measures and with a view to reducing the questionnaire burden
in the main trial.
Table 8 summarises the outcome measures and their time of completion by participants. The main
questionnaire packages are completed at baseline (at trial entry assessment) and follow-up (3 and 6 months
post randomisation). A pain severity (today) score was recorded daily for 35 days from 7 days before first
treatment session and following this weekly until 3-month follow-up. Health utility (EQ-5D-5L) was recorded
weekly from 1 week prior to first treatment session until the night before injection appointment when we asked
participants to record it daily for 8 days and then weekly until the 3-month follow-up. In addition, intervention
participants record a pain severity 45–60 minutes before and after receiving an injection. Clinical data were
collected and recorded by physiotherapists and clinicians, covering patients’ assessments, injections and
involvement in the physiotherapy intervention. Copies of questionnaires are provided in Appendices 4 and 5.
Primary outcome
The primary outcome for this feasibility trial was a numerical rating scale for pain collected via text
messaging over 3 months following randomisation.84
A method for frequent (daily) collection of pain-related outcome data using a text messaging system was
developed and piloted within the feasibility trial. To test the feasibility of using an electronic diary, a review
of studies using electronic diary-related pain or pain-related disability measurement was conducted, as well
as the identification or development of an application or text system with candidate diary prompts and
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choice of prompts and frequency.117 Research participants find electronic symptom diaries acceptable and
can generate valid symptom data.118 During the exploratory phase, initial feasibility testing, we refined the
diary recording for the needs of the trial.
For those participants unable or unwilling to use a text messaging system, we used a paper-based system.
We collected data on pain severity using an 11-point numerical rating scale (Pain-NRS).84 Data on pain were
collected daily for 35 days starting 1 week prior to randomisation and then weekly for until 3 months after
randomisation. It was felt that any benefit or harm in the immediate post-injection period was likely to change
on a daily basis, and, therefore, less frequent data collection should identify any between-group differences.
Our second primary outcome focused on back pain related disability. We used the RMDQ at baseline and
3 months (follow-up collected using a postal questionnaire).
TABLE 8 Outcome measures and delivery time points
Type of data Outcome measures
Time points
1a 2b 3c 4d 5e
Demographic Age, gender, ethnic group, age at leaving full-time
education, occupation, current work status
Yes
History Time since completely free of back pain Yes
History Previous back pain treatments Yes
Medications Current medications Yes Yes
History Satisfaction with health state Yes Yes
History Troublesomeness question Yes Yes
Back pain related disability RMDQ83 Yes Yes
Back pain related disability The MVK questionnaire disability score84,99 Yes Yes
Back Pain Severity The MVK questionnaire pain scale99 Yes Yes
Modified form of PGI109,110 Yes Yes
Psychological distress DAPOS111 Yes Yes
Pain self-efficacy Pain self-efficacy questionnaire112 Yes Yes
Health-related quality of life SF-12v2, reported as physical and mental
component scores113
Yes Yes
Health utilities EQ-5D-5L114,115 Yes Yes Yes Yes
Well-being WEMWEBS116 Yes Yes
Pain distribution Troublesomeness grid103 Yes
Back Pain Severity today 11-point pain rating scale84 Yes Yes
Current work status If appropriate date of return to work Yes
Health and social service
resource use
Including hospital and community resource,
as well as costs to individuals and carers
Yes
DAPOS, Depression, Anxiety, and Positive Outlook Scale; MVK, Modified Von Korff; SF-12v2, Short Form questionnaire-12
items version 2; WEMWEBS, Warwick–Edinburgh Mental Well-Being Scale.
a Baseline: following clinical assessment.
b Intervention only: day of injection 45–60 minutes before and after injection.
c Daily pain score: for a period of 35 days starting 7 days before first physiotherapy treatment (via text messaging),
after which weekly until the end point (3 months).
d EQ-5D-5L: weekly from first physiotherapy treatment session until the night before injection appointment when daily for
8 days; then back to weekly until the end point (3 months).
e Follow-up: 3 months after randomisation.
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It was planned that the between-group analysis would be looking for a ‘signal’ that the intervention
package might be effective. If we failed to find an indication that there may be a worthwhile benefit,
there would be no need to proceed to a full trial. We were not, here, interested in the point estimate for
any between-group differences. Rather, we were interested in whether or not it was plausible that FJIs
would achieve a benefit of sufficient magnitude to make them a worthwhile intervention. Thus, a decision
not to proceed to a main trial would have been based on it being implausible that the intervention would
achieve a worthwhile clinical effect. The size of effect below which the clinical and academic community
accept that the use of FJIs was not worth considering was decided at the consensus development
conference. However, because of the early closure of recruitment, no between-group analyses were
undertaken (see Analyses).
Sample size
There were several drivers for the sample size estimate: gaining sufficient experience to be confident of
recruitment rates for a main trial, estimating the proportion who gain immediate pain relief and obtaining
sufficient outcome data to inform a decision to proceed while keeping absolute numbers manageable in
a short time frame. We aimed to randomise 150 participants over 6 months into two equal groups
stratified by trust. This is as large as any existing RCT of FJIs.60
We considered how the effect size found in a between-group comparison within this pilot may influence a
decision to run a main trial. Essentially, if the limit for the 95% CI includes a value that would be indicative
of a clinically important difference then we should proceed and if it does not then we should not proceed.
At the design stage we calculated the probability of deciding to proceed to main study when the true
treatment effect is zero for a range of desired standardised mean differences that would be within the
95% CI from the analysis of pilot data. This calculation suggested that if the desired standardised mean
difference indicative of a minimally clinically important difference is in the range 0.3–0.4, if we recruit
around 150 participants, after allowing for 20% loss to follow-up, then the probability of proceeding to a
full trial if true effect is zero is around 50% (see Appendix 6). This effect size expressed as a standardised
mean difference is consistent with the effect size agreed at the consensus conference expressed as MID
units for the RMDQ, meaning that no change was required for this calculation.
The resulting 75 patients in the active injection group would allow us to estimate the proportion with
‘true’ facet joint pain, based on achieving immediate pain relief, with a precision of 11% if the true
proportion was 62%.119,120
Our original plan for our primary analysis here, for pain, was to be the difference in the area under the
curve (AUC) values from our pain measurements over 3 months. For the second primary outcome, we
were going to use the difference in RMDQ at 3 months. If there was not a positive signal suggesting an
early reduction in pain, or in the RMDQ score, then we would not have wanted to proceed to a full trial.
Randomisation
Written informed consent for entry into the trial and the immediate pre-treatment pain score were
obtained prior to randomisation. Participants were randomised sequentially, using randomised permuted
blocks, stratified by trust, participant age and troublesomeness of LBP.
Randomisation was performed centrally by the WCTU using a remote telephone randomisation system
to ensure concealment and avoidance of bias. The randomisation system was managed by the WCTU
randomisation service.
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Randomisation was sequential in a 1 : 1 ratio to FJI plus ‘BUC’ or ‘BUC’ only. A unique trial number was
assigned to the participant in order to maintain anonymity and this was recorded in the CRF.
Any telephone contact for data collection after randomisation was undertaken by a member of the
investigator trial team blind to randomisation.
When possible, an entry was recorded in the clinical record of each participant noting the date of
enrolment, name of the investigator’s trial team member that authorised enrolment and the unique trial
number of the patient.
All forms related to randomisation are included in Appendix 7.
Monitoring and quality assurance of trial procedures
Monitoring and quality assurance was carried out in line with WCTU standard operating procedures.
Formal approvals
Sponsor and governance arrangements
The University Hospitals Coventry and Warwickshire NHS Trust and University of Warwick acted as
cosponsors for this trial.
Ethics
Originally we submitted an ethics application for approval with a full protocol and all of the relevant
paperwork (e.g. patient information sheets, consent forms) on 7 April 2014. In this application we noted
that we were seeking approval for the general methodology of the study but that it was possible that some
things, such as the drugs used for the intervention, would change after our developmental conference.
This application was rejected and we were instructed to reapply after the consensus conference. After
resubmission we received approval on 11 August 2014 (Research Ethics Committee reference 14/YH/0161).
This initial refusal prevented us from being able to set up sites for the trial when originally planned. There
were a number of amendments, which are outlined below along with their dates of approval:
l approval for new documents (24 October 2014):
¢ a cover letter to supplement the follow-up questionnaires
¢ a reminder letter for non-return of follow-up questionnaires
¢ a daily/weekly pain diary
¢ a weekly health diary
¢ a daily health diary
l approval to add a new site/PI (20 November 2014):
¢ added Castle Hill Hospital, Cottingham, Mr Marek Karpinski
l approval to add a new site/PI and to remove a site/PI (as pain service discontinued at this time)
(13 February 2015):
¢ added The James Cook University Hospital, Middlesbrough, Dr Sam Eldabe
¢ removed South Warwickshire NHS Foundation Trust, Warwick Hospital, Warwick,
Dr James (Hugh) Antrobus
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l approval to add a new site/PI (29 June 2015) (reinstating site after pain management service restored):
¢ added South Warwickshire NHS Foundation Trust, Warwick Hospital, Warwick,
Dr James (Hugh) Antrobus
l approval to make changes to the protocol and information sheets and gain approval for a new clinic
poster (14 September 2015)
l approval for the new scheduled diagnostic assessment and screening questionnaire response letters
(16 December 2015).
Regulatory authorities
The FIS comes under the definition of a Clinical Trial of an Investigational Medicinal Product under the
European Union Clinical Trials Directive 2001/20/EC121 and, therefore, required submission to the Medicines
and Healthcare products Regulatory Agency (MHRA). The trial did not start before the necessary approvals
from Research Ethics Committee and the MHRA were obtained in accordance with the International
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human
Use E6-Good Clinical Practice.122 Before commencing recruitment, each PI was required to obtain local NHS
permission from within their trust.
Approval was granted on 18 November 2014. A copy of all regulatory/ethics/NHS permission approval
documentation was provided to WCTU prior to commencing recruitment of participants into the trial.
Adverse event management
As this study was classified as an Investigational Medicinal Product study we carefully prepared an adverse
event management system that covered all areas of the trial. We did not expect any adverse events,
however, it was important to consider this aspect of the trial and have policies in place to manage any
that occurred in line with Good Clinical Practice122 and MHRA guidance.123
Adverse events
The monitoring and reporting of potential adverse events was carried out in line with WCTU standard
operating procedures.
The following were expected adverse events and, if found, were recorded in the CRF:
l pain, bleeding, discomfort and minor bruising at the injection site (transient)
l numbness in the buttocks and legs from local anaesthetic (transient)
l infection of injection site; inadvertent intravenous injection (uncommon)
l musculoskeletal injuries requiring medical attention including serious sprains, joint dislocation, falls or
other injuries occurring as a direct consequence of the intervention (i.e. while participating in the ‘BUC’
physiotherapy treatment intervention in real time).
Procedures in case of pregnancy
Pregnancy was an exclusion criterion for entry into the study; however, we planned to follow up and
document the outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth or
congenital abnormality) even if the patient had been discontinued from the trial.
All female participants were advised to notify the investigator immediately if they became pregnant during
the trial. The investigator would then report any pregnancy to the WCTU. As noted, we planned to follow
up any pregnancy, and any complications were recorded as an adverse event. All reports of congenital
abnormalities/birth defects would be reported and followed up as serious adverse events.
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Complete study procedures for adverse reactions, adverse events, serious adverse events and suspected
unexpected serious adverse events were included in the study protocol.
Data management
Submitted data were reviewed for completeness and entered onto a secure, backed-up, bespoke
database. Due care was taken to ensure data safety and integrity and compliance with the Data Protection
Act 1998.124 Participants were identified using a unique trial number, which was allocated at the time of
enrolment, and their initials in order to maintain anonymity. The unique trial number was recorded in the
participant’s CRF. We outline our data management in the following section (see Data collection and
management), but more detail on data storage, access, quality assurance, archiving and data sharing are
included in the protocol.
Data collection and management
All data for an individual participant were collected by a member of the investigator’s research team and
recorded in the CRF. Participant identification in the CRF was through their initials and unique trial number
allocated at the time of enrolment. Data were collected from the time the patient was considered for entry
into the trial through to the completion of the intervention.
All data were entered into the CRF; a copy of each form was returned to the WCTU and a duplicate was
retained at the participating site. The unique trial number and other contact details of all participants were
supplied to the WCTU to allow follow-up telephone or postal questionnaires to be administered to the
participant at 3 months and 6 months after randomisation.
Data collection was restricted to variables required to define patient characteristics at enrolment, to
monitor the treatment received, to monitor adverse effects and to determine quality of life and the use
of health-care resources.
Database
The database was developed and managed by the programming team at the WCTU, and all specifications
(i.e. database variables, validation checks and screens) were agreed between members of the project team,
including the programmer and statistician.
Pre-pilot study
A pre-pilot study was planned ahead of the main feasibility randomised trial, with the aim of testing all of
the trial processes. Our objectives were to:
1. test our recruitment process (by recruiting 10–12 participants)
2. allow our assessing physiotherapists to gain experience of the diagnostic assessment
3. evaluate the acceptability of our baseline questionnaire
4. test, when possible, our procedures for injections
5. allow our treating physiotherapists to gain experience of delivering ‘BUC’ package
6. explore patient experiences of trial processes.
Staff training
As noted in Chapter 2, Consensus conference (Diagnosis; Injection technique the process of therapeutic
intra-articular facet joint injection; and Best usual care), the research team developed manuals/protocols for
diagnosis, BUC and injection technique, informed by best current evidence and consensus. Training days
were scheduled for the appropriate staff in these trial procedures (e.g. physiotherapists for diagnosis and
BUC, and clinicians for injections). We piloted this training in the pilot study. The manuals/training were
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updated before the main feasibility trial based on the experiences and observations of their use in the
pilot study.
Pilot procedure
We planned to recruit around 10–12 participants to the pilot study from one or more of our participating
trusts. The recruitment and assessment processes would be the same as those designed for the main
study. At the end of the diagnostic assessment, participants with suspected facet joint pain who gave
informed consent were asked to complete the baseline questionnaire. The participants in the pilot study
were not randomised.
All of those participants who met the eligibility criteria were offered the whole treatment package
(including the injection and ‘BUC’ package). Once treatment was complete, a member of the research
team contacted participants by telephone to get their feedback on their experience of the assessment and
treatment process. This included asking for comments on the face validity and acceptability of the baseline
questionnaire. The research team obtained feedback from the treating physiotherapists about the study
processes. The data from participants and therapists were used to refine the assessment process and
treatment package prior to the randomised feasibility trial being launched.
Analyses
Statistical analysis
At the outset it was planned that the main quantitative outputs from this feasibility trial would, first,
be process outcomes, including:
l proportion of eligible participants who are randomised and complete follow-up
l proportion who obtain immediate (diagnostic) pain relief
l recruitment rates, that is, the number of referrals per site and proportion of referrals converted to
participants. These data are needed to estimate the number of sites needed for, and the duration of,
the main trial
l completeness of data from short-term electronic data collection.
Our primary effectiveness analyses was planned to be the overall difference in average pain and back
pain related disability between intervention and control groups with a 95% CI. We planned to adjust our
models for baseline stratification factors and other baseline covariates and missing values imputed.
However, early closure precluded us from taking this approach, and the following plan was developed.
Overview
The proposed statistical analyses were conducted on data collected from participants randomised prior to
study closure. The objectives outlined in this plan are based on previously stated objectives from the FIS
protocol and an earlier version of a full statistical analysis plan developed before recruitment began.
None of our prespecified effectiveness analyses outlined in the protocol and statistical analysis plan was
carried out. Given the number of participants recruited at study closure, there is insufficient statistical power
to detect any ‘true’ treatment difference between interventions, if one did exist. If any underpowered
comparative analyses were presented, inappropriate inferences and conclusions may be made. However,
overall descriptive data summaries (e.g. means, SDs) are presented.
Key objectives
The main objectives of the revised analyses are to:
l present descriptive summaries and graphical representations of baseline and 3-month outcomes, with
no between-group analyses
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l describe participant flow through the study, including a Consolidated Standards of Reporting Trials
diagram, to summarise participation from screening through to follow-up
l evaluate recruitment rates, number of referrals per site and conversion percentages in order to better
inform decisions regarding estimates of parameters for a main trial
l assess the completeness of data collected via text message (the text messaging service used to collect
daily and weekly pain scores from participants) and the quality of these data in comparison with postal
paper pain diary data, when appropriate
l evaluate the performance of CRFs and patient questionnaires for collecting data at baseline and at
follow-up time points by presenting summaries of data completeness at baseline and 3-month
follow-up
l estimate the proportion of participants obtaining immediate pain relief in the FJI group as a measure of
diagnostic accuracy
l assess performance of secondary outcome measures to inform decisions regarding questionnaire
burden for a main trial.
Scoring of measures
Roland–Morris Disability Questionnaire scores were calculated using the recommended scoring approach,
suggested by the creators, whereby all positive responses are summed: the instrument does not have any
‘no’ boxes to indicate activities that are not affected. Modified Von Korff scores were calculated only for
those participants with a full set of responses to ensure domain scores can be calculated. Short Form
questionnaire-12 items version 2 (SF-12v2) scoring software was used to calculate SF-12v2113 mental and
physical component scores. 2009 US norms were used to calculate scores in line with developer advice.125
EQ-5D-5L scores were calculated using the most recent available UK value set published in January
2016.126 Warwick–Edinburgh Mental Well-Being Scale (WEMWEBS)116 and all three Depression, Anxiety,
and Positive Outlook Scale (DAPOS)111 domain scores were calculated for those participants with a full set
of responses. The Pain Self-Efficacy Questionnaire (PSEQ)112 was scored and presented as the creators
recommended. The modified PGI109,110 scores were calculated by multiplying the score given to each
domain by the points allocated to the domain. This sum was then divided by the number of points
awarded, which was 10 for all participants, and transformed into a 0–100 scale for ease of interpretation.
Text messaging scores
For the interpretation of the text messaging results, we developed a set of three simple assumptions and
imputations to manage duplicate text responses, a mixture of text and diary responses and missing data:
1. If two scores were submitted on the same day then the earliest score that was received after 6 p.m.
was used for analysis. The other score was ignored.
2. If a text response was received instead of an integer, it was then converted into a score (e.g. nine
converted to 9).
3. If a weekly score was received after the specified day, then the score was used. For example, if a score
was requested on day 49 and received on day 50 during the weekly follow-ups then this observation
counted as the day 50 score.
Area under the curve calculation: scoring algorithm details and details of assumptions
To calculate AUC scores, a full set of 42 observations (35 daily and seven weekly scores) must be specified.
There is missingness in both the text message and paper diaries so a scoring algorithm was created in
order to analyse a complete set of scores for each participant. The development of the algorithm used the
following rules.
l A blank score for each day is created.
l If there is a valid text message response for this day, then the blank value is replaced with the text
message score.
l If the participant did not register with the text messaging service and there is a valid paper diary score,
then the blank value is replaced with this paper diary score.
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l If the participant has completed only one data source (either text message or paper diaries) and day X
is missing in the middle of the data set (not day 1 or day 84), then the score for day X is calculated as:
(Day X−1) + (Day X+1)
2
. (1)
l If two or more adjacent scores are missing, then a monotonic assumption is made for the missing
values between the most recent valid score and the next available valid daily score. For example if two
consecutive scores are missing, day X and day X + 1, then the scores for day X – 1 and day X + 2 are
used to calculate the imputed values for day X and day X + 1 as follows:
Day X = Day X−1 +
(Day X + 2)− (Day X−1)
Number of missing days + 1
. (2)
Day X + 1 = Day X+
(Day X + 2)− (Day X−1)
Number of missing days + 1
. (3)
l If the participant has agreed to complete both data sources and has completed both, then the text
message score is used.
l If the participant has agreed to complete both data sources and the text message score is missing, then
the paper-based score is used.
l If the participant has agreed to complete both data sources and both scores are missing, then the
method described above to calculate day X scores is used.
l If day 1 is missing, then the day 1 score will be calculated using the Modified Von Korff pain scale from
the baseline questionnaire, if available. If this is missing then the first valid observation for this
participant is backfilled.
l If day 84 is missing, then the pain score reported on the 3-month follow-up questionnaire will be used,
if available. If this score is missing then the last observation carried forward is used.
Area under the curve analysis
The AUC was calculated for each participant with a complete set of pain scores from day 0 to day 84
(week 12). Stata/SE 14.1 was used for all data analysis. The pkexamine command was used to calculate an
AUC value for each participant. The pkexamine command is part of a family of commands available in
Stata, namely the pk family of commands, which allows users to perform analyses of pharmacokinetic data
including AUC analyses.127 The pkexamine command allows the user to specify which rule should be used
for calculating AUC results. For these, data cubic splines were used to calculate scores. AUC was then
calculated based on all data points from 0 (day 1) to the final measurement (day 84/week 12).
Health economic analyses
Objectives
An economic analysis was conducted as part of the early termination. The objectives of the economic
analysis were to:
l estimate the health-care and broader resource use and costs of FJIs and BUC, the two interventions
being evaluated in the study
l evaluate the performance of trial CRFs (and our client service receipt inventory forms) for collecting
health-care and broader resource utilisation data over a 3-month follow-up period that will inform any
future trial-based economic evaluation
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l estimate the health-care and broader resource utilisation and costs over the 3-month follow-up period
of the feasibility study and provide a description of key cost drivers
l describe the health-related quality of life profile of study participants over the 3-month follow-up period.
Cost of facet joint injections and best usual care for low back pain
Prior to receiving the decision to terminate the feasibility study, a micro-costing exercise was conducted to
estimate the resource use and costs associated with provision of FJIs and BUC for LBP. BUC consists of a
package of physiotherapy sessions and exercises, details of which are outlined in the study protocol. Relevant
resource inputs associated with the comparator interventions were collected from each participating centre
and were combined with the unit cost of relevant resource inputs to estimate the likely costs of delivering the
FJIs and BUC to NHS patients with LBP as well as variability in costs across centres.
Analyses of resource utilisation, economic costs and health-related quality of life
As part of the feasibility study, health-care and broader utilisation data were collected prospectively from
participants recruited and randomised into the study using CRFs designed specifically for this study. The
performance of the CRFs for collecting resource utilisation and health-related quality-of-life data for
patients with LBP was evaluated. Appropriate sources of unit costs of resource use variables reported in
the CRFs were obtained. Between-group comparisons of clinical effectiveness and cost-effectiveness
outcomes were considered inappropriate given the small number of patients recruited before termination
of the study. Hence, only descriptive summaries and graphs have been generated using all of the available
data to give an indication of the probable health-related quality-of-life profile of patients with LBP as well
as the health-care and broader resource utilisation and costs associated with the condition. To gauge
appropriate time intervals for collecting health-related quality-of-life data (expressed in terms of health
utilities) to inform a cost-effectiveness analysis of the interventions being evaluated, comparisons were
made of quality-adjusted life-year (QALY) estimates based on daily and weekly reports of health-related
quality-of-life (EQ-5D-5L) data over the 3-month follow-up period and the QALYs generated using only
baseline and 3-month data.
Process evaluation
A process evaluation was undertaken using mixed methodologies. Data included quantitative data
collected as part of recording trial activity (e.g. attendance rates, compliance) and qualitative data from
interviews and small group discussions with patients, research therapists and staff.
Table 9 outlines the key items of the evaluation and the data and how these were analysed. Our items are
based on established frameworks128,129 and our experience of implementing these frameworks.130–133 In
addition, we include outcome data in this process evaluation, as these are not being analysed elsewhere.
Patient Generated Index
The majority of PROMs, such as the RMDQ83 and Von Korff pain grade,99 contain a set number of
standardised questions that may or may not include the outcomes that are considered important to
patients. Individualised measures, such as the PGI, provide an alternative assessment format that enables
respondents to specify those areas of life affected by the nominated condition that they judge to be most
important, thus increasing content validity and relevance of assessment to the individual.134 An international
expert panel has recommended use of the PGI, alongside more standardised PROMs specific to LBP
assessment, as a method of assessing the individualised nature of LBP and the meaning of recovery.63
The PGI was originally developed in the UK in the 1990s for application across a range of conditions,135
including LBP.135,136 Although PGI was widely utilised in prospective cohort studies to complement more
traditional PROM-based assessment (e.g. Haywood et al.137), the complicated formats of earlier versions
meant that its application was limited in clinical trial settings.134,138 However, recent revisions of the PGI have
resulted in improved acceptability and completion rates.137,139 The version of the PGI evaluated in this study
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retains the three completion stages of the original, but scoring (stage 2) and point spending (stage 3) have
been revised. Stage 1 requires the respondents to list up to five important areas of life affected by their LBP.
This is facilitated by the provision of a ‘trigger list’ generated for the target condition:134 a 17-item trigger list
was created, informed by qualitative evidence of the impact of LBP,63,64,140,141 items included in widely used
LBP-specific measures63,65 and recent application of the PGI in a Norwegian LBP population113 (Box 9).
A sixth predefined area relates to all other areas of life affected by their LBP and not listed separately.
Stage 2 utilises a shorter, 7-point response scale (each nominated area is scored between 0 and 6, where
0 is as ‘bad as could possibly be’ and 6 is ‘as good as could possibly be’). Finally, in stage 3, a reduced
number of points are available; respondents spend a total of 10 points to indicate the areas in which they
would most value an improvement. A closed format version of the PGI was adopted for the clinical trial.
TABLE 9 Outline of process evaluation
Item Data Analysis
Context: description of
the clinical site where
recruitment was undertaken
1. Documents/websites of service descriptions
2. Case load of patients relevant to the trial
in relevant clinical services from routine
reports internal to the NHS trust
3. Interviews with NHS staff based at each site
(a) Descriptive summary of each study
site: pain services and pain-related
services (e.g. physiotherapy,
psychological therapy); alternatives to
pain clinics (e.g. orthopaedic clinics
and musculoskeletal physiotherapy)
(b) Comparison of descriptive summaries
to understand how service
configuration factors may have
influenced recruitment
Reach: have we reached
the right population?
1. Trial screening data
2. Prevalence data for pain likely to be
included in trial: local or national internal
or publicly available reports
Proportion of expected patient population
recruited to trial at each site and overall
Recruitment: of field sites
and trial participants
1. Project documents including field notes,
minutes of meetings, ethics approval,
MHRA approval and R&D approvals
2. Screening logs and interviews with staff
recruiting to trial and interviews
with patients
(a) Descriptive summary of the process
of site recruitment and the reasons
for each step and the timing/duration
of each step
(b) Descriptive summary of the process of
recruitment at each site, descriptive
summary of flow of patients through
recruitment processes, thematic
analysis of perceived barriers to, and
enablers of, recruitment and thematic
analysis of experience of recruitment
by patients
Dose delivered 1. Appointment records and CRF records
2. Clinical records of interventions delivered
(a) For each site and overall: number of
appointments made; number
cancelled and reasons
(when available)
(b) Number of interventions delivered
Dose received Patient interviews Patient perception of intervention received
Outcome data 1. Patient questionnaires
2. Patient diaries
3. Patient interviews
(a) Proportion of questionnaires and
diaries returned
(b) Completion rates
(c) Thematic analysis of patient
interviews for barriers to, and
facilitators of, completion
Impact Patient interviews Thematic analysis of patient interviews for
patient perception of impact of intervention
R&D, research and development.
FEASIBILITY RANDOMISED CONTROLLED TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
At follow-up, respondents were presented with the first and the last columns completed using data
brought forward from their baseline forms. They were then asked to score each item (stage 2) related to
how they felt about it now.
The PGI score is generated by multiplying the area scores (stage 2) by the proportion of points awarded
(stage 3) and summing and transforming to a 0–100 score, in which higher scores are representative of a
better quality of life.134 Here, we describe the first application of a revised format of the PGI in a UK LBP
patient cohort and the first application of the revised format in a clinical trial setting.
BOX 9 Patient Generated Index–LBP trigger list
Pain, sleep, fatigue.
Work, social life, hobbies, completing tasks, housework.
Driving, travelling, walking.
Relationships – with family or friends, sexual relationships.
Feeling depressed, loss of self-esteem, self-image.
Slow to do things.
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Chapter 5 Results
Recruitment started on 26 June 2015 and was terminated by the funder on 11 December 2015 becauseof poor recruitment, at which point 26 participants had been randomised. The reasons for slow
recruitment are described in detail in the process evaluation. In total, 320 people were approached about
the study and 164 (51%) completed a screening questionnaire. Of these, 56 (34%) were interested in and
appeared to be eligible for the study. At the time that recruitment closed 33 people had been assessed for
the study, 27 of whom (81%) had suspected facet joint pain. One was not randomised because of the
termination of recruitment, which meant that the final randomised total was 26 people. Assuming that a
similar conversion rate in potential participants had not yet been assessed, we would have randomised
around 42 participants from the 320 approached, a conversion rate of around 13% (Figure 4 and Table 10).
In the original grant application we expected to approach 1500 people, with the aim of recruiting 150
participants: a conversion rate of 10%.
Feasibility randomised controlled trial results
One baseline questionnaire (4%) was not received by the co-ordinating centre. The mean age of
participants was 53 years (range 30–80 years). Three-quarters (19/25, 76%) of participants were female
and 10 out of 25 (40%) were not working at the time. No participants were prevented from working by
back pain; 8 out of 25 (32%) were retired from work.
Baseline patient-reported outcomes (Table 11) indicate a population with substantial pain and disability and
an overall poor quality of life. Many participants had at least moderately troublesome pain in other parts
of the body (Table 12). Five (20%) participants had ‘at least moderately troublesome’ pain for only LBP.
Approximately half of our participants (12/25, 48%) also had at least moderately troublesome headaches.
Diagnostic assessment
We obtained diagnostic assessment data on 27 participants (Table 13). These show that our participants
typically had very longstanding LBP, had tried multiple previous treatments and had continued with very or
extremely troublesome LBP.
Best usual care
Adherence to study treatments was good. All participants, inevitably, attended the first BUC session.
Three people (23%) randomised to BUC only subsequently withdrew from BUC, two because their LBP did
not improve and one because they had problems travelling to the intervention. One of these participants
also withdrew from follow-up. Attendance at BUC was good, with 21 out of 26 (81%) attending at least
four treatment sessions (Table 14). Overall, the process data indicate that participants received the essential
components of the package. This included acceptance, goal-setting and pacing. Participants were also
given specific homework tasks to complete between sessions. In comparison with other studies, adherence
for CBT for chronic back pain has shown to be associated with treatment gains in a variety of outcome
measures including accomplishment of daily goals.142 Attendance was good, with 23 participants (88%)
attending at least half of the sessions.
Facet joint injections
One person randomised to injection decided against this after their first BUC session. We obtained injection
records for 12 out of 12 (100%) of those injected. These showed that most people had had at least one
injection at each spinal level and over one-third had had six facet joints injected. There is evidence that
clinicians were making a judgement as to which joints were appropriate to inject. There was a wide variation
in the reported time of exposure to radiation, ranging from 35 to 600 seconds. We have not been able to
resolve queries on the total radiation exposure because of the incompatibility of different approaches to
radiation exposure and different machinery. We also have some concerns about the quality of recorded data
on the duration of radiation exposure because of the wide difference in times recorded.
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Number sent a screening questionnaire
(n = 320)
Number returning a screening questionnaire
(n = 164)
Number eligible for a diagnostic assessment
(n = 56)
Number assessed at a diagnostic assessment
(n = 33)
• No LBP in past 4 weeks, n = 4
• Less than 6 months of constant pain, n = 15
• Not troublesome enough LBP, n = 1
• No previous therapist-delivered treatment, n = 25
• Previous injections into spine for LBP, n = 4
• Previous spinal surgery, n = 3
• Pain spreads below the knee, n = 14
• LBP not most troublesome of all pain, n = 2
• Other reason, n = 12
Met inclusion/exclusion criteria
• Unable to attend for treatment, n = 1
• Underlying serious psychiatric disorder, n = 1
• Does not meet clinical criteria, n = 1
• Not fluent in written and spoken English, n = 1
• Other reason, n = 2
Not assessed 
(n = 5)
Number eligible
(n = 27)
Total number of patients with 3-month questionnaire data
(n = 19)
Number randomised
(n = 26)
Number pending at study closure 
(n = 28)
Number pending at study closure 
(n = 18)
Number pending at study closure 
(n = 1)
• Completed 3-month questionnaire, n = 11
• Lost to follow-up, n = 2
• Withdrew from follow-up, n = 0
Allocated to FJI and BUC
(n = 13)
• FJI and BUC, n = 12
• BUC only, n = 1
Received
• Completed 3-month questionnaire, n = 8
• Lost to follow-up, n = 4
• Withdrew from follow-up, n = 1
Allocated to BUC only
(n = 13)
• BUC only, n = 13
• FJI and BUC, n = 0
Received
FIGURE 4 The Consolidated Standards of Reporting Trials (CONSORT) chart.
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TABLE 10 Baseline demographic characteristics of patients who returned baseline questionnaires (N = 25)
Variables N Mean SD Median Minimum Maximum Missing N/A
Continuous variables
Age (years) 25 53 14.4 56 30 80 0
Age left full-time education (years) 25 17 3.0 16 15 27 0
If working, number of hours’ work
per week
15 33 9.4 37 16 48 0 10
Categorical variables
Gender, n (%)
Male 6 (24)
Female 19 (76)
Missing 0 (0)
Current work status, n (%)
Full-time 11 (44)
Part-time 4 (16)
Not at the moment 10 (40)
Missing 0 (0)
If not working, which applies, n (%)
Retired 8 (80)
At home 0
Unable to work because of LBP 0
Unable to work because of illness 1 (10)
Unemployed and looking 0
In full-time education 0
Other 1 (10)
N/A 15
N/A, not applicable.
TABLE 11 Baseline clinical characteristics and outcomes of patients who returned baseline questionnaires (N = 25)
Outcome measures N Mean SD Median Minimum Maximum Missing
Continuous variables
RMDQ83 (0–24)a 25 11.6 4.5 12 2 20 0
MVK questionnaire disability
score84,99 (0–100)a
24 65 20.5 68 30 100 1
MVK questionnaire pain scale84
(0–100)a
25 70 18.9 70 34 96 0
SF-12v2 physical component score113
(0–100)b
24 31.6 7.7 30.0 19.0 50.0 1
SF-12v2 mental component score113
(0–100)b
24 42.7 9.6 42.1 26.0 60.3 1
EQ-5D-5L score114,115 (–0.11 to 1)b 24 0.547 0.25 0.543 0.117 0.942 1
continued
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
55
TABLE 11 Baseline clinical characteristics and outcomes of patients who returned baseline questionnaires (N= 25)
(continued )
Outcome measures N Mean SD Median Minimum Maximum Missing
EQ-5D VAS114,115 (0–100)b 25 59 20.6 60 15 95 0
WEMWEBS116 (14–70)b 24 45.7 9.6 44.5 26 62 1
DAPOS – Depression Scale111 (5–25)a 25 9.8 3.9 9 5 20 0
DAPOS – Anxiety Scale111 (3–15)a 25 6.1 3.2 5 3 15 0
DAPOS – Positive Outlook Scale111
(3–15)a
25 10.7 2.5 11 5 15 0
PSEQ112 (0–60)b 24 32.7 12.8 34 3 52 1
PGI109,110 (0–100)b 25 38.6 18.3 36 0 72 0
Categorical variables
Current health satisfaction, n (%)
Very dissatisfied 12 (48)
Somewhat dissatisfied 10 (40)
Neither satisfied nor dissatisfied 2 (8)
Somewhat satisfied 0 (0)
Very satisfied 1 (4)
Missing 0
EQ-5D, EuroQoL-5 Dimensions; MVK, Modified Von Korff; VAS, visual analogue scale.
a A lower score indicates a better outcome.
b A higher score indicates a better outcome.
TABLE 12 Baseline troublesomeness reported by participantsa (N= 23)
Troublesomeness grid
symptom
Less than moderately
troublesome, n (%)
At least moderately
troublesome, n (%) Missing, n (%)
Headache 13 (52) 12 (48) 0 (0)
Neck pain 18 (72) 7 (28) 0 (0)
Shoulder pain 21 (84) 4 (16) 0 (0)
Elbow pain 23 (92) 2 (8) 0 (0)
Wrist/hand pain 21 (84) 4 (16) 0 (0)
Chest pain 25 (100) 0 (0) 0 (0)
Abdominal pain 25 (100) 0 (0) 0 (0)
Upper back pain 20 (80) 4 (16) 1 (4)
LBP 0 (0) 25 (100) 0 (0)
Hip/thigh pain 17 68) 8 (32) 0 (0)
Knee pain 21 (84) 4 (16) 0 (0)
Ankle/foot pain 24 (96) 1 (4) 0 (0)
Other pains 23 (92) 2 (8) 0 (0)
Pain in at least one other area 5 (20) 20 (80) 0 (0)
a Data were dichotomised from the six category troublesomeness grid, with the three lower categories (no pain, not at all
troublesome or slightly troublesome) being classified as less than moderately troublesome and the three higher
categories (moderately, very or extremely troublesome) as at least moderately troublesome.
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TABLE 13 Diagnostic assessment (N= 27)
Condition Item Total, n (%)
How long has the participant had back pain? 6–12 months 3 (11)
1–2 years 3 (11)
2–5 years 8 (30)
> 5 years 13 (48)
Previous back pain treatmentsa Physiotherapy 25 (93)
Osteopathy 3 (11)
Chiropractic 8 (30)
Acupuncture 7 (26)
Other 3 (11)
Troublesomeness of back pain during assessment visit Moderately troublesome 10 (37)
Very troublesome 8 (30)
Extremely troublesome 9 (33)
When undertaking active movements did the patient indicatea Increased pain on rising from flexion 13 (48)
Symptoms best on walking 16 (63)
Symptoms best when sitting 11 (41)
Onset of pain paraspinal 20 (74)
a Participants can select more than one answer in this category so percentage totals are calculated accordingly with a
denominator of 25 for each category.
TABLE 14 Best usual-care session data (N = 26)
Category Subcategory
Session
1 2 3 4 5 6
Number of participants attending session, n (%) 26a (100) 24 (92) 23 (88) 21 (81) 17 (65) 15 (58)
Components used during sessions
Acceptance 26 19 15 12 9 8
Goal-setting 24 19 18 12 9 8
Pacing 25 20 16 14 12 8
Exercises Specific 9 10 11 10 8 5
Motor control retraining 7 10 11 7 8 6
Cardiovascular 1 2 3 3 2 3
Strength 6 9 11 7 10 5
Stretches 19 10 14 10 6 5
Other exercises 4 0 0 0 0 0
continued
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We had immediate pre-injection and 60-minute post-injection data on pain for 12 participants (Figure 5).
There was an overall reduction in pain scores, falling from 5.9 to 2.6 following injection. Seven participants
reported a > 50% reduction in pain, five of whom reported that they were pain free following the injection.
One participant reported that their pain was worse, and their pain score increased from 3 to 6 (Table 15).
This study was not designed to assess the validity of our clinical assessment of possible facet joint pain
against a gold-standard test.119 Nevertheless, these data suggest that we have identified a population that
has some potential to benefit from intra-articular FJIs, with one-third of participants achieving the target
level of immediate pain relief (a 50% reduction) suggested by the consensus conference.
Adverse events
No adverse events resulting from either intervention were recorded.
TABLE 14 Best usual-care session data (N = 26) (continued )
Category Subcategory
Session
1 2 3 4 5 6
Advice Pain terminology,
mechanisms and pathways
12 8 7 3 2 1
Activities of daily living 11 12 8 6 4 6
Work and ergonomics 6 3 5 3 4 1
Lifestyle changes 5 6 5 4 4 2
Management of flare ups
and changing symptoms
2 8 5 6 5 8
Paced home exercises 12 9 12 4 6 8
Other advice 2 1 0 0 1 1
Manual therapy Kaltenborn 0 0 0 0 0 0
McKenzie 4 3 3 2 2 1
Maitland 5 5 5 3 0 0
Cyriax 0 0 0 0 0 0
Osteopathic techniques 0 0 0 0 0 0
Mulligans 1 0 1 1 0 0
NAGs/SNAGs/MVMs 1 1 1 1 0 0
Other manual therapy 0 0 0 0 0 0
Soft tissue Myofascial 4 4 2 1 3 2
Trigger point 3 4 1 2 2 2
Soft tissue massage 0 0 0 0 1 1
Manipulation 0 0 0 0 0 1
Soft tissue release 1 1 2 2 1 1
Other soft tissue 0 0 0 0 0 0
Challenging negative thoughts 5 5 5 3 3 1
Mindfulness 3 1 3 3 4 3
MVM, movement valued manual therapy; NAG, natural apophyseal glide; SNAG, sustained natural apophyseal glide.
a The complete data set was available for only 26 out of 27 participants, as one had missing data.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
TABLE 15 Injection visit data (FJI and BUC group participants with a complete CRF: N= 12)
Variable Description
FJI and BUC only
(N= 12)
Category
Pain score immediately before injection
(within 60 minutes)
Mean 5.9
n 12
SD 2.1
Median 6.5
Minimum 3
Maximum 9
Missing 0
Total number of facet joints injected, n (%) 1 1 (8)
2 2 (17)
3 2 (17)
4 2 (17)
5 0 (0)
6 5 (42)
Missing 0 (0)
Which joints injected, n (%) L3/L4, L4/L5 and L5/S1 7 (59)
L4/L5 and L5/S1 4 (33)
L3/L4 only 1 (8)
Missing 0 (0)
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FIGURE 5 Box plot of pre- and post-injection pain scores.
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TABLE 15 Injection visit data (FJI and BUC group participants with a complete CRF: N= 12) (continued )
Variable Description
FJI and BUC only
(N= 12)
Resistance to injection?, n (%) Yes 5 (42)
No 7 (58)
Missing 0 (0)
If yes to resistance, reason for resistance
(more than one reason allowed), n (%)
Abutment of needle bevel to
surface
3 (60)
Filing of the intra-articular space 4 (80)
Other 0 (0)
Pain score immediately AFTER injection
(within 60 minutes)
Mean 2.6
n 12
SD 3.0
Median 2
Minimum 0
Maximum 9
Missing 0
Cumulative exposure time (seconds) Mean 199
n 12
SD 242
Median 60.5
Minimum 35
Maximum 600
Missing 0
Injection site monitoring pre injection,
if done, n (%)
Normal 12 (100)
Bleeding 0 (0)
Haematoma 0 (0)
Redness 0 (0)
Infection 0 (0)
Other 0 (0)
Injection site monitoring post injection,
if done, n (%)
Normal 12 (100)
Bleeding 0 (0)
Haematoma 0 (0)
Redness 0 (0)
Infection 0 (0)
Other 0 (0)
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Area under the curve for pain
Although there were missing data in the text messaging responses for pain, these were largely replaced
with the results of the written pain diary (Table 16). A priori we set three assumptions for this, which were
as follows:
1. If two text scores were submitted on the same day, then the earliest score that was received after
6 p.m. was used for the analysis. The other score would be ignored (n = 20 occasions).
2. If a written response was received instead of a number, then this was converted into a score (n = 1
occasion on which a participant replied ‘nine’ = pain and the score was calculated as 9 for this day).
3. If a weekly score was received after the specified day, then the score would be used. For example,
if a score was requested on day 49 and received on day 50 during the weekly follow-ups, then this
observation would count as the day 50 score (n = 8 occasions).
A simple imputation rule allowed us to estimate the AUC when no values were available for any
individual day. This has provided good-quality data, allowing us to see the pattern of pain over the initial
post-randomisation period. We achieved usable outcome data on 23 out of 26 (88%) of our participants
TABLE 16 Completeness of daily pain scores: text messaging service and paper diaries
Day
Text messaging (N= 16 registered) Paper diaries (N= 14 registered)
n replies % replied n replies % replied
1 12 75 14 100
2 12 75 14 100
3 12 75 14 100
4 11 69 14 100
5 12 75 14 100
6 14 88 14 100
7 15 94 14 100
8 14 88 14 100
9 16 100 14 100
10 16 100 14 100
11 16 100 14 100
12 15 94 14 100
13 16 100 14 100
14 15 94 13 93
15 16 100 14 100
16 14 88 14 100
17 14 88 14 100
18 13 81 14 100
19 14 88 14 100
20 14 88 13 93
21 13 81 13 93
22 11 69 13 93
continued
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for this, our primary outcome (Table 17). Visual inspection of the graph of the pooled outcome over time
shows that there is a modest improvement over the first 35 days of daily measurement, with little further
improvement after this time (Figure 6). This is also reflected in the responses given to questions on
improvement since baseline in the 3-month questionnaire.
The plot (see Figure 6) represents the mean pain score for all participants on each given day of data
collection and shows the overall trajectory of pain scores. The dotted vertical line indicates the proposed
date of the intervention at day 7 and the solid line at day 35 represents the transition point from daily
scores to weekly scores.
TABLE 16 Completeness of daily pain scores: text messaging service and paper diaries (continued )
Day
Text messaging (N= 16 registered) Paper diaries (N= 14 registered)
n replies % replied n replies % replied
23 13 81 13 93
24 11 69 12 86
25 15 94 13 93
26 14 88 13 93
27 13 81 13 93
28 15 94 13 93
29 13 81 13 93
30 14 88 13 93
31 15 94 13 93
32 14 88 13 93
33 14 88 13 93
34 11 69 12 86
35 14 88 12 86
Week
6 13 81 12 86
7 13 81 13 93
8 13 81 12 86
9 11 69 12 86
10 12 75 12 86
11 11 69 12 86
12 12 75 11 79
TABLE 17 Back pain severity, summarised by AUC scores
Measure Mean 95% CI n SD Median Minimum Maximum Missing
AUC 454 392.8 to 515.2 23 141.5 464.6 178.6 696.8 0
RESULTS
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Three-month questionnaire
Seven 3-month questionnaires were not received, resulting in a follow-up rate of 73% for the 3-month
questionnaire outcomes. One of these participants withdrew from questionnaire follow-up prior to
3-month follow-up and the remainder did not respond.
The small numbers mean that extreme caution is needed in interpreting the follow-up findings.
Nevertheless, all pain-related outcomes show the expected improvement between baseline and follow-up.
For example, for the RMDQ the difference is 2.8 points on a 0–24 scale and for the Modified Von Korff
pain scale the difference is 10 points on a 0–100 scale. However, for psychological and attitudinal
outcomes (SF-12v2 mental component score, WEMWEBS, DAPOS and PSEQ) there does not appear to
have been any meaningful change between baseline and follow-up. With the exception of the PGI, all of
the measures used are established outcome measures and we will not assess their performance further
within this study (Table 18).
TABLE 18 Secondary outcomes at 3 months (N = 19)
Outcome measures Mean N SD Median Minimum Maximum Missing
Continuous variables
Back pain scale143 (0–10)a 5.8 18 1.9 6 3 8 1
RMDQ83 (0–24)a 8.8 18 4.9 9 1 19 1
MVK questionnaire disability score84,99 (0–100)a 48.7 19 27.7 54 4 100 0
MVK questionnaire pain scale84 (0–100)a 60 19 21.2 64 30 86 0
SF-12v2 physical component score113 (0–100)b 46.6 17 8.1 46 32.5 61.4 2
SF-12v2 mental component score113 (0–100)b 37.6 17 9 37.9 22.3 52.9 12
EQ-5D-5L Crosswalk Index Score114,115 (–0.11 to 1)b 0.644 19 0.249 0.71 0.084 0.942 0
EQ-5D VAS114,115 (0–100)b 65.3 19 17.4 65 20 90 0
WEMWEBS116 (14–70)b 42.7 15 12.2 47 24 58 4
DAPOS – Depression Scale111 (5–25)a 10.4 17 5.0 11 5 20 2
DAPOS – Anxiety Scale111 (3–15)a 6.7 17 3.4 7 3 13 2
DAPOS – Positive Outlook Scale111 (3–15)a 9.7 17 2.8 9 5 15 2
PSEQ112 (0–60)b 34.2 17 15.4 38 8 56 2
PGI109,110 (0–100)b 50 16 23.2 49 12 100 3
Categorical variables
Change in LBP, n (%)
Vastly worse 0 (0)
Much worse 1 (5)
Slightly worse 0 (0)
No change 7 (37)
Slightly better 6 (32)
Much better 4 (21)
Completely better 0 (0)
Missing 1 (5)
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TABLE 18 Secondary outcomes at 3 months (N = 19) (continued )
Outcome measures Mean N SD Median Minimum Maximum Missing
Change in ability to perform daily tasks, n (%)
Vastly worse 0 (0)
Much worse 0 (0)
Slightly worse 1 (5)
No change 8 (42)
Slightly better 6 (32)
Much better 3 (16)
Completely better 0 (0)
Missing 1 (5)
Troublesomeness of lower back symptoms in past 4 weeks, n (%)
No pain experienced 0 (0)
Not at all troublesome 0 (0)
Slightly troublesome 2 (11)
Moderately troublesome 10 (53)
Very troublesome 6 (31)
Extremely troublesome 0 (0)
Missing 1 (5)
Benefit gained from treatment or advice received since joining the study, n (%)
Substantial harm 0 (0)
Moderate harm 1 (5)
No benefit 5 (26)
Moderate benefit 10 (53)
Substantial benefit 2 (11)
Missing 1 (5)
Satisfaction with treatment received for back pain, n (%)
Very dissatisfied 2 (11)
Somewhat dissatisfied 2 (11)
Neither satisfied nor dissatisfied 3 (16)
Somewhat satisfied 6 (31)
Very satisfied 5 (26)
Missing 1 (5)
Satisfaction with current health, in relation to LBP, n (%)
Very dissatisfied 3 (16)
Somewhat dissatisfied 3 (16)
Neither satisfied nor dissatisfied 5 (26)
Somewhat satisfied 7 (37)
Very satisfied 0 (0)
Missing 1 (5)
EQ-5D, EuroQoL-5 Dimensions; MVK, Modified Von Korff; VAS, visual analogue scale.
a A lower score indicates a better outcome.
b A higher score indicates a better outcome.
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Results of Patient Generated Index completion
The PGI was correctly completed by all patients who returned a baseline questionnaire (n = 25); a score
was calculable for all participants. All participants correctly completed stage 1. The small numbers limited a
meaningful evaluation of the psychometric properties of the PGI in this population [COnsensus-based
Standards for the selection of health Measurement INstruments (COSMIN)].144 However, the content
validity of PGI completion was explored for stage 1.
The baseline PGI scores were a mean of 38.6 (SD 18.3, median 36, range 0–72), on a scale of 0–100,
where 100 is the best quality of life.
At the 3-month follow-up, 16 out of 19 (84%) participants completed the PGI. The mean score had
increased to 50 (SD 23.2, median 49, range 12–100) (see Table 18).
Content validity
All patients completing the PGI entered at least three areas in stage 1 (n = 23, range 3–5). Five areas were
entered by 18 participants (69.5), four by two participants (8.6%) and three by five participants (21.7%).
Most respondents (24/25) completed the sixth item: ‘all other areas affected by your LBP and not listed above’.
A total of 33 areas, including 14 out of 17 of the trigger list items, were listed in stage 1 (Table 19). The
most frequently listed areas affected by LBP were walking (n = 13), sleeping (n = 12), driving (n = 10) and
work (n = 10) (see Table 19).
The 33 areas were categorised into seven broad themes (Table 20): symptoms, activities/function, basic
activities of daily living, emotional well-being, participation (social function and social relationships) and
other. A miscellaneous category was also created. The frequency with which items were listed reflects the
importance of the impact of LBP on functional activities and the symptomology associated with LBP,
followed by the impact on social function and relationships.
Health economic results
Resource use and cost estimates of facet joint injection treatment for low
back pain relief
The average resource use and costs estimates associated with the delivery of the FJI procedure for LBP relief
are presented in Table 21. Cost categories included use of the treatment room/injection facility (equipped
with a radiograph or equipped with C-arm fluoroscopy machine, resuscitation trolley and/or monitoring
back-up equipment), staff time, anaesthetic drugs and disposable medical consumables. The mean duration
of the FJI procedure was estimated to be 36 minutes (range 15–60 minutes) based on data from four of the
trial participating centres. The unit costs for resource use variables were obtained primarily from the Personal
Social Services Research Unit (PSSRU) Unit Costs of Health and Social Care 2015 compendium146 and the
NHS Prescription Cost Analysis 2015 database.147 The unit costs of syringes and needles and other medical
consumables were obtained from online sources (www.medisave.co.uk, www.farlamedical.co.uk; both
accessed 21 November 2015) when more direct NHS sources were unavailable. The cost of the treatment
room facility was estimated to be £183.34. This was based on treatment lasting 36 minutes on average
and on a treatment room cost of £175 per hour as reported in a report for NICE Technology Appraisal 279
(Stevenson et al.145) and updated to 2015 prices using the NHS Hospital & Community Health Services
inflation index.146 It was assumed that the FJIs are performed in a similar treatment facility as percutaneous
vertebroplasty or percutaneous balloon kyphoplasty for treatment of osteoporotic vertebral fractures, the
interventions being appraised in NICE Technology Appraisal 279. The mean total cost of 36 minutes of clinical
staff time was £191.60 and the mean total cost of drugs and disposable medical equipment/consumables
was £44.28 per patient, respectively. Thus, the mean total cost of performing a FJI was estimated at £419.22
per patient.
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TABLE 19 Frequency distribution of areas listed (total 33 individual items) (N= 25 participants)
Trigger list item? Rank Area of importance Frequency (%)
Yes 1 Walking 13 (52)
Yes 2 Sleeping 12 (48)
Yes 3 Driving 10 (40)
Yes 4 Work 10 (40)
Yes/no = 5 Hobbies (4) plus recreation (2) plus dancing (1)
(combined)
7 (28)
Yes = 5 Housework 7 (28)
Yes 7 Pain 6 (24)
Yes 8 Fatigue 5 (20)
No = 9 Sitting 4 (16)
Yes = 9 Sexual relations 3 (12)
Yes = 9 Travelling 3 (12)
Yes = 9 Self-esteem 3 (12)
Yes = 9 Relationships (1) plus relationships family/
friends (1) plus family (1)
3 (12)
Yes = 9 Social life 3 (12)
No = 14 Sport: cycling/football/rugby 2 (8)
No = 14 Decorating (1)/do-it-yourself (1) 2 (8)
Yes = 14 Slow to do things 2 (8)
No = 14 Shower (1)/washing (1) 2 (8)
No Lifting granddaughter/lifting 2 (8)
No Family activities 1 (4)
No Spectating: sport 1 (4)
No Standing 1 (4)
No Toilet 1 (4)
No Putting underwear on 1 (4)
No Motorcycle riding 1 (4)
No Gardening 1 (4)
No Looking after my kids 1 (4)
No Playing with my child 1 (4)
No Weight gain because of lack of exercise 1 (4)
No Quality of life 1 (4)
No Not being able to do what other people my
age do and what I used to do
1 (4)
No Shopping 1 (4)
No Moaning 1 (4)
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TABLE 20 Categorisation of the 33 areas listed in stage 1 of PGI completion (completed by 25 participants)
Area of importance Count (total 113) Frequency %
Symptoms
Sleeping 12 48
Pain 6 24
Fatigue 5 22
Activities/function
Walking 13 52
Housework 7 28
Lifting granddaughter/lifting 2 4
Decorating/do-it-yourself 2 9
Gardening 1 4
Shopping 1 4
Sitting 4 16
Standing 1 4
Driving 10 43
Travelling 3 12
Motorcycle riding 1 4
Basic activities of daily living
Shower/washing 2 9
Toilet 1 4
Putting underwear on 1 4
Emotional well-being
Self-esteem 3 12
Moaning 1 4
Participation
Social function
Work 10 39
Recreation/hobbies (combined) 7 26
Sport: cycling/football/rugby 2 8
Spectating: sport 1 4
Family activities 1 4
Social relationships
Relationships family/friends 3 12
Social life 3 12
Looking after my kids 1 4
Playing with my child 1 4
Sexual relations 3 12
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TABLE 20 Categorisation of the 33 areas listed in stage 1 of PGI completion (completed by 25 participants)
(continued )
Area of importance Count (total 113) Frequency %
Other
Slow to do things 2 8
Weight gain because of lack of exercise 1 4
Quality of life 1 4
Not being able to do what other people my age
do and what I used to do
1 4
TABLE 21 Average resource use and cost profile per patient randomised to FJIs
Resource use category
Unit of
analysis
Quantity
(range)
Unit
costa (£) Source of unit cost
Cost per
patient (£)
Mean treatment duration Minutes 36 (15–60) – – –
Treatment room Minutes 36 305.57b Stevenson et al. (2012)145 183.34
Staff c
Consultant physician 1 140.00 PSSRU 2015146 84.00
Nurse, band 6 2 51.00 PSSRU 2015146 61.20
Radiographer, band 6 1 40.00 PSSRU 2015146 24.00
Health-care assistant 1 24.00 PSSRU 2015146 14.40
Administration support Minutes 20 20.00 PSSRU 2015146 8.00
Total staffing cost 191.60
Injection drugs/and medical disposables
Intravenous access 1 0.60 Prescription Cost
Analysis: England
2015147
0.60
ChloraPrep® with Tint (CareFusion,
Basingstoke, UK), 3-ml applicator
1 18.55 Prescription Cost
Analysis: England
2015147
18.55
Sterile pack/dressing 1 0.43 www.medisave.co.ukd 0.43
Levobupivacaine (5.0 mg/ml) 1 3.15 Prescription Cost
Analysis: England
2015147
3.15
Triamcinolone (10 mg/ml), 1-mg ampoule 3 (1–6) 1.59 Prescription Cost
Analysis: England
2015147
4.77
Local anaesthesia (Lidocaine) 1 2.65 Prescription Cost
Analysis: England
2015147
2.65
BD™ spinal needle (Becton Dickinson,
Franklin Lakes, NJ, USA) (22 gauge)
3 (1–6) 2.06 www.farlamedical.co.ukd 6.18
Filter needle 1 7.22 www.medisave.co.ukd 7.22
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Resource use and cost estimates for programme of physiotherapy treatment for low
back pain
Table 22 presents the resource use and cost estimates associated with the delivery of the programme of
physiotherapy treatment to relieve LBP as specified in the FIS feasibility protocol. The unit costs were
obtained from the PSSRU Unit Cost 2015 compendium146 and the published Department of Health
National Reference Cost 2014–15 schedules.148 The mean total cost of the full course of physiotherapy
treatment, consisting of one initial consultation (diagnostic assessment) followed by four follow-up
treatment consultations, was estimated to be £264 per participant.
The mean total cost of the overall treatment package (comprising one injection and six physiotherapy
sessions) was estimated at £683.22 per participant. This is similar to a NHS tariff cost for a course of FJIs
of £686.84 (National Reference Costs 2014/15148 – main schedule, currency code AB16Z). What is not
included here is cost of the initial consultant appointment (£144.79, National Reference Costs 2014/15148 –
main schedule) at which a decision to offer FJIs is made. The minimum overall cost of the overall FJI
package is thus £831.63. This does not account for the care costs of patients who have a consultant
appointment and do not proceed to FJIs.
TABLE 21 Average resource use and cost profile per patient randomised to FJIs (continued )
Resource use category
Unit of
analysis
Quantity
(range)
Unit
costa (£) Source of unit cost
Cost per
patient (£)
Green needle (21 gauge) 1 0.03 www.medisave.co.ukd 0.03
Orange needle (25 gauge) 1 0.03 www.medisave.co.ukd 0.03
Syringes (10 cc) 1 0.15 www.medisave.co.ukd 0.15
Syringes (2 cc) 3 (1–6) 0.16 www.medisave.co.ukd 0.48
Disposable gloves 1 (1–2) 0.04 www.medisave.co.ukd 0.04
Total cost of drugs and disposables 44.28
PSSRU, Personal Social Services Research Unit.
a Unit costs for staff time per hour (with qualifications).
b Inflated to 2015 prices using the PSSRU 2015 hospital and community health services inflation indices.
c Staff costs except administration support are weighted by average duration of treatment (36 minutes).
d Accessed 21 November 2015.
TABLE 22 Estimated resource use and cost profile associated with delivery of BUC (physiotherapy) for LBP relief as
per trial protocol
Resource use variable Number Unit cost (£)a Source Total cost (£)
Physiotherapy, band 6
Diagnostic assessment (initial
consultation)
1 54.00 WF01B, non-consultant lead services
(National Reference Costs 2014/15)148
54.00
Follow-up consultation 5 42.00 WF01A, non-consultant lead services
(National Reference Costs 2014/15)148
210.00
Total cost of full treatment
programme
264.00
a Unit costs per contact (physiotherapy) or per hour (administrative support).
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Health-care utilisation and costs during trial follow-up
Tables 23–27 present summaries of patient self-reports of health-care resource use and costs for the 3-month
period prior to randomisation (medication use only) and the 3-month post-randomisation follow-up period
for all resource use categories including pain relief medication. In total, 25 (96%) and 19 (73%) of the
TABLE 23 Pain relief medication use and costs at baseline and during follow-up period
Type of medication
Cost per patient (£), mean (standard error)
3 months pre randomisation (n= 25) 3 months post randomisation (n= 19)
Pain relief medication, gels and patches
Tabletsa 85.64 (37.36) 31.81 (18.84)
Gels 0.00 (0.00) 1.53 (1.53)
Patches/padsb 0.63 (0.44) 0.00
Total medication use 86.27 (37.33) 33.34 (18.79)
a Various pain relief medications (e.g. paracetamol, tramadol) were reported. Unit costs were taken from 2015 prescription
costs analysis.147
Note
n= number of patients with reporting medication use at baseline and end of follow-up.
TABLE 24 Primary and secondary care utilisation and costs at 3 months post randomisation
Resource use variable
Resource utilisation,
mean (SE)
Unit cost per
contact (£) Unit cost sourcea
Cost per patient
(£), mean (SE)
Inpatient care
Admitted care 0.000 0.00 0.00
Day case 0.059 (0.059) 686.84 AB16Z148 40.4 (40.40)
Outpatient care
Consultant (pain clinic) 0.412 (0.173) 144.79 Service code 191148 59.62 (25.01)
Physiotherapy 1.000 (0.411) 46 Service code 650148 46 (18.92)
Radiology: MRI 0.235 (0.106) 137 RD01A148 32.24 (14.53)
Radiology: CT 0.059 (0.059) 93 RD20A148 5.47 (5.47)
Radiology: ultrasound 0 55.00 RD40Z148 0.00
Blood testsb 0 0.00 0.00
Hospital nurse (band 6)c 0.059 (0.059) 62.5 PSSRU 2015146 3.68 (3.68)
Occupational therapyd 0.059 (0.059) 65.99 Service code 651148 3.88 (3.88)
General surgery 0.059 (0.059) 138.65 Service code 100148 8.16 (8.16)
Primary care
GP surgery visit 0.824 (0.395) 44 PSSRU 2015146 36.24 (17.39)
GP home visit 0 59.05e PSSRU 2013149 0.00
Practice nurse 0.118 (0.081) 7.88 PSSRU 2015146 0.93 (0.63)
District nurse: surgery 0 12.73 PSSRU 2015146 0.00
District nurse: home visit 0 12.73 PSSRU 2015146 0.00
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TABLE 24 Primary and secondary care utilisation and costs at 3 months post randomisation (continued )
Resource use variable
Resource utilisation,
mean (SE)
Unit cost per
contact (£) Unit cost sourcea
Cost per patient
(£), mean (SE)
Rehabilitation specialist 0 PSSRU 2015146 0.00
Physiotherapist: surgery visit 0 38.00 PSSRU 2015146 0.00
Physiotherapist: home visit 0 38.00 PSSRU 2015146 0.00
Occupational therapist 0 38.00 PSSRU 2015146 0.00
Counsellor 0 58.00 PSSRU 2015146 0.00
Psychologist 0 225.37 PSSRU 2015146 0.00
Social worker 0 95.00 PSSRU 2015146 0.00
CT, computerised tomography; MRI, magnetic resonance imaging; SE, standard error.
a Unit costs were taken from Reference Costs schedules (2014–15) unless otherwise stated. Codes refer to service or
Healthcare Resource Group code as appropriate. The service code identifies the clinical specialty in the reference
costs schedules.
b All blood tests done on 1 day are counted as one test.
c Assumed contact with hospital nurse in the last 30 minutes.
d Assumed counselling services (mindfulness) was provided by psychotherapy.
e Unit costs taken from PSSRU Unit Costs of Health and Social Care 2013149 and adjusted to 2015 prices.
Note
Number of patients with complete primary and secondary care utilisation data at 3 months post randomisation (n = 17).
TABLE 25 Three months’ private health-care utilisation and costs reported by trial participants
Resource use variable Mean (SE) resource use
Costs (£), mean (SE)
Medical insurance contribution Personal contribution
Physiotherapy 0.059 (0.059) 0.00 17.65 (17.65)
Bowen practitioner 0.059 (0.059) 0.00 20.59 (20.59)
Occupational therapy 0 0.00 0.00
Counsellor 0 0.00 0.00
Psychologist 0 0.00 0.00
Radiology: MRI 0 0.00 0.00
Radiology: CT 0 0.00 0.00
Radiology: radiograph 0 0.00 0.00
Radiology: ultrasound 0 0.00 0.00
Consultant service 0 0.00 0.00
Osteopath 0 0.00 0.00
Chiropractor 0 0.00 0.00
Acupuncturist 0 0.00 0.00
Homeopath 0 0.00 0.00
Special equipment use 0 0.00 0.00
Total private medical cost 0.00 38.24 (38.24)
CT, computerised tomography; MRI, magnetic resonance imaging; SE, standard error.
Note
Number of patients with complete private health-care utilisation data at 3 months post randomisation (n= 17).
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26 participants provided complete data on medication use at baseline and the 3-month follow-up time point,
respectively. The total cost of prescribed pain relief tablets, patches and gels was £86.27 (standard error
£37.33) per patient and £33.34 (standard error £18.79) per patient in the 3 months prior to randomisation
and the 3 months following randomisation, respectively (see Table 23).
Complete primary and secondary care utilisation data were available from 17 (65%) of the 26 study
participants for the 3-month post-randomisation period (see Table 24). None of the study participants was
admitted for an overnight stay in hospital and one patient was treated as a day case, generating a mean
cost of £40.40 per patient. There was no reported use of some outpatient services such as blood tests and
TABLE 26 Additional health resource use and out-of-pocket expenses incurred by patients with LBP relief at
3 months post randomisation
Resource use variable
3 months pre randomisation 3 months post randomisation
n (%)a Cost (£), mean (SE) n (%)a Cost (£), mean (SE)
Pain relief medication, gels and patches
Tablets 25 (96) 2.48 (1.26) 19 (73) 9.09 (3.46)
Gels 25 (96) 0.44 (0.44) 19 (73) 6.83 (2.63)
Patchesb 25 (96) 0.00 19 (73) 2.37 (1.64)
Total over-the-counter medication 25 (96) 2.92 (1.30) 19 (73) 18.28 (5.05)
Travel costs (e.g. bus fares) incurred by patient 14 (54) 1.08 (1.08)
Travel costs incurred by partner of patient 14 (54) 1.86 (1.86)
Child care costs 14 (54) 0.00
Cost of help with housework 14 (54) 0.00
Cost of laundry services 14 (54) 0.00
Total out-of-pocket costs 14 (54) 24.42 (6.89)c
SE, standard error.
a Number reporting out-of-pocket expense (as a percentage of the total number of patients randomised, n= 26).
b Includes buprenorphine transdermal patch 10mcg/hour, heat patches and Actipach® (BioElectronics Corporation,
Frederick, MD, USA).
c Only 14 patients with complete data on all the out-of-pocket expense variables are included in the total out-of-pocket
expenses.
TABLE 27 Employment- and income-related status of trial participants at end of 3-month follow-up period
Productivity variable n (%) Mean (SE)
Reported current employment status 17 (65) –
Employed 9 (35) 0.53 (0.121)
Not in employment because of ill health 2 (8) 0.25 (0.11)
Not in employment because of retirement 6 (23) 0.75 (0.11)
Lost income because of ill health (yes/no) 11 (42) 0.08 (0.08)
Work days lost because of ill health 8 (31) 2.78 (2.22)
Lost income (monetary terms) 11 (42) £34.08 (£34.08)
SE, standard error.
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ultrasound investigations, as well as the majority of community care services. The mean (standard error)
cost per patient for outpatient services ranged from £3.68 (£3.68) for hospital nursing services to £59.62
(£25.01) for consultant pain clinic services. The mean (standard error) cost of primary care services was
£36.24 (£17.39) for GP surgery services and £0.93 (£0.63) for practice nursing services, with both lasting
11.7 minutes on average. The mean (standard error) total cost to the health services over the first 3
months post randomisation was £236.60 (£79.65). Private health-care utilisation was entirely self-funded
by one patient reporting private health-care use and cost £38.24 per patient on average (see Table 25).
The health-care resource use and out-of-pocket expenses incurred by patients and their relatives are
presented in Table 26. The mean cost per patient of over-the-counter pain relief medication, gels and patches
increased from £2.92 (standard error £1.30) in the 3-month pre-randomisation period to £18.28 (standard
error £5.05) in the 3-month post-randomisation period. The mean cost per patient of health-care-related
travel (e.g. bus fares and taxis) was £1.15 (standard error £1.15) for study participants and £2.00 (standard
error £2.00) for their partners. Overall, the mean total health-related out-of-pocket expenditure was £26.23
(standard error £7.19) per patient in the 3 months post randomisation. There were no reported costs
associated with child care, laundry- and household-related services that could have been associated with the
delivery of the study interventions.
The employment- and income-related status of trial participants at the end of the 3-month follow-up
period is summarised in Table 27. Nine of the 17 patients with complete data on employment status were
in work, six were retired and two were unemployed because of ill health. Twelve patients reported
information related to loss of income: one patient reported lost income of £409 because of ill health,
translating into an income loss of £34.08 (£34.08) per patient on average. The mean number of work days
lost was 2.78 (standard error 2.22).
Health-related quality of life at baseline and 3 months’ post randomisation
Self-reports of the health-related quality of life of patients with LBP were made using the EQ-5D-5L
instrument at baseline and at 3-month follow-up; the results are summarised in Tables 28 and 29,
respectively. The proportion of missing data among responders was negligible and there was evidence of
floor effects in the EQ-5D-5L dimensions related to self-care and anxiety and depression and, to some
extent, the mobility, dimension at both baseline and end of follow-up. The mean health utility score on a
scale (range –0.28 to 1), generated using recently derived UK tariffs for the EQ-5D-5L,126 changed from
0.50 (standard error 0.10) at baseline to 0.60 (standard error 0.20) by the end of the 3-month follow-up
period. Similarly, patients’ self-rating of their health-related quality of life on the EQ-5D visual analogue
scale (VAS; 0–100) indicated an improvement from 59.3 (standard error 4.4) at baseline to 65.6 (standard
error 17.88) at the end of follow-up.
TABLE 28 Health-related quality of life of people with LBP
EQ-5D-5L
dimensions Range
Baseline scores (n= 25) 3 months (n= 19)
% missing Median % floora % ceilingb % missing Median % floora % ceilingb
Mobility 1–5 0 3 15.4 0 0 2 11.5 0
Self-care 1–5 3.8 2 38.5 0 0 2 34.6 0
Usual activities 1–5 0 3 7.7 0 0 2 7.7 0
Pain and discomfort 1–5 0 4 0 3.8 0 3 0 0
Anxiety and depression 1–5 0 2 26.9 11.5 0 2 34.6 0
a Floor is defined as number scoring the lowest item score/total number of patients completing the questionnaire.
b Ceiling is defined as number scoring the highest item score/total number of patients completing the questionnaire.
Note
Total number of patients = number of patients with complete data at baseline and 3 months post randomisation.
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The plots in Figure 7 compare 3-month health-related quality-of-life profiles of patients generated using
(1) self-completed questionnaires at baseline and at the end of follow-up (3-month time point) and (2) daily
(during the first week) and then weekly (for the remainder of the 3-month follow-up period) self-assessment of
health-related quality of life recorded in daily/weekly health diaries. Not all patients completed both versions
of the questionnaire at each time point. Figure 7a shows the mean health-related quality-of-life profiles of all
participants who completed the baseline/end of follow-up version of the EQ-5D-5L questionnaire (baseline,
n= 25; follow-up, n= 19) and the daily/weekly diary records (n= 15). Figure 7b shows the profiles for a subset
of participants (n= 11) completing both approaches to data collection. The diary scores indicate marked
fluctuations in health-related quality of life (both EQ-5D-5L index and VAS scores) in the first few weeks post
randomisation. In particular, there is a substantial short-lived improvement in both EQ-5D-5L index and VAS
scores in the first few days after the initial treatment. The fluctuation in health-related quality of life is less
pronounced during the remainder of the follow-up period, almost returning to the baseline rating at the end
of the 3-month follow-up period.
The QALY estimates for the 3-month follow-up period were generated based on the EQ-5D index-derived
utility values for the 11 patients who reported both baseline/follow-up questionnaire and daily/weekly diary
data. The mean QALY estimate was 0.141 (standard error 0.018) based on health-related quality-of-life
outcomes measured at baseline and at the end of follow-up, and 0.170 (standard error 0.017) based on
the more regular diary records. Over the 3-month follow-up period, the mean QALY difference generated
by daily/weekly assessment of health-related quality of life, compared with the normal practice of assessing
health-related quality of life at less regular time points (typically at baseline and end of follow-up), was
0.029 (standard error 0.01).
Figure 7a is based on the scores of all participants who completed the postal questionnaire (baseline,
n = 24; follow-up, n = 19) or on diary records (n = 15). Figure 7b is based on scores from a subset of
participants (n = 11) who provided both postal questionnaire and diary EQ-5D data.
Process evaluation results
This evaluation draws on national published data, audit data from one study site, study process data,
observation notes made by the research team during site initiation visits and visits during recruitment, and
group interviews with all study site teams.
On recruitment, 21 patients consented to be approached for interview. Interviews were planned to take
place shortly after the participant completed 3-month follow-up. Of those 21 patients, 13 were sent
information and invited to consent to an interview, six responded/consented to be interviewed and five
TABLE 29 Health-related quality-of-life weights of people with LBP
Follow-up time
point
Quality of
life weight Range
%
missing
%
floora
%
ceilingb
Lower
quartile Mean Median
Upper
quartile
Standard
error
Baseline (n = 25) EQ-5D index –0.28 to 1 3.8 0 0 0.4 0.5 0.5 0.7 0.1
EQ-5D VAS 0 to 100 0 0 0 45 59 60 75 4.1
3 months (n = 19) EQ-5D index 0 0 0 0 0.5 0.6 0.7 0.8 0.1
EQ-5D VAS 0 0 0 0 55 65.3 65 75 4
a Floor is defined as number scoring the lowest item score/total number of patients.
b Ceiling is defined as number scoring the highest item sore/total number of patients.
Note
Total number of patients = number of patients with complete data at baseline and 3 months post randomisation.
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were interviewed, with one withdrawing on the day of the interview. The five interviewees, all female,
were from three sites (James Cook, n = 3; Kidderminster, n = 1; Kingsmill, n = 1). Of these five, four
received the FJI and one received the control intervention. As there were so few interviews with study
participants, we cannot be confident about the representativeness of these data. We have limited
ourselves to interrogating them for the study participant voice on issues raised by the study site teams.
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FIGURE 7 Three months’ QALY profile of patients with LBP generated via daily and weekly self-reports of EQ-5D-5L
scores and self-completed questionnaire at baseline and at end of follow-up. (a) Scores of all participants who
completed the postal questionnaire or diary records; and (b) scores from a subset of participants who provided
postal questionnaire and diary EQ-5D data.
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Project timeline of study approvals
Figure 8 gives a brief overview of the study approvals and includes planned and revised timelines.
Full ethics approval was obtained in September 2014 in line with our planned timeline, although we had
originally planned to have an outline approval in early 2014 with an updated/amended approval post
consensus in July/August 2014. The ethics committee rejected our early submission and advised that we
should resubmit after we had held our consensus conference, which we did.
Full ethics approval is the driver to start the formal processes of obtaining research and development
(R&D) and site approvals. This proved to be a long process. This study sought approvals at the time that an
older system of approvals was being changed over to a newer system, operated by the Health Research
Authority, and this may explain some of the severe delays we experienced in setting up sites. Our request
for global R&D approval was submitted in August 2014 but was not approved until February 2015, which
was a far longer period of time than normal and meant that approval was gained far later than planned.
Repeated requests for updates from the team, who had provided all of the relevant materials, did not help
to resolve this. Once global R&D was approved, each of the sites required site approval that had to be in
place before any recruitment took place. This again proved to be a slow process. One site was approved
within 1 month, three sites were approved in 4 months, and for the final two sites approval took over
5 months.
These delays, which were largely outside the study team’s control, impacted on the timeline of the study.
The planned 6-month recruitment process that was meant to start in November 2014 was delayed for
7 months until June 2015. The study team provided the staff training needed at three of our sites in
preparation for the start of recruitment in late 2014.
Study research sites
Sites
Table 30 provides an overview of the study sites outlining the type and level of pain management services
offered in the pain clinics. Services vary across all six trusts; some trusts offer a fully integrated service that
is well provisioned and others have more fragmented services.
Site initiation
As noted, recruitment was delayed because of severe delays in gaining research governance approvals that
were beyond the control of the study team. In addition, recruitment from site 2 was delayed because the
pain service was suspended by commissioners after a consultant retired, and recruitment from site 5 did
not occur before the study closed. Figure 8 details site set-up timelines. Site initiation took place within
1 month of approvals being granted. In two sites, staff training for the study ran in the month prior to
recruitment initiation. However, in three sites staff training took place up to 9 months prior to the initiation
of recruitment because of the delay in gaining approvals. Staff at these sites reported frustration at being
unable to initiate recruitment.
Reach of the study across the eligible population
It was necessary to know the size and characteristics of the population that had the potential to benefit
from the intervention to identify if the recruited population was comparable. Although Table 30 gives an
indication of the overall population that our study pain clinics serve, we have little information on the local
prevalence of back pain.
Study site 2, which provided a pain management service, collected data on referrals received and
treatments provided during a period of 8 months that overlapped with the study period. During this time
they received 335 referrals, of which 116 (35%) had back pain. Of the patients with back pain, 34%
received physiotherapy, 22% received advice only and 13% were referred to a pain management group.
Four patients received FJI, of whom one was recruited to our study and the remainder were seen by the
service outside our recruitment phase. It is not possible to draw a conclusion about the reach of our study
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from this audit but it suggests that pain management services may see only small numbers of patients who
may benefit from FJIs.
Screening and recruitment participants
The study plan was to recruit 150 participants in a 6-month recruitment period. It was calculated that each
site would recruit around 30 patients. Recruitment was planned to be primarily from pain clinic services,
which was an approach that was congruent with the commissioning brief. As noted at the beginning of this
chapter, recruitment started on 26 June 2015 and was terminated by the funder on 11 December 2015
when only 320 patients had been approached, which had resulted in the 26 patients who were randomised.
In the following sections we look at the recruitment process in more detail.
Screening for eligible patients
The research team had planned for the site teams to identify patients who were referred with back pain
from referral letters and to send a screening letter to these patients. This proved to be more complex than
originally thought. Numbers of referrals at sites were not at the level originally expected and site teams
were finding that it was impractical to mass-mail all referrals, as this was a very labour-intensive task. Most
site teams adopted a pre-screening process to try to ensure that letters went out only to potentially eligible
participants, but even this process proved difficult and time-consuming, requiring time that the site staff
did not have. Hence not as many letters were sent out from sites as we would have expected. Three sites
adopted the pre-screening approach, one site chose to approach patients when they attended the clinic
and one site used both approaches (see Table 30). Although the numbers are small, the data suggest that
the face-to-face approach resulted in a higher proportion of the people who were approached being
recruited. The delays in gaining approvals also had an impact on the screening and selection process.
Similar to the study team, sites were expecting study activities to take place on or near a particular time.
Sites planned and provisioned for this, with staff in place. Delays proved costly, as recruiting and screening
staff were either no longer available or on sick or holiday leave by the time we were ready to begin
recruitment.
During group interviews, staff said that they found it straightforward to identify patients in the clinic and
that patients appreciated this type of approach. Staff who identified potential participants through referral
letters found that this was a difficult task. Referral letters (e.g. GP referral letters) were often either very
specific, such as requesting a particular treatment, or non-specific when the reason for referral was
unclear. Thus, staff found it hard to identify patients who had been referred for treatment of back pain.
Patient expectation of receiving facet joint injection
The expectation of receiving a FJI was identified by the site teams as a barrier to recruitment. Our study
protocol excluded patients who had previously received FJIs (or any injection in the back). Site staff
reported that some patients excluded themselves because they specifically wanted a FJI as they knew of
others who had received this treatment. Others had been referred to the service by their GP because the
service was known to provide FJIs. Of the five sites that recruited to the study, three were commissioned to
provide injections, although NICE guidance,6 which was current at the time of the study, did not support
this approach for those patients with LBP present for < 1 year. Study site staff reported that the name of
the study and its logo showing an injection going into the spine raised expectations with patients that they
were going to get an injection. The patient who withdrew from interview and from the study cited the fact
that they wanted the injection treatment but had been randomised to the control. None of the patients
who were interviewed said that they expected an injection but talked more generally about wanting to be
rid of their back pain:
. . . I thought to myself at the time was whatever you offered me, if it took away some of the pain,
I would have done anything.
#1
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Well I just thought if I had this injection I might not have to take tramadol.
#2
I don’t know, I was hoping it would get rid of my back [pain], that’s all.
#3
I was hoping for that I would get a vast improvement, or a lot better than what I was . . .
#4
Anything! Anything at all, I knew it wouldn’t make it worse and I’d got nothing to lose.
#5
It is unclear the extent to which the expectation of injection impacted on patient decisions to engage or
not engage with the study, as we have no data from non-recruited patients.
Additional recruitment approaches
Positive discussions were held in three sites with orthopaedic teams about recruiting to the study, but this
was not initiated prior to study closure.
Study site staff suggested recruiting from primary care, as many of those attending a pain service were
patients who had undergone procedures before and were likely to be ineligible for the trial. We sought
approval to put up posters in community physiotherapy departments and GP surgeries in the locality of our
local study site. This commenced approximately 3 weeks prior to study closure. The local site staff noted
that the posters were generating enquires, but there was no indication of numbers.
Eligibility assessment and consent
Physiotherapists reported that our manual and training had prepared them well for undertaking the
eligibility assessment, which was a set of specific tasks that all patients were to attempt. One physiotherapist
reported a reluctance to put patients through this number of tests, particularly if they were elderly and frail.
Another described the tests as necessary and appropriate and stated that they were not too onerous on the
patient; this physiotherapist had specialised in back care for many years. One physiotherapist commented
that our manual and training had led them to change their clinical practice.
Initially, study site staff had expressed fears about the amount of paperwork required for the study, but
in practice they found completing the paperwork to be straightforward. No site team reported problems
with the study processes or paperwork. The laminated guides were useful when undertaking tasks such as
explaining the text messaging and diaries to patients. All of the teams found the consent and trial registration
process straightforward. Initially, there had been concerns about the number of tasks to be done with patients
after registration: explaining the collection of pain scores by text, providing paper diaries as an alternative,
asking patients to complete the EQ-5D diaries and completion of the baseline questionnaire. Most staff felt
that they found these tasks straightforward once they had become accustomed to them. All sites noted that
time to complete these tasks varied from < 30 minutes to nearly 1 hour, with some patients requiring more
time and support than others.
Four out of the five interviewees used the text messaging service to report their pain score and reported
no problems. The fifth interviewee used the paper version to report their daily pain score. No interviewee
reported problems with completing the pain diaries. The key themes that emerged from the participant
interviews about how they made their decision were mainly in terms of their own appraisal of what they
could physically do and, to a lesser extent, how they perceived that they were feeling:
What I couldn’t do . . . what it stopped me doing, like what I used to be able to do?
#1
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But some days I really think about what I’m doing and how I feel down sometimes with it and that
would sort of affect how I was scoring things.
#2
It’s very difficult to put into words really sometimes, never mind on a bit of paper on numbers! I
looked at that paper many a time and I was thinking ‘well they’re numbers, how do you gauge, at this
minute what number you’re at?’ It’s alright when it’s at the most, you can ‘oh right, yeah, it’s nine, it’s
ten or whatever’ but then when it comes down but it never goes away, it’s difficult to rate it.
#3
I think I worried that I was thinking sometimes it was quite . . . it was quite good, you know, if things
had gone well that day for me and then other days they hadn’t.
#4
How I’d felt on the previous day and what I’d put on the previous day from that and that and it was
the things that I could do . . .
#5
When asked about the frequency of completing these scores, interviewees had no concerns. One found
score completion to be a tedious task, but another said that they missed sending the scores once the
trial ended:
If you weren’t in a lot of pain, you think ‘well it is there, it does ache, it hasn’t gone away’ . . . yeah,
it was a little bit tedious at times near the end when I wasn’t in drastic pain.
#1
Oh no, no, I felt quite lost when I finished actually! I was looking for it thinking, ‘where’s it gone,
where’s my bits of paper?’.
#2
Interviewees expressed no concerns about completing the EQ-5D. One participant said it helped them to
reflect on how they had improved:
You know, it made you think about yourself. Yeah, that was okay and then I could see as I was
coming out it, literally as I was feeling better, I could sort of look back and think ‘yeah, I do feel better
than what I did, I do feel the improvements’.
#1
Patients generally found the baseline questionnaires a bit repetitive:
I did feel that some of the questions were repeating themselves but I know that the questions would
have been set for a reason so I just had to try and read each question on its own, without thinking
‘oh I’ve just answered something like this’.
#5
First best usual-care session: assessment and randomisation
The physiotherapists who delivered these sessions appreciated the longer than normal time that they had
with the patient. Most said that they were able to carry out a full assessment of the patient and develop a
personalised treatment plan as outlined in our manual. All said that the training manual and support were
excellent. Staff at sites that received training many months before recruitment found that they needed to
revisit this material before starting. Randomisation took place after this first assessment session. All staff
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spoken to reported that the assessment and randomisation processes were straightforward. Four of the
patient interviewees reported no problems with the assessment processes:
Now I found that gradually, beginning to talk to the lady and her giving me the courses of exercises
to do and I actually said to her – because we had nice conversations which I found in general quite
helpful because the one question she said to me, ‘what do you for relaxation?’ and I laughed, I said
‘work’. She said ‘don’t you have any hobbies?’, I said, ‘no, I work’, and she said, really kindly she said,
‘I think it’s time you took time for you, like to do something that you like to do’. And that’s when
we discussed about the exercises, my hobby used to be going to the gym, riding my bike, going
swimming, you know?
#1
I mean she was very, very good, she sat down and asked me what sorts of things I was looking to get
on with and how far ahead did I want to go and what sort of things I was looking forward to. But I
mean we went through quite a bit together, yes, it was very good.
#4
One felt that the BUC was ‘basic’:
I found the physiotherapy appointment strange in all honesty. After I’d had a full assessment [from the
lead physiotherapist], who’d gone into quite detail about where my problems are with my back and
what it could be [during eligibility assessment], but then physiotherapy was very much ‘how have you
been today’, ‘where’s the pain’ . . . it was very basic.
#5
Delivery of the interventions to recruited patients
Facet injection procedure
Four out of the five clinicians who were ‘injectors’ in this study were interviewed, and the research nurse
who attended the injections at the fifth site commented on the process during group interviews. Staff
from all sites stated that there were no problems with the procedure and that the study instructions and
material were easy to follow. One clinician noted that because of their site’s late start in the study they
had not given anyone an injection, but they felt that, if patients at the site had been entered into the
study, good systems were in place.
Best usual-care package (five sessions per patient)
Physiotherapists at all of the sites reported that these sessions were straightforward to deliver and that the
materials provided by the study team were useful. The physiotherapists were positive about the package
but several reported that they were less confident with the psychological components than with the
physical components. They felt that they needed a little more training in these areas.
A number of the sites reported that they had patients who did not attend organised sessions. The first
session (pre randomisation) was attended by all 26 patients. All patients were offered five follow-up
sessions and over half attended all five sessions, three attended no follow-up and one of these had
withdrawn from the study (Table 31). Study site staff suggested that some patients expected to have an
injection and when they were not randomised to receive this they chose not to attend. At one site the
availability of car parking was cited as a possible barrier to attendance.
The physiotherapists, when asked, were of the opinion that if participants completed all of the therapy
sessions then they benefited from the treatment package.
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All interviewees attended all of their sessions. Most interviewees liked the physiotherapy sessions and
reported benefits. One, however, felt that it was strange that the session was not more ‘hands on’:
From start to finish and I think to myself ‘well if I’ve got no pain today, there’s no reason why if I carry
on doing this, that I shouldn’t have less pain, regularly, as long as I keep doing what I was, you know,
shown what to do . . .‘ So therefore it’s taught me to give myself time to unwind, you know, to let
myself relax, you know, to make myself more comfortable rather than . . . I’m more conscious of my
body, let me put it that way. If I think ‘oh that aches’, well why does it ache and you do a couple of
breathing sessions and you think ‘well that’s alright, it’s gone now’. You’ve just got too uptight if
you’ve been too stressed over something.
#1
Yes, yes, I’m not doing all of them but I am doing the ones that I felt were more beneficial. When I
get up on the mornings sometimes I think ‘my back is really sore’ and then I do some of these
exercises and I can move around alright, I feel better for it. So I’ve found what works for me and
what doesn’t.
#2
Well I went before all this [outside of the study], she was hands on but this one wasn’t, she was just
exercising, she didn’t touch me at all on my back . . . It just was exercising, I could do most of them
but they gave me these bands and they’re so strong I just didn’t do them so I just did the bottles –
I still exercise, I do the bottles every day and all the bending and everything else, you know?
#3
Yes, I still use them, I’ve even got myself an exercise bike which I have a go on now and again.
#4
I found the physiotherapy appointment strange in all honesty. After I’d had a full assessment from the
nurse, Steve [Surname], who’d gone into quite detail about where my problems are with my back and
what it could be, but then physiotherapy was very much ‘how have you been today’, ‘where’s the
pain’ . . . it was very basic.
#5
Intervention delivery: paperwork
In general, it was felt that the paperwork was well organised and fairly simple to complete. Two
physiotherapists noted that the CRF was at times difficult to follow when completing the assessments, as
statements seemed contradictory or were not in the order outlined in the manual. Support provided over
the telephone was helpful. One of the lead physiotherapists who had no significant research nurse support
found the paperwork burdensome.
TABLE 31 Best usual-care session attendances
BUC sessions n
First BUC session 26
Plus ≥ 1 follow-up session 23
Plus ≥ 2 follow-up sessions 22
Plus ≥ 3 follow-up sessions 18
Plus ≥ 4 follow-up sessions 16
Plus 5 follow-up sessions 15
No follow-up sessions attended 3
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Process evaluation strengths and weaknesses
The process evaluation provided us with insights about implementing this complex study within the NHS.
Engagement with the clinical teams throughout the study allowed us to collect qualitative data about the
study while they were fresh to those involved with the study. Study teams were willing to share positives
and negatives about the study.
Our recruitment of participants to interview was disappointing and reflects the low and slow recruitment
rate to the study. We have used the interview data from study participants cautiously to avoid overclaiming
from this very small data set.
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Chapter 6 Discussion
This was a feasibility study. Our overall aim was to explore the feasibility of running a RCT to test thehypothesis that, for people with suspected facet joint pain contributing to persistent LBP, adding the
option of FJIs, with local anaesthetic and corticosteroids, to best usual non-invasive care available from
the NHS is clinically effective and cost-effective.
The results of this feasibility study are both encouraging and disappointing. At the start of the project we
set ourselves eight specific objectives and it is very pleasing to report that we were successful in achieving
most of these. However, the recruitment of participants to the study through pain clinics was not at the
level that had been expected and we failed to recruit to an acceptable level within the planned timeline.
This in itself, although disappointing, is an important outcome from a feasibility study.
To develop, and evaluate, agreed criteria for identifying people
with suspected facet joint pain
A major success of this project was to achieve consensus from a multidisciplinary group on a clinical
assessment to identify people with suspected facet joint pain (Box 10). The absence of such criteria has
been a major barrier to performing research in this area. We have some preliminary validation from within
this study. Although the numbers providing immediate data in the injection arm of the study were small,
most reported a substantial level of immediate pain relief. Seven (58%) report a > 50% reduction on
pain, which is congruent with the benchmark of 62% used in our original proposal. Although far from
conclusive, these data suggest that facet joint problems may be making a contribution to the pain
affecting our participants, that is, we have the correct population group that might be considered for
intra-articular FJIs within the NHS. However, it is not possible in this study to isolate the effect of local
anaesthetic from the placebo effect of having spinal injections. Future work could validate these criteria
for suspected facet joint pain against the results of double-blind diagnostic medial branch blocks or
intra-articular injections with local anaesthetic.119 Nevertheless, our criteria have been cited in the 2016
NICE guidance on LBP and sciatica to identify people who should be considered for a diagnostic medial
BOX 10 Clinical assessment for suspected facet joint pain
l Increased pain unilaterally or bilaterally on lumbar paraspinal palpation.
l Increased back pain on one or more of the following:
¢ extension (more than flexion)
¢ rotation
¢ extension/side flexion
¢ extension/rotation.
AND
l No radicular symptoms.
AND
l No sacroiliac joint pain elicited using provocation tests.
Based on consensus.26
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branch block prior to radiofrequency denervation.11 This approach is a stand-alone output from
this project.
To develop an agreed protocol for the injection of facet joints
in a consistent manner
Failure to adequately define the intervention is a recurring criticism of interventional studies for LBP.152
There was some variation in the detail of what we originally proposed and the final protocol. This protocol
was acceptable to our clinical leads and has been satisfactorily implemented across several sites, although
with a limited number of participants. There is evidence from our process data that clinicians are using
their clinical assessment to decide on the numbers and levels of joints to inject. Pragmatically, this reflects
what is likely to happen in clinical practice and represents an intervention that we can test in a main study.
One concern for the conduct of the main study is that sites were unable to record radiation exposure in a
consistent manner. This will need addressing for any main study to ensure that the potential risk from
radiation exposure during the injections can be quantified. Radiation exposure during screening for FJIs is,
however, part of normal clinical practice. We have no concerns that this poor recording indicates that any
patients may have been put at unnecessary risk. Nevertheless, for any main trial these data will be needed
to allow us to model any long-term consequences from low-level radiation exposure during FJIs.
We now have an agreed injection procedure to use in the main trial.
To develop, and evaluate, a standardised control treatment deliverable
in the NHS and congruent with 2009 National Institute for Health and
Care Excellence guidance (best usual care)
We have successfully developed a package of care using a multimodal approach for people with suspected
facet joint pain. This approach has been endorsed by the multidisciplinary group at our consensus meeting.
We have successfully implemented this. The overall approach was acceptable to participants, with 81%
attending four sessions and 58% attending all six sessions. Our process data indicate that the components
of the care package were delivered, and that the physiotherapists found them to be straightforward to
deliver and were generally positive. Unsurprisingly, they were less confident about the psychological
components than about the physical components. There may need to be more focus on this aspect in
training for any future use of the programme. Interview data with study participants were largely supportive
of the approach used in the BUC package.
We have developed a manualised package of BUC for people with suspected facet joint pain that is deliverable
in the NHS. It has not been formally tested against alternative conservative approaches. Nevertheless, the
rigour of its development means that clinicians may wish to adopt this approach in preference to other less
structured approaches. There is the potential for this package to be assessed in a RCT against an alternative
treatment package, or no treatment, in this population of people with LBP. The package is ready to deliver as
the control arm in a future main trial. This package is a stand-alone outcome from this project, although it
should be noted that we have developed a one-to-one package, whereas 2009 NICE back pain guidelines
favour group interventions.
To develop and test systems for collecting short-term and long-term pain
outcomes, including measures required for economic evaluation
Here, we focus on the developmental aspects of outcome assessment.
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Early pain outcomes
Short-term benefits and harms from interventional procedures are important to capture. The conventional
approach of using postal questionnaires for which outcomes are often not collected until 1 or 3 months
after randomisation will not capture these. It may be that, even if there is little difference in long-term
outcomes, the short-term benefits mean that FJIs are worthwhile. Our original intention had been to
collect these using text messaging only. It became clear as the project developed that we also needed to
offer a paper alternative. Indeed, the age range of our participants, up to 80 years, suggests that using
text messaging alone might have meant that we missed useful information. Although there were missing
data in both text and paper versions of daily/weekly pain scores, we obtained sufficient data to have
useable outcome data on the pattern of pain over the first 3 months following randomisation of 23 out of
26 (88%) participants. This is an important development.
Patient Generated Index
The revised PGI was correctly completed by all baseline questionnaire respondents, although these
constituted a small cohort. This compares favourably with completion rates in another study that applied
the revised format in a LBP population (89% completion)113 and with the original format that was
completed in a LBP population (68% completion).136
A Norwegian translation of the revised PGI has recently been completed by LBP participants in a
longitudinal postal survey.113 Participants listed more than 380 areas in stage 1; the most frequently
reported were pain (65%), sleep (47%), stiffness (34%), socialising (34%) and housework (33%).
We found that the impact of LBP on an individual’s ability to walk and sleep were the most frequently
reported areas of concern, at 52% and 48%, respectively. In the Norwegian study,113 sleep disturbance
was identified as the second most frequent area of concern at 48% after pain, at 65%; however, only
24% of our participants identified pain as an important symptom. Fatigue is increasingly recognised as an
important symptom across many chronic, long-term and rheumatological conditions.153,154 We found that
20% identified fatigue as a concern. Neither sleep nor fatigue is part of the RMDQ.83 The Oswestry
Disability Index155 includes sleep but not fatigue. Comparisons between the areas of concern identified
within these two aforementioned studies of the PGI and the domains within leading back pain in specific
outcome measures indicate discrepancies between what participants consider to be important and the
items we are measuring in our trials. A systematic review of qualitative studies has also identified that
current outcome measures may not be adequately capturing the social component of the impact of LBP.156
Although the numbers in our study are limited, people appear to have been able to complete the adapted
follow-up PGI score satisfactorily. The results show the expected improvement over time. This was also the
experience in the Norwegian study.113 Overall, our preliminary data indicate that it would be worthwhile
exploring further the performance of the PGI as an outcome measure in back pain trials.
Health economic outcomes
There are two components ensuring that we have satisfactory health economic outcomes: costs and
outcomes. We have produced detailed micro-costing of both the BUC and the injection treatments that
reflect the true cost of delivery.
Our overall micro-costing of £419.22 per injection compares with a NHS tariff cost for FJIs of £686.84
(National Reference Costs 2014/15148 – main schedule, currency code AB16Z). What is not included here is
cost of the initial consultant appointment (£144.79, National Reference Costs 2014/15148) at which a
decision to offer FJIs is made.
Although the number of completed follow-up questionnaires is limited, we have been able to satisfactorily
estimate NHS and personal health-care costs from our participants.
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An important concern at the start of the study was how to capture short-term benefits and harms. We
described earlier the process for collecting and analysing pain data. We also wanted overall health utility
data to assess how these early changes might impact on cost-effectiveness. For these, we sought to
collect data weekly throughout follow-up rather than the early data we used for pain. This was to reduce
questionnaire burden. We had originally planned to collect these electronically, but the only licensed
versions of the EQ-5D were not suitable for use when linked to smartphones, which would have allowed a
seamless collection of data on pain and the EQ-5D. For this reason, the pain score was completed as
weekly diaries. Participants found these difficult to complete fully and we received only 13 fully completed
sets of data. These limited data show a very interesting pattern, with a marked short-term increase in
health utility soon after joining the study (see Figure 7). At the end of 3 months, the diary data are similar
to the data collected in the final postal questionnaire. There is a clinically important difference in QALYs
accruing over this time according to the two collection methods of 0.029 (standard error 0.01). This
provides us with a challenge for the main study, as there are potentially important short-term effects that
should be captured in the main trial for which we do not have an approach to data collection that yields
data on enough participants.
In developing our main trial proposal, we will develop a decision-analytic model to simulate the clinical
pathway of patients with LBP within the UK NHS and over the lifetime of the individual. The model
parameters for prevalence of LBP in the target population, health outcomes (in QALYs) and health-care
utilisation and associated costs will be informed by results of the FIS feasibility study and systematic review
of the relevant literature. Bayesian evidence synthesis methods will be used to derive distributions for
model parameters based on all available information. The model will be used to estimate the expected
value of sample information of a trial of the protocolised intervention and management plan, using
algorithms developed by Madan et al.157 and Strong et al.158 The expected value of sample information
calculations will be performed for alternative study designs to determine the optimal design in terms of
factors such as sample size, length of follow-up and study population.
To demonstrate that recruitment to the main trial is feasible
That we did not achieve our recruitment target within the lifetime of the study was disappointing. The
randomised pilot faced some substantial challenges, not least that, congruent with the commissioning brief,
recruitment was planned to be primarily from pain clinic or orthopaedic services. Although initially this seemed
to be a good idea, it soon became apparent that patients fitting our criteria were sparse in these areas.
Study site staff were comfortable with face-to-face recruitment. Screening referral letters proved to be more
problematic than expected. Identifying those referred for treatment of non-specific LBP from referral letters
proved to be very problematic. A further unexpected problem was that many of those who were identified
as being referred because of non-specific LBP had had previous spinal injections, meaning that they were not
eligible to be invited to take part in the study. This may reflect our decision to mainly use sites with an active
programme of FJIs. We made this decision in the expectation that this would make delivery of the study
interventions easier. In fact, perversely, it may have meant that many potential participants were excluded.
The research and site teams discussed this problem at length, trying to identify at which point in the patient
journey it would be appropriate to capture the patients who could benefit the most from our treatments.
A number of solutions were put forward, including recruiting through physiotherapy services, primary care
and/or through orthopaedic clinics, as suggested in the brief but not operationalised in this study.
We also note that delays in getting approvals made it difficult to maintain momentum at sites, and staff who
were prepared to start on or around the planned start date were often not available because of the delay.
There was no culture of applied research within most of the clinics in which we were working, there was
little history of the pain clinics working collaboratively with the physiotherapy services and there were some
anxieties on the part of some staff as to how the study would run. At one site, staff illness essentially
prevented any recruitment.
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A further unexpected problem was our approach to the naming and marketing of the study. The working
title of ‘Facet Injection Study’ and the use of a trial logo with an image of an injection appears to have led
to people interpreting this to be a study of FJIs rather than a study of adding FJI to best conservative
treatment and to not have understood the nature of the randomisation and our overall aim.
Notwithstanding all of these issues, at the time the study was closed a number of barriers to recruitment
had been identified. Our initial sites were all actively recruiting: one site had just started recruiting and a
final site had just obtained all the relevant approvals. We had made changes to recruitment processes so
that we could recruit from physiotherapy departments, from orthopaedic clinics and take referrals to the
study directly from primary care. At the time the study closed, we had established a very good flow of
referrals into the study. There were 28 patients who were awaiting initial assessments for study entry.
Thus, having identified barriers to recruitment, we had addressed these and we have some evidence that
we could recruit satisfactorily to the main study.
To collect the recruitment and outcome data required to inform
sample size and number of sites needed for the main study
We have obtained sufficient baseline data to inform development of a sample size estimate for the main
trial. Our data on recruitment indicate that we need a different approach to participant identification.
Notwithstanding the 47 potential participants who were pending, at different stages of the recruitment
process, at the time of closure we randomised 8% of those approached. Allowing for just five of the
47 potential participants to eventually have been randomised, our conversion rate from initial approach to
randomisation would have been 10%. This is a good conversion rate for a study of this nature, which
gives us confidence that we can recruit to a main study. In calculating the number of sites for the main
study, we will use throughput of physiotherapy back pain services in interested localities to estimate
number of sites needed.
Drawing on our work on defining the MID for this study and our baseline data, we can estimate the
sample size needed (Table 32). Here we have estimated sample size needed for 90% power and 5% or
2.5% significance. If any future study has two primary outcomes, for example AUC for pain over 3 months
and back pain disability at 3 months, we may need to make a formal correction for multiple comparisons.
In each case, we have looked for sample size needed for either a 0.5 or 1.0 MID unit difference for which
this is expressed in natural units and for a 30% difference in baseline score.
For the AUC analysis we have set our MID to be 84% of the values we arrived at for a Pain-NRS/visual
analogue score MIC, that is, 2 × 0.84. This reflects that the data are collected over 84 days, meaning that
the maximum AUC (a pain score of 10 on every occasion) cannot exceed 0.84 and that the AUC, similar to
a visual analogue score, allows for a full range of values between 0 and 10. Thus, we consider that the
smaller MIC suggested for a visual analogue score is the appropriate benchmark.87 MIDs and changes for
the AUC in this context have not, however, been formally established.
We suggest that a definitive study should aim to recruit 275 participants. Allowing for a maximum of 20%
loss to follow-up, data on 220 participants will have 90% power at the 2.5% significance level to show a
15% difference in the AUC and a 2.5-point difference on the RMDQ at 3 months. If there are no positive
effects at 3 months, then long-term benefits are unlikely, making clinical outcomes up to 3 months
appropriate for the primary analysis. One-year follow-up will still be needed for health economic analyses
and to identify any long-term benefits if there is a positive result at 3 months. We are aware that for the
RMDQ we are suggesting the use of absolute difference and for the AUC the use of a percentage
difference to define the sample size. Using a percentage difference approach to setting the MID difference
for the RMDQ would require a doubling of sample size. We do not think this can be justified when we
expect that the primary mode of action is through the reduction of pain. However, as the AUC approach
to assessment of short-term pain has not been established as an outcome measure in back pain trials,
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we are not suggesting that only pain measurements should be used as a primary outcome. For this reason,
we consider it important to include an established measure of back pain disability as a second primary
outcome.
Based on an assumption that 500 people annually will be seen in a physiotherapy service with continuing
pain after treatment and that 10% of these will choose to join the study, six sites should be sufficient for
recruitment. At each site, physiotherapy referral can be supplemented by referral from other secondary
care services and from direct GP referral to the trial.
To conduct a between-group analysis to inform the decision on the need
for a full trial
We were unable to achieve this objective because of the closure of the trial.
To carry out a process evaluation of patient experience within the trial
We have satisfactorily completed a formative process evaluation. Data were limited by small numbers in
the study. Nevertheless, we have gained some important insights into how the trial ran in our sites and
identified some key areas to address in order to ensure any main trial recruits in a timely manner.
TABLE 32 Sample size estimates
MIC Parameters
Effect size (MID unit)
Significance (%)
Sample sizea (MID unit)
0.5 1.0 0.5 1.0
RMDQ
30% Baseline 11.5, 3/12 SD 5.1 1.725 3.45 5 370 94
2.5 438 112
5 2.5 5 5 176 46
2.5 210 56
Pain-NRS
30% Baseline 7.1, 3/12 SD 2.0 1.07 2.13 5 152 40
2.5 178 46
2 1.0 2.0 5 172 46
2.5 202 52
AUC
30% AUC 454, SD 142 68 136 5 186 46
2.5 218 58
168 84 168 5 124 34
2.5 146 38
a Power = 90%, two equal-sized groups.
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Strengths and weaknesses
Many of the key uncertainties that needed to be addressed before running the main trial have been
considered. We have also demonstrated in the randomised pilot that eligible patients who are invited
to join the study are interested in the study and can comply with the study procedures. We have also
successfully collected a frequent short-term outcome allowing us to identify any relevant short-term harms
and benefits.
That we have achieved consensus on describing our population of interest and our control and active
interventions is a real strength of this project. Furthermore, we have demonstrated that participants are able
to comply with the recruitment process for the study and provide initial data for us to assess our non-standard
approaches to clinical data collection: the PGI. Interestingly, the SD of the AUC as an outcome is quite small
compared with the plausible reduction in pain over 3 months that might be considered clinically worthwhile.
This means that by using this as a primary outcome for a future study a smaller overall study size may be
possible and that any short-term benefits or harms for intervention will be captured.
Study procedures and paperwork require only minor improvements but the title of the study needs to be
reconsidered to avoid raising patient expectations of receiving an injection. In a future trial, additional
training may be needed for physiotherapists in the psychological treatment approaches.
In undertaking this process evaluation we aimed to identify aspects of the study design that have potential
to threaten the success of a full trial. Although our data were limited in their scope, particularly from
patients, we would argue that it was sufficient to identify major threats.
The key weakness of this study was failure to achieve our expected recruitment targets and the consequent
early closure by the funder. There had been very substantial organisational barriers to the set-up of the
trials. Long delays, outside our control, in receiving governance approvals giving us the green light to start
recruitment at our first site meant that adequate recruitment would be a challenge. Although the funding
brief specified that recruitment should be sought from pain clinics, it became apparent in the course of this
study that this was insufficient. The people attending these clinics were, on the whole, less likely to be
suitable for the study than those who had not yet been referred. There were also substantial operational
issues with the clinics, which were unfamiliar with recruiting to RCTs, meaning that the start of recruitment,
even after approvals had been obtained, was delayed. Although not drawn out in the process evaluation,
our impression was that clinical staff were reluctant to start recruitment because of uncertainty as to how
patients might feel about the study. Once sites had started recruitment, there seemed to be less concern.
At our best recruiting site, all recruitment stopped for several months because staff were either no longer
available or on sick leave and there was, as a result, lack of capacity on the part of the comprehensive
research network. At the time the study was terminated, we had established a good recruitment flow that
was starting to feed into an increased randomisation rate.
Is a main study still needed?
It has been argued that the question of the effectiveness of intra-articular FJIs may not be important, as
this approach has been superseded by radiofrequency denervation of the medial branch of relevant lumbar
nerves. The 2016 NICE guidance recommends radiofrequency denervation in selected patients who have
had a positive diagnostic block. Their conclusions do not agree with the most recent Cochrane review
of radiofrequency denervation.159 Our view is that neither the NICE nor the Cochrane meta-analysis on
radiofrequency denervation are robust because of the poor quality of the underpinning data. There is an
economic model in 2016 NICE back pain and sciatica guidance suggesting that radiofrequency denervation
is cost-effective with a cost per QALY of £11,178. The cost of a diagnostic block and radiofrequency used
by NICE were £521 and £640, respectively, based on Healthcare Resource Group codes AB05Z and AB08Z.
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This compares with a cost of £420 that we have calculated for delivery of FJIs. Thus, intra-articular FJIs are
substantially cheaper than radiofrequency denervation.
A Dutch RCT of radiofrequency denervation has now been carried out but, at the time of writing, the
findings are available only as a conference abstract.160 These data were not available to the 2016 NICE
guideline development group. This study, which is substantially larger than previous studies, did not
show a benefit from radiofrequency denervation, and there was a very low probability that it would be a
cost-effective intervention at any willingness to pay. A smaller Egyptian trial, the results of which were
published immediately prior to the publication of NICE guidance, found that radiofrequency denervation in
people with proven facet joint pain was more beneficial than a sham procedure.161
Intra-articular FJIs remain a treatment option for suspected facet joint pain that has not been adequately
assessed in RCTs. The NICE guideline development group did not find sufficient evidence to support their
use and our 2016 systematic review did not find data that could support the use of FJIs.60 Their acquisition
costs are, however, substantially lower than those of radiofrequency denervation, and FJIs may represent
good value even if they are less effective than radiofrequency denervation.
There remains a need for robust studies of both the efficacy and the effectiveness of invasive procedures
such as intra-articular FJIs and radiofrequency denervation for people with suspected facet joint pain.
Conclusions
We are cautious here in our overall interpretation of the results of this feasibility study. A feasibility study
can be defined as ‘an assessment of the practicality of a proposed plan or method’ and, in this respect,
this study has been very successful. Study procedures and paperwork require only minor improvements
and the title of the study needs to be reconsidered to avoid raising patient expectation of receiving an
injection. In a future trial, additional training may be needed for physiotherapists in the psychological
treatment approaches. However, we cannot ignore the poor recruitment into the study. The feasibility has
shown us that recruitment from pain clinics alone (undertaken in accordance with the funding brief) is not
sufficient and this is an important finding. In response to the poor recruitment rates, we put considerable
effort into trying to identify the most appropriate places to access our required patient sample. A number
of these were being tested when recruitment was stopped. We have insufficient data to determine if these
recruitment strategies would have been successful, but they were encouraging.
The evidence still shows the need for a RCT of intra-articular FJIs for patients with suspected facet joint
pain when added to a package of best usual conservative care. Here, we provide a solid methodology for
screening, assessment and monitoring as well as an agreed package of conservative care. We also provide
valuable information about recruitment to such a trial. We therefore suggest that a full trial with an in-built
pilot study to test recruitment is feasible.
Recommendations for research
A definitive trial of adding intra-articular FJIs to BUC for people with suspected facet joint pain that is not
resolving after conservative treatment.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
Acknowledgements
We would like to acknowledge and thank all of the people involved in all aspects of the FIS.
Trial Management Group
Martin Underwood (Chief Investigator).
Hugh Antrobus (Co-applicant and PI).
Frances Griffiths (Professor of Medicine in Society).
Nigel Stallard (Co-applicant and Statistician).
Stavros Petrou (Co-applicant and Health Economist).
Charles Hutchinson (Co-applicant and Professor of Clinical Imaging).
Melinda Cairns (Co-applicant and Clinical Research Fellow).
Kirstie Haywood (Co-applicant and Senior Research Fellow).
Harbinder Sandhu (Associate Professor in Health Psychology).
Shyam Balasubramanian (Co-applicant and PI).
David Walsh (Co-applicant and PI).
Alan Bennett (PI).
Sallie Brown (Co-applicant and Lay Member).
Colin Tysall (Co-applicant and Lay Member).
Ranjit Lall (Statistician).
James Griffin (Statistician).
Felix Achana (Health Economist).
David R Ellard (Principal Research Fellow).
Becky Chadwick (Sponsor Representative, Co-applicant and Delivery Manager – Research, Development
and Innovation).
Katie Bruce (Sponsor Representative and Trial Manager).
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
95
Trial Steering Committee
Nefyn Williams (Chairperson).
Obi Ukoumunne.
Sujaan Singh.
Nadine Foster.
Bronek Boszcyzk.
Deb Smith.
Owen Bodycombe.
Data management and administrative support
Sarah Lowe (Trial Co-ordinator).
Sukhdeep Dosanjh (Senior Project Manager).
Suzanne Keohane (Senior Project Manager).
Constance Jacobs (Data Clerk).
Penny Cox (Data Clerk).
Craig Turner (Trial Administrator).
Kate Packard (Trial Administrator).
Hayley Johnson (Trial Administrator).
Cheryl Ritchie (Research Facilitator).
Paul Beeby (Management Accountant).
Janice Denham (Senior Finance Assistant).
Danny Wesley (Finance Assistant).
Paul Lindford (Senior Research Finance Assistant).
Claire Daffern (Quality Assurance Manager).
Natalie Strickland (Clinical Trials Unit Manager).
Sarah Duggan (Clinical Trials Unit Manager).
Sonia Davies (Trial Co-ordinator).
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
Kerry Barkan (Administration Support).
Morna Wood (Transcriber).
Adrian Willis (Senior Programmer).
Henry Adjei (Programmer).
Emmanuel Oluwaseun (Programmer).
Rebecca Silver (Assistant Research Contracts/Funding Officer).
Phil Ryan (Contracts Officer).
Erika Wright (Research Funding Officer).
Debbie Ranger (Head of Governance and Quality).
Graham Hewitt (Programme Quality Manager).
Emily Dight (Research and Ethics Governance Administrator).
Jane Prewitt (Lead Sponsor and Deputy Director).
Ceri Jones (Cosponsor and Head of Research, Development and Innovation).
Navdeep Bains (Head of Research Support Funding and Contracts).
Sonia Kandola (Research Governance Specialist).
Randomisation Service (Warwick CTU Randomisation Team).
Jonathan Dove (Community Physiotherapist, Coventry and Warwickshire NHS Trust).
Tom Mars (Research Fellow, University of Warwick).
Melina Dritsaki (Research Fellow, Health Economist, University of Warwick).
Research team
University Hospitals Coventry and Warwickshire NHS Trust
Shyam Balasubramanian (PI and Injector).
Davina Hewitt (Research Nurse).
Nicolas Aldridge (Research Nurse).
Sarah O’Toole (Research Nurse).
Stefanie Gwynne (Administrator).
Janet King (Administrator).
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
97
Jo Freelove (Diagnostic Assessor).
Tim Rhodes Jones (Treating Physiotherapist).
Lizzie Fort (Treating Physiotherapist).
Lois Burton (Treating Physiotherapist).
Allan Jackson (Treating Physiotherapist).
Atique Rehman (Treating Physiotherapist).
Mojid Khan (Lead Pharmacist).
Worcestershire Acute Hospitals NHS Trust
Alan Bennett (PI and Injector).
Julie Wollaston (Research Nurse).
Terry Martin (Research Nurse).
Sharon Williams (Research Sister).
Janice Gastinger (Diagnostic Assessor).
Vicky Chapman (Diagnostic Assessor).
Dianne Spalding (Treating Physiotherapist).
Judith Jehring (Treating Physiotherapist).
Ann White (Lead Pharmacist).
Sherwood Forest Hospitals NHS Foundation Trust
David Walsh (PI and Diagnostic Assessor).
Bala Veemaraon (Injector).
Yvette Girvan (Research Nurse).
Deborah Wilson (Research Nurse).
Debbie Bottomley (Research Nurse).
Stephen Bliss (Diagnostic Assessor).
Asha Gudibandi (Treating Physiotherapist).
Amanda Buckley (Treating Physiotherapist).
Linda Otter (Lead Pharmacist).
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
South Warwickshire NHS Foundation Trust
Hugh Antrobus (PI and Injector).
Dev Talik (Injector).
Cheryl Ritchie (Research Facilitator).
Suzanne Jones (Diagnostic Assessor).
Roger Wedden (Diagnostic Assessor).
Glynn Alderman (Treating Physiotherapist).
Elizabeth Rourke (Treating Physiotherapist).
Julia Jones (Lead Pharmacist).
South Tees Hospitals NHS Foundation Trust
Sam Eldabe (PI and Injector).
Vicky Phelps (Research Nurse).
Morag Brookes (Research Nurse).
Grace Madzinga (Research Nurse).
Karoline Middleton (Administrator).
Nicolas Harland (Diagnostic Assessor).
Amada Hughes (Diagnostic Assessor).
Victoria Robinson (Diagnostic Assessor).
Crystal Rosser (Treating Physiotherapist).
Richard King (Treating Physiotherapist).
Samantha Cook (Treating Physiotherapist).
Jason Wong (Lead Pharmacist).
The team wish to acknowledge all of those who contributed to the FIS consensus conference
(see tables below).
The team acknowledge the support of the Revalidation and Continuing Professional Development Team at
The Royal College of Anaesthetists for providing continuing professional development points for this event.
We also extend thanks to Warwick conferences for the excellent facilities and refreshments.
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
99
The Facet Injection Study team
Warwick team
Professor Martin Underwood.a
Dr Hugh Antrobus.a
Dr Shyam Balasubramanian.a
Ms Kerry Barkan.
Dr Alan Bennett.
Mrs Sally Brown.a
Dr Melinda Cairns.a
Ms Sonia Davies.
Dr David Ellard.
Professor Frances Griffiths.a
Dr Kirstie Haywood.a
Professor Charles Hutchinson.a
Ms Amy Ismay.
Ms Suzanne Keohane.
Dr Ranjit Lall.
Ms Claudia Lega.
Mr Tom Mars.
Mr Luke Parsons.
Professor Stavros Petrou.a
Dr Rachel Potter.
Ms Sophie Radford.
Ms Marie Reynolds.
Azam Saied.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
Dr Harbinder Sandhu.a
Professor Nigel Stallard.a
Mr Colin Tysall.a
Professor David Walsh.a
Ms Christelle Kennedy.
Mr James Griffin.
The facet joint consensus delegates
Olayinka Agbejule.
Kanar Al-Quragooli.
Hugh Antrobus.
Shyam Balasubramanian.
Keith Bell.
Alan Bennett.
Stephen Bliss.
Sally Brown.
Julian Campbell.
Helen Challinor.
Robin Correa.
Rob Froud.
Janice Gastinger.
David George.
Aditi Ghei.
Dorothy Goodwin.
Jane Griffiths.
Andrew Gunatilleke.
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
101
Julie Hall.
Jing Lee.
Richard Makin.
John O’Hanlon.
Shilpa Patel.
Sarah Paterson.
Helen Richmond.
Cheryl Ritchie.
Nicholas Roberts.
David Rogers.
Audrey Rose.
Yadi Jayran-Nejad.
Louise C Jeynes.
Janet King.
Zbigniew M Kirkor.
Yvonne Krantz.
Karen Le Marchand.
Geoff Rose.
Sujaan Singh.
Eilish Simpson.
Di Spalding.
Bhaskar Tandon.
Madan Thirugnanam.
Justin Turner.
Colin Tysall.
Bala Veemarajan.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
102
Thirunavukkarasu Vishwanathan.
David Walsh.
Rebecca Warren.
Helen Welch.
Lars Williams.
a Denotes co-applicants on the funding proposal.
All reported delegates consented to inclusion.
The team also acknowledges the American Society of Interventional Pain Physicians (Holly Long) for
permission to reproduce material from our consensus conference results paper within our consensus
conference results section.
Finally, the team would like to thank Mosio (www.mosio.com) for providing the text messaging service for
the collection of daily/weekly pain scores from participants, in particular Charlotte Justice, who was our
account manager at Mosio.
This project benefited from facilities funded through Birmingham Science City Translational Medicine
Clinical Research and Infrastructure Trials Platform, with support from Advantage West Midlands.
Contributions of authors
All of the named authors contributed substantially to the development of the research question and study
design, implementation, analysis and/or interpretation of data and submission of the final report.
Particular contributions are as follows.
David R Ellard (Principal Research Fellow, University of Warwick) contributed to the design of the process
evaluation, collected the process evaluation data, undertook the qualitative and quantitative analyses of
the process evaluation and managed and contributed to the writing of the background, methods, results
and discussion sections of this report.
Martin Underwood (Professor of Primary Care Research, University of Warwick) was the lead applicant
and chief investigator for the trial. He made substantial contributions to the overall design of the study, the
statistical analysis plan and the writing of the background, methods, results and discussion sections of
the report.
Felix Achana (Research Fellow, University of Warwick) contributed to the design, conduct, analysis and
writing of the health economic evaluation.
James HL Antrobus (Consultant, Anaesthesia & Pain Medicine, South Warwickshire NHS Foundation
Trust) was a co-applicant and contributed to the design and conduct of the study. In particular, he was
involved with the development of the injection procedure used in this trial. As PI at his trust, within the
pain management service, he provided the injection procedure to participants randomised to this arm.
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
103
Shyam Balasubramanian (Consultant, Anaesthesia & Pain Medicine, University Hospitals Coventry and
Warwickshire NHS Trust) was a co-applicant and contributed to the design and conduct of the study. As PI
at his trust, within the pain management service, he provided the injection procedure to participants
randomised to this arm.
Sally Brown (Lay Representative, University of Warwick) was a co-applicant and provided a much-needed
lay perspective, overseeing and commenting on all aspects of the trial and its documentation.
Melinda Cairns (Postdoctoral Research Fellow, University of Hertfordshire) was a co-applicant and
physiotherapy lead. She contributed to the design and conduct of the study. In particular, she was involved
in bringing together the consensus data and building both the studies diagnostic criteria and ‘BUC’
package.
James Griffin (Research Fellow, University of Warwick) contributed to the statistical analysis plan and
undertook the statistical analyses and their reporting.
Frances Griffiths (Professor of Medicine in Society, University of Warwick) was a co-applicant and made
substantial contributions to the overall design of the study and the writing of the background, methods,
results and discussion sections of the report.
Kirstie Haywood (Senior Research Fellow, University of Warwick) was a co-applicant and contributed to
the overall design of the study, in particular the PROMs, and the writing of the report.
Charles Hutchinson (Professor of Clinical Imaging, University of Warwick) was a co-applicant and
contributed to the overall design of the study and the writing of the report.
Ranjit Lall (Principal Research Fellow, University of Warwick) contributed to the statistical analysis plan,
the design of the study and the writing of the report.
Stavros Petrou (Professor in Health Economics, University of Warwick) was a co-applicant and health
economics lead. He contributed to the health economic analysis plan and commented on the final draft of
the report.
Nigel Stallard (Professor of Medical Statistics, University of Warwick) was a co-applicant, lead trial
statistician and contributed to the statistical analysis plan and writing of the results section of the report.
Colin Tysall (Lay Representative, University of Warwick) was a co-applicant and provided a much-needed
lay perspective overseeing and commenting on all aspects of the trial and its documentation.
David A Walsh (Professor of Rheumatology, University of Nottingham) was a co-applicant and
contributed to the overall design of the study and the writing of the report.
Harbinder Sandhu (Associate Professor, University of Warwick) was a co-applicant and health psychology
lead on the study. She contributed to the design and conduct of the study. In particular, she was involved
in bringing together the consensus data and building the ‘BUC’ package.
Publications
Cairns M. Diagnostic Assessment Manual. University of Warwick, Warwick Medical School, Clinical Trials
Unit; 2014. URL: http://wrap.warwick.ac.uk/78982 (accessed 23 May 2016).
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
104
Cairns M, Sandhu H. Best Usual Care Physical Rehabilitation Combined with Psychology Physiotherapy
Manual. University of Warwick, Warwick Medical School, Clinical Trials Unit; 2014. URL: http://wrap.
warwick.ac.uk/78986 (accessed 23 May 2016).
Underwood M, Antrobus H. Injection Manual. University of Warwick, Warwick Medical School, Clinical
Trials Unit; 2014. URL: http://wrap.warwick.ac.uk/78985 (accessed 23 May 2016).
Underwood M, Antrobus H, Barkan K, Cairns M, Ellard DR, Griffiths F, et al. Facet-Joint Injections for
People with Persistent Non-Specific Low Back Pain (FIS). University of Warwick, Warwick Medical School,
Clinical Trials Unit; 2014. URL: http://wrap.warwick.ac.uk/78978 (accessed 23 May 2016).
Ellard DR, Griffiths F. Facet-joint Injections for People with Persistent Nonspecific Low Back Pain (FIS). University
of Warwick, Warwick Medical School, Clinical Trials Unit; 2015. URL: http://wrap.warwick.ac.uk/78987
(accessed 23 May 2016).
Mars T, Ellard DR, Antrobus JH, Cairns M, Haywood K, Keohane S, et al. Intraarticular facet injections for
low back pain: design considerations, consensus methodology to develop the protocol for a randomized
controlled trial. Pain Physician 2015;18:473–93.
Sandhu H, Ellard DR, Achana F, Antrobus JH, Balasubramanian S, Brown S, et al. Facet-joint injections for
people with persistent non-specific low back pain (FIS): study protocol for a randomised controlled
feasibility trial. Trials 2015;16:588.
Vekaria R, Bhatt R, Ellard DR, Henschke N, Underwood M, Sandhu H. Intra-articular facet joint injections
for low back pain: a systematic review. Eur Spine J 2016;25:1266–81.
Data sharing statement
We shall make data available to the scientific community with as few restrictions as feasible. Requests for
the data should be made to the corresponding author (Professor Martin Underwood).
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
105

References
1. Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C, et al. The global burden of low back pain:
estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73:968–74.
http://dx.doi.org/10.1136/annrheumdis-2013-204428
2. Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain 2000;84:95–103.
https://doi.org/10.1016/S0304-3959(99)00187-6
3. Luo X, Pietrobon R, Sun SX, Liu GG, Hey L. Estimates and patterns of direct health care
expenditures among individuals with back pain in the United States. Spine 2004;29:79–86.
http://dx.doi.org/10.1097/01.BRS.0000105527.13866.0F
4. Deyo RA, Gray DT, Kreuter W, Mirza S, Martin BI. United States trends in lumbar fusion surgery
for degenerative conditions. Spine 2005;30:1441–5. https://doi.org/10.1097/01.brs.0000166503.
37969.8a
5. Manchikanti L, Pampati V, Singh V, Falco FJ. Assessment of the escalating growth of facet joint
interventions in the medicare population in the United States from 2000 to 2011. Pain Physician
2013;16:E365–78.
6. NICE. Low Back Pain: Early Management of Persistent Non-specific Low Back Pain. London:
NICE; 2009. URL: www.nice.org.uk/guidance/cg88/resources/guidance-low-back-pain-pdf
(accessed 2 June 2016).
7. Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, Baisden J, et al. Interventional therapies,
surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice
guideline from the American Pain Society. Spine 2009;34:1066–77.
8. The Pain Society. The NICE Back Pain Issue. The Controversy Discussed. Pain News. 2009.
URL: http://britishpainsociety.org/bps_nl_autumn_2009.pdf (accessed 23 May 2014).
9. Manchikanti L, Abdi S, Atluri S, Benyamin RM, Boswell MV, Buenaventura RM, et al. An update
of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain.
Part II: guidance and recommendations. Pain Physician 2013;16(Suppl. 2):49–283.
10. Manchikanti L, Datta S, Gupta S, Munglani R, Bryce DA, Ward SP, et al. A critical review of the
American Pain Society clinical practice guidelines for interventional techniques: part 2. Therapeutic
interventions. Pain Physician 2010;13:E215–64.
11. NICE. Low Back Pain and Sciatica in Over 16s: Assessment and Management 2016. London:
NICE; 2016. URL www.nice.org.uk/guidance/ng59 (accessed 11 December 2016).
12. Celik B, Er U, Simsek S, Altug T, Bavbek M. Effectiveness of lumbar zygapophysial joint blockage
for low back pain. Turk Neurosurg 2011;21:467–70. http://dx.doi.org/10.5137/1019-5149.
JTN.4057-10.1
13. Fuchs S, Erbe T, Fischer HL, Tibesku CO. Intraarticular hyaluronic acid versus glucocorticoid
injections for nonradicular pain in the lumbar spine. J Vasc Interv Radiol 2005;16:1493–8.
https://doi.org/10.1097/01.RVI.0000175334.60638.3F
14. Manchikanti L, Hirsch JA, Falco FJ, Boswell MV. Management of lumbar zygapophysial (facet)
joint pain. World J Orthop 2016;7:315–37. http://dx.doi.org/10.5312/wjo.v7.i5.315
15. Manchikanti L, Malla Y, Wargo BW, Cash KA, Pampati V, Fellows B. Complications of
fluoroscopically directed facet joint nerve blocks: a prospective evaluation of 7,500 episodes with
43,000 nerve blocks. Pain Physician 2012;15:E143–50.
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
107
16. Manchikanti L, Pampati V, Bakhit CE, Rivera JJ, Beyer CD, Damron KS, Barnhill RC. Effectiveness
of lumbar facet joint nerve blocks in chronic low back pain: a randomized clinical trial. Pain
Physician 2001;4:101–17.
17. Manchikanti L, Singh V, Falco FJ, Cash KA, Pampati V. Lumbar facet joint nerve blocks in
managing chronic facet joint pain: one-year follow-up of a randomized, double-blind controlled
trial: Clinical Trial NCT00355914. Pain Physician 2008;11:121–32.
18. Marks RC, Houston T, Thulbourne T. Facet joint injection and facet nerve block: a randomised
comparison in 86 patients with chronic low back pain. Pain 1992;49:325–8. https://doi.org/
10.1016/0304-3959(92)90239-8
19. Falco FJ, Manchikanti L, Datta S, Sehgal N, Geffert S, Onyewu O, et al. An update of the
systematic assessment of the diagnostic accuracy of lumbar facet joint nerve blocks. Pain
Physician 2012;15:E869–907.
20. Manchikanti L, Singh V, Falco FJ, Cash KA, Fellows B. Comparative outcomes of a 2-year
follow-up of cervical medial branch blocks in management of chronic neck pain: a randomized,
double-blind controlled trial. Pain Physician 2010;13:437–50.
21. Health and Social Care Information Centre. Hospital Episode Statistics, Admitted Patient Care –
England 2016. Leeds: Health and Social Care Information Centre; 2016. URL: www.hscic.gov.uk/
searchcatalogue?q=title%3A%22Hospital+Episode+Statistics%2C+Admitted+patient+care
+-+England%22&area=&size=10&sort=Relevance (accessed 10 June 2016).
22. NIHR Evaluation, Trials and Studies Coordinating Centre. HTA – 11/31/01: Facet Feasibility (FF).
Southampton: National Institute for Health Research; 2015. URL: www.nets.nihr.ac.uk/projects/
hta/113101 (accessed 28 July 2016).
23. NIHR Evaluation, Trials and Studies Coordinating Centre. HTA – 11/31/02: A Multicentre
Double-Blind Randomised Controlled Trial to Assess the Clinical- and Cost-effectiveness of
Facet-Joint Injections in Selected Patients with Non-Specific Low Back Pain: A Feasibility Study.
2015. URL: www.nets.nihr.ac.uk/projects/hta/113102 (accessed 28 July 2016).
24. Hancock M, Herbert RD, Maher CG. A guide to interpretation of studies investigating subgroups
of responders to physical therapy interventions. Phys Ther 2009;89:698–704. http://dx.doi.org/
10.2522/ptj.20080351
25. Patel S, Hee S, Mistry D, Jordan J, Brown S, Dritsaki M, et al. Identifying back pain subgroups:
developing and applying approaches using individual patient data collected within clinical trials.
Programme Grants Appl Res 2016;4(10).
26. Mars T, Ellard DR, Antrobus JH, Cairns M, Underwood M, Haywood K, et al. Intraarticular Facet
injections for low back pain: design considerations, consensus methodology to develop the
protocol for a randomized controlled trial. Pain Physician 2015;18:473–93.
27. Brinjikji W, Luetmer PH, Comstock B, Bresnahan BW, Chen LE, Deyo RA, et al. Systematic
literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR
Am J Neuroradiol 2015;36:811–16. http://dx.doi.org/10.3174/ajnr.A4173
28. Kalichman L, Li L, Kim DH, Guermazi A, Berkin V, O’Donnell CJ, et al. Facet joint osteoarthritis
and low back pain in the community-based population. Spine 2008;33:2560–5. http://dx.doi.org/
10.1097/BRS.0b013e318184ef95
29. van Kleef M, Vanelderen P, Cohen SP, Lataster A, Van Zundert J, Mekhail N. 12. Pain originating
from the lumbar facet joints. Pain Pract 2010;10:459–69. http://dx.doi.org/10.1111/j.1533-2500.
2010.00393.x
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
30. Revel M, Poiraudeau S, Auleley GR, Payan C, Denke A, Nguyen M, et al. Capacity of the clinical
picture to characterize low back pain relieved by facet joint anesthesia. Proposed criteria to
identify patients with painful facet joints. Spine 1998;23:1972–6. https://doi.org/10.1097/
00007632-199809150-00011
31. Laslett M, Oberg B, Aprill CN, McDonald B. Zygapophysial joint blocks in chronic low back pain:
a test of Revel’s model as a screening test. BMC Musculoskelet Disord 2004;5:43. https://doi.org/
10.1186/1471-2474-5-43
32. Hooten WM, Martin DP, Huntoon MA. Radiofrequency neurotomy for low back pain:
evidence-based procedural guidelines. Pain Med 2005;6:129–38. https://doi.org/10.1111/
j.1526-4637.2005.05022.x
33. Sharma H, Duggan S, Nazir J, Andrews J, Fender D, Sanderson P, et al. Setting ‘diagnostic
reference levels’ for fluoroscopy-guided spinal procedures. J Bone Joint Surg Br
2012;94–B(Suppl. X):118.
34. Laslett M, McDonald B, Aprill CN, Tropp H, Oberg B. Clinical predictors of screening lumbar
zygapophyseal joint blocks: development of clinical prediction rules. Spine J 2006;6:370–9.
https://doi.org/10.1016/j.spinee.2006.01.004
35. Hancock MJ, Maher CG, Latimer J, Spindler MF, McAuley JH, Laslett M, Bogduk N. Systematic
review of tests to identify the disc, SIJ or facet joint as the source of low back pain. Eur Spine J
2007;16:1539–50. http://dx.doi.org/10.1007/s00586-007-0391-1
36. DePalma MJ, Ketchum JM, Trussell BS, Saullo TR, Slipman CW. Does the location of low back
pain predict its source? PM R 2011;3:33–9. http://dx.doi.org/10.1016/j.pmrj.2010.09.006
37. Mayer TG, Robinson R, Pegues P, Kohles S, Gatchel RJ. Lumbar segmental rigidity: can its
identification with facet injections and stretching exercises be useful? Arch Phys Med Rehabil
2000;81:1143–50. https://doi.org/10.1053/apmr.2000.9170
38. Wilde VE, Ford JJ, McMeeken JM. Indicators of lumbar zygapophyseal joint pain: survey of an
expert panel with the Delphi technique. Phys Ther 2007;87:1348–61. https://doi.org/10.2522/
ptj.20060329
39. Wasan AD, Jamison RN, Pham L, Tipirneni N, Nedeljkovic SS, Katz JN. Psychopathology predicts
the outcome of medial branch blocks with corticosteroid for chronic axial low back or cervical
pain: a prospective cohort study. BMC Musculoskelet Disord 2009;10:22. http://dx.doi.org/
10.1186/1471-2474-10-22
40. Hahne AJ, Ford JJ, Surkitt LD, Richards MC, Chan AY, Thompson SL, et al. Specific treatment of
problems of the spine (STOPS): design of a randomised controlled trial comparing specific
physiotherapy versus advice for people with subacute low back disorders. BMC Musculoskelet
Disord 2011;12:104. http://dx.doi.org/10.1186/1471-2474-12-104
41. Ford J, Thompson S, Hahne A. A classification and treatment protocol for low back disorders:
part 1 – specific manual therapy. Phys Ther Rev 2011;16:168–77.
42. Underwood M, Mistry D, Lall R, Lamb S. Predicting response to a cognitive-behavioral approach
to treating low back pain: secondary analysis of the BeST data set. Arthritis Care Res
2011;63:1271–9. http://dx.doi.org/10.1002/acr.20518
43. Challinor H, Hourigan P, Powell R, Conn D. Movement Test Diagnose Lumbar Facet Joint Pain?
London: Society of Back Pain Research; 2013.
44. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for
treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;2:CD005328.
http://dx.doi.org/10.1002/14651858.CD005328.pub2
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
109
45. Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane Database
Syst Rev 2003;1:CD004016. http://dx.doi.org/10.1002/14651858.CD004016
46. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based
recommendations for the management of hip osteoarthritis: report of a task force of the EULAR
Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann
Rheum Dis 2005;64:669–81. https://doi.org/10.1136/ard.2004.028886
47. van Vliet-Daskalopoulou E, Jentjens T, Scheffer RT. Intra-articular rimexolone in the rheumatoid
knee: a placebo-controlled, double-blind, multicentre trial of three doses. Br J Rheumatol
1987;26:450–3. https://doi.org/10.1093/rheumatology/26.6.450
48. Sehgal N, Dunbar EE, Shah RV, Colson J. Systematic review of diagnostic utility of facet
(zygapophysial) joint injections in chronic spinal pain: an update. Pain Physician 2007;10:213–28.
49. Boswell MV, Colson JD, Sehgal N, Dunbar EE, Epter R. A systematic review of therapeutic facet
joint interventions in chronic spinal pain. Pain Physician 2007;10:229–53.
50. Artus M, van der Windt DA, Jordan KP, Hay EM. Low back pain symptoms show a similar pattern
of improvement following a wide range of primary care treatments: a systematic review of
randomized clinical trials. Rheumatology 2010;49:2346–56. http://dx.doi.org/10.1093/
rheumatology/keq245
51. Boswell MV, Trescot AM, Datta S, Schultz DM, Hansen HC, Abdi S, et al. Interventional
techniques: evidence-based practice guidelines in the management of chronic spinal pain.
Pain Physician 2007;10:7–111.
52. Carette S, Marcoux S, Truchon R, Grondin C, Gagnon J, Allard Y, Latulippe M. A controlled trial
of corticosteroid injections into facet joints for chronic low back pain. N Engl J Med
1991;325:1002–7. http://dx.doi.org/10.1056/NEJM199110033251405
53. Chou R, Atlas SJ, Stanos SP, Rosenquist RW. Nonsurgical interventional therapies for low back
pain: a review of the evidence for an American Pain Society clinical practice guideline. Spine
2009;34:1078–93.
54. Henschke N, Kuijpers T, Rubinstein SM, van Middelkoop M, Ostelo R, Verhagen A, et al. Injection
therapy and denervation procedures for chronic low-back pain: a systematic review. Eur Spine J
2010;19:1425–49. http://dx.doi.org/10.1007/s00586-010-1411-0
55. Lilius G, Laasonen EM, Myllynen P, Harilainen A, Grönlund G. Lumbar facet joint syndrome.
A randomised clinical trial. J Bone Joint Surg Br 1989;71:681–4.
56. Datta S, Lee M, Falco FJ, Bryce DA, Hayek SM. Systematic assessment of diagnostic accuracy and
therapeutic utility of lumbar facet joint interventions. Pain Physician 2009;12:437–60.
57. Froud R, Eldridge S, Lall R, Underwood M. Estimating the number needed to treat from
continuous outcomes in randomised controlled trials: methodological challenges and worked
example using data from the UK Back Pain Exercise and Manipulation (BEAM) trial. BMC Med Res
Methodol 2009;9:35. http://dx.doi.org/10.1186/1471-2288-9-35
58. Mayer TG, Gatchel RJ, Keeley J, McGeary D, Dersh J, Anagnostis C. A randomized clinical trial of
treatment for lumbar segmental rigidity. Spine 2004;29:2199–205. https://doi.org/10.1097/
01.brs.0000142009.73869.8d
59. Civelek E, Cansever T, Kabatas S, Kircelli A, Yilmaz C, Musluman M, et al. Comparison of
effectiveness of facet joint injection and radiofrequency denervation in chronic low back pain.
Turk Neurosurg 2012;22:200–6. http://dx.doi.org/10.5137/1019-5149.JTN.5207-11.1
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
60. Vekaria R, Bhatt R, Ellard DR, Henschke N, Underwood M, Sandhu H. Intra-articular facet joint
injections for low back pain: a systematic review. Eur Spine J 2016;25:1266–81. http://dx.doi.org/
10.1007/s00586-016-4455-y
61. Kawu AA, Olawepo A, Salami AO. Facet joints infiltration: a viable alternative treatment to
physiotherapy in patients with low back pain due to facet joint arthropathy. Niger J Clin Pract
2011;14:219–22. http://dx.doi.org/10.4103/1119-3077.84021
62. Ribeiro LH, Furtado RN, Konai MS, Andreo AB, Rosenfeld A, Natour J. Effect of facet joint
injection versus systemic steroids in low back pain: a randomized controlled trial. Spine
2013;38:1995–2002. http://dx.doi.org/10.1097/BRS.0b013e3182a76df1
63. Hush JM, Kamper SJ, Stanton TR, Ostelo R, Refshauge KM. Standardized measurement of
recovery from nonspecific back pain. Arch Phys Med Rehabil 2012;93:849–55. http://dx.doi.org/
10.1016/j.apmr.2011.11.035
64. Hush JM, Refshauge K, Sullivan G, De Souza L, Maher CG, McAuley JH. Recovery: what does
this mean to patients with low back pain? Arthritis Rheum 2009;61:124–31. http://dx.doi.org/
10.1002/art.24162
65. Kamper SJ, Stanton TR, Williams CM, Maher CG, Hush JM. How is recovery from low back pain
measured? A systematic review of the literature. Eur Spine J 2011;20:9–18. http://dx.doi.org/
10.1007/s00586-010-1477-8
66. Staniszewska S, Haywood KL, Brett J, Tutton L. Patient and public involvement in patient-reported
outcome measures: evolution not revolution. Patient 2012;5:79–87. http://dx.doi.org/10.2165/
11597150-000000000-00000
67. Deyo RA, Battie M, Beurskens AJ, Bombardier C, Croft P, Koes B, et al. Outcome measures for
low back pain research. A proposal for standardized use. Spine 1998;23:2003–13. https://doi.org/
10.1097/00007632-199809150-00018
68. Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, et al. Developing patient-
reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain
2006;125:208–15. https://doi.org/10.1016/j.pain.2006.09.028
69. Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, et al. Identifying important
outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain
2008;137:276–85. https://doi.org/10.1016/j.pain.2007.09.002
70. Beale M, Cella M, Williams AC. Comparing patients’ and clinician-researchers’ outcome choice
for psychological treatment of chronic pain. Pain 2011;152:2283–6. http://dx.doi.org/10.1016/
j.pain.2011.06.007
71. NICE. Diagnosis and Management of Headache in Young People and Adults. London: NICE; 2012.
URL: www.nice.org.uk/guidance/CG150 (accessed 2 June 2016).
72. Cairns M. Diagnostic Assessment Manual. 2014. URL: http://wrap.warwick.ac.uk/78982 (accessed
23 May 2016).
73. Cairns M, Sandhu H. Facet Injection Study: Best Usual Care Physical Rehabilitation Combined
with Psychology Physiotherapy Manual. 2014. URL: http://wrap.warwick.ac.uk/78986 (accessed
23 May 2016).
74. Ellard DR, Griffiths F. Facet-Joint Injections for People with Persistent Nonspecific Low Back Pain
(FIS). Consensus Conference Report. 2015. URL: http://wrap.warwick.ac.uk/78987 (accessed
23 May 2016).
75. Underwood M, Antrobus H. Facet Injection Study: Injection Manual. 2014. URL: http://wrap.
warwick.ac.uk/78985 (accessed 23 May 2016).
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
111
76. Underwood M, Antrobus H, Barkan K, Cairns M, Ellard DR, Griffiths F, et al. Facet-joint Injections
for People with Persistent Non-Specific Low Back Pain (FIS): Facet Injection Study Consensus
Conference (FISCC) Evidence Document. 2014. URL: http://wrap.warwick.ac.uk/78978 (accessed
23 May 2016).
77. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. URL: www.handbook.
cochrane.org. (accessed 16 September 2016).
78. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking
Reviews in Health Care. York: Centre for Reviews and Dissemination, University of York; 2009.
URL: www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf
79. Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria
and guideline development. Semin Arthritis Rheum 2011;41:95–105. http://dx.doi.org/10.1016/
j.semarthrit.2010.12.001
80. Edwards B. Manual of Combined Movements. Oxford: Butterworth-Heinemann; 1999.
81. McCarthy C. Neurological Assessment. In McCarthy C, editor. Combined Movement Theory.
Rotational Mobilization of the Vertebral Column. London: Churchill Livingstone; 2010.
82. Chapman JR, Norvell DC, Hermsmeyer JT, Bransford RJ, DeVine J, McGirt MJ, Lee MJ. Evaluating
common outcomes for measuring treatment success for chronic low back pain. Spine
2011;36(Suppl. 21):54–68. http://dx.doi.org/10.1097/BRS.0b013e31822ef74d
83. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable
and sensitive measure of disability in low-back pain. Spine 1983;8:141–4. https://doi.org/10.1097/
00007632-198303000-00004
84. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain
1992;50:133–49. https://doi.org/10.1016/0304-3959(92)90154-4
85. Lamb SE, Hansen Z, Lall R, Castelnuovo E, Withers EJ, Nichols V, et al. Group cognitive
behavioural treatment for low-back pain in primary care: a randomised controlled trial and
cost-effectiveness analysis. Lancet 2010;375:916–23. http://dx.doi.org/10.1016/S0140-6736(09)
62164-4
86. UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM)
randomised trial: effectiveness of physical treatments for back pain in primary care. BMJ
2004;329:1377. https://doi.org/10.1136/bmj.38282.669225.AE
87. Ostelo RW, Deyo RA, Stratford P, Waddell G, Croft P, Von Korff M, et al. Interpreting change
scores for pain and functional status in low back pain: towards international consensus
regarding minimal important change. Spine 2008;33:90–4. http://dx.doi.org/10.1097/
BRS.0b013e31815e3a10
88. Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the
clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations.
Pain 2009;146:238–44. http://dx.doi.org/10.1016/j.pain.2009.08.019
89. Froud R, Eldridge S, Kovacs F, Breen A, Bolton J, Dunn K, et al. Reporting outcomes of back pain
trials: a modified Delphi study. Eur J Pain 2011;15:1068–74. http://dx.doi.org/10.1016/j.ejpain.
2011.04.015
90. Froud R, Underwood M, Carnes D, Eldridge S. Clinicians’ perceptions of reporting methods for
back pain trials: a qualitative study. Br J Gen Pract 2012;62:e151–9. http://dx.doi.org/10.3399/
bjgp12X630034
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
112
91. Henschke N, van Enst A, Froud R, Ostelo RW. Responder analyses in randomised controlled trials
for chronic low back pain: an overview of currently used methods. Eur Spine J 2014;23:772–8.
http://dx.doi.org/10.1007/s00586-013-3155-0
92. Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, et al. Patient-reported outcomes to
support medical product labeling claims: FDA perspective. Value Health 2007;10(Suppl. 2):125–37.
https://doi.org/10.1111/j.1524-4733.2007.00275.x
93. Copay AG, Subach BR, Glassman SD, Polly DW, Schuler TC. Understanding the minimum clinically
important difference: a review of concepts and methods. Spine J 2007;7:541–6. https://doi.org/
10.1016/j.spinee.2007.01.008
94. Guyatt G. Understanding the fundamentals of quality of life measurement. Evid Based Cardiovasc
Med 1998;2:35–6. https://doi.org/10.1016/S1361-2611(98)80079-1
95. Wyrwich KW, Norquist JM, Lenderking WR, Acaster S, Industry Advisory Committee of
International Society for Quality of Life Research (ISOQOL). Methods for interpreting change over
time in patient-reported outcome measures. Qual Life Res 2013;22:475–83. http://dx.doi.org/
10.1007/s11136-012-0175-x
96. Johnston BC, Patrick DL, Thorlund K, Busse JW, da Costa BR, Schünemann HJ, Guyatt GH.
Patient-reported outcomes in meta-analyses-part 2: methods for improving interpretability
for decision-makers. Health Qual Life Outcomes 2013;11:211. http://dx.doi.org/10.1186/
1477-7525-11-211
97. Johnston BC, Thorlund K, Schünemann HJ, Xie F, Murad MH, Montori VM, Guyatt GH. Improving
the interpretation of quality of life evidence in meta-analyses: the application of minimal
important difference units. Health Qual Life Outcomes 2010;8:116. http://dx.doi.org/10.1186/
1477-7525-8-116
98. Marx RG, Jones EC, Angel M, Wickiewicz TL, Warren RF. Beliefs and attitudes of members of the
American Academy of Orthopaedic Surgeons regarding the treatment of anterior cruciate
ligament injury. Arthroscopy 2003;19:762–70. https://doi.org/10.1016/S0749-8063(03)00398-0
99. Underwood MR, Barnett AG, Vickers MR. Evaluation of two time-specific back pain outcome
measures. Spine 1999;24:1104–12. https://doi.org/10.1097/00007632-199906010-00010
100. Lamb SE, Lall R, Hansen Z, Castelnuovo E, Withers EJ, Nichols V, et al. A multicentred randomised
controlled trial of a primary care-based cognitive behavioural programme for low back pain.
The Back Skills Training (BeST) trial. Health Technol Assess 2010;14(41). http://dx.doi.org/10.3310/
hta14410
101. Hay EM, Mullis R, Lewis M, Vohora K, Main CJ, Watson P, et al. Comparison of physical
treatments versus a brief pain-management programme for back pain in primary care: a
randomised clinical trial in physiotherapy practice. Lancet 2005;365:2024–30. https://doi.org/
10.1016/S0140-6736(05)66696-2
102. Sandhu H, Ellard DR, Achana F, Antrobus JH, Balasubramanian S, Brown S, et al. Facet-joint
injections for people with persistent non-specific low back pain (FIS): study protocol for a
randomised controlled feasibility trial. Trials 2015;16:588. http://dx.doi.org/10.1186/
s13063-015-1117-z
103. Parsons S, Carnes D, Pincus T, Foster N, Breen A, Vogel S, Underwood M. Measuring
troublesomeness of chronic pain by location. BMC Musculoskelet Disord 2006;7:34.
https://doi.org/10.1186/1471-2474-7-34
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
113
104. Lamb SE, Mistry D, Lall R, Hansen Z, Evans D, Withers EJ, Underwood MR, Back Skills Training
Trial Group. Group cognitive behavioural interventions for low back pain in primary care:
extended follow-up of the Back Skills Training Trial (ISRCTN54717854). Pain 2012;153:494–501.
http://dx.doi.org/10.1016/j.pain.2011.11.016
105. Campbell NC, Murray E, Darbyshire J, Emery J, Farmer A, Griffiths F, et al. Designing and
evaluating complex interventions to improve health care. BMJ 2007;334:455–9. https://doi.org/
10.1136/bmj.39108.379965.BE
106. Savigny P, Watson P, Underwood M, Guideline Development Group. Early management of
persistent non-specific low back pain: summary of NICE guidance. BMJ 2009;338:b1805.
http://dx.doi.org/10.1136/bmj.b1805
107. Maitland G, Hengeveld E, Banks K, English L, editors. Maitland’s Vertebral Manipulation. 7th edn.
Oxford: Elsevier; 2005.
108. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome
domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003;106:337–45.
https://doi.org/10.1016/j.pain.2003.08.001
109. Klokkerud M, Grotle M, Lochting I, Kjeken I, Hagen KB, Garratt AM. Psychometric properties of
the Norwegian version of the patient generated index in patients with rheumatic diseases
participating in rehabilitation or self-management programmes. Rheumatology 2013;52:924–32.
110. Løchting I, Grotle M, Storheim K, Werner E, Garratt A. Individualised quality of life in patients
with low back pain: reliability and validity of the Patient Generated Index (PGI). J Rehab Med
2014;46:781–7. https://doi.org/10.2340/16501977-1826
111. Pincus T, Rusu A, Santos R. Responsiveness and construct validity of the depression, anxiety,
and positive outlook scale (DAPOS). Clin J Pain 2008;24:431–7. http://dx.doi.org/10.1097/
AJP.0b013e318164341c
112. Nicholas MK. The pain self-efficacy questionnaire: taking pain into account. Eur J Pain
2007;11:153–63. https://doi.org/10.1016/j.ejpain.2005.12.008
113. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and
preliminary tests of reliability and validity. Med Care 1996;34:220–33. https://doi.org/10.1097/
00005650-199603000-00003
114. The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life.
Health Policy 1990;16:199–208.
115. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the
SF-36. J Health Econ 2002;21:271–92. https://doi.org/10.1016/S0167-6296(01)00130-8
116. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-Edinburgh Mental
Well-Being Scale (WEMWBS): development and UK validation. Health Quality Life Outcomes
2007;5:63. https://doi.org/10.1186/1477-7525-5-63
117. Morren M, van Dulmen S, Ouwerkerk J, Bensing J. Compliance with momentary pain measurement
using electronic diaries: a systematic review. Eur J Pain 2009;13:354–65. http://dx.doi.org/10.1016/
j.ejpain.2008.05.010
118. Burton C, Weller D, Sharpe M. Are electronic diaries useful for symptoms research? A systematic
review. J Psychosom Res 2007;62:553–61. https://doi.org/10.1016/j.jpsychores.2006.12.022
119. Bogduk N. Diagnosing lumbar zygapophysial joint pain. Pain Med 2005;6:139–42. https://doi.org/
10.1111/j.1526-4637.2005.05023.x
120. Bogduk N. A narrative review of intra-articular corticosteroid injections for low back pain.
Pain Med 2005;6:287–96. https://doi.org/10.1111/j.1526-4637.2005.00048.x
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
121. European Commission. European Union Clinical Trials Directive 2001/20/EC. Luxembourg:
European Commission; 2001.
122. International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use. Integrated Addendum to ICH E6 (R1): Guideline for Good
Clinical Practice E6(R2). ICH Harmonised Guideline. URL: www.ich.org/fileadmin/Public_Web_Site/
ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4.pdf (accessed 21 February 2017).
123. Gov.UK. Good Clinical Practice for Clinical Trials. URL: www.gov.uk/guidance/good-clinical-
practice-for-clinical-trials (accessed 21 February 2017).
124. Great Britain. Data Protection Act 1998. London: The Stationery Office; 1998.
125. Fryback DG, Dunham NC, Palta M, Hanmer J, Buechner J, Cherepanov D, et al. US norms for six
generic health-related quality-of-life indexes from the National Health Measurement study.
Medical care 2007;45:1162. https://doi.org/10.1097/MLR.0b013e31814848f1
126. Devlin N, Shah K, Feng Y, Mulhern B, Van Hout B. Valuing Health-Related Quality of Life:
An EQ-5D-5L Value Set for England. 2016. URL: www.ohe.org/publications/valuing-health-
related-quality-life-eq-5d-5l-value-set-england (accessed 10 June 2016).
127. StataCorp. Stata 14 Base Reference Manual. College Station, TX: Stata Press; 2015.
128. Moore G, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process Evaluation of
Complex Interventions: UK Medical Research Council (MRC) Guidance. 2014. URL: www.ioe.ac.uk/
MRC_PHSRN_Process_evaluation_guidance_final(2).pdf (accessed January 2015).
129. Steckler A, Linnan L, editors. Process Evaluation for Public Health Interventions and Research.
San Francisco, CA: Jossey-Bass; 2002.
130. Ellard D, Parsons S. Process Evaluation: Understanding How and Why Interventions Work.
In Thorogood M, Coombes Y, editors. Evaluating Health Promotion Practice and Methods.
3rd edn. Oxford: Oxford University Press; 2010. pp. 87–104. https://doi.org/10.1093/acprof:oso/
9780199569298.003.0007
131. Ellard DR, Chimwaza W, Davies D, O’Hare JP, Kamwendo F, Quenby S, Griffiths F, ETATMBA
Study Group. Can training in advanced clinical skills in obstetrics, neonatal care and leadership,
of non-physician clinicians in Malawi impact on clinical services improvements (the ETATMBA
project): a process evaluation. BMJ Open 2014;4:e005751. http://dx.doi.org/10.1136/
bmjopen-2014-005751
132. Ellard DR, Taylor SJ, Parsons S, Thorogood M. The OPERA trial: a protocol for the process
evaluation of a randomised trial of an exercise intervention for older people in residential and
nursing accommodation. Trials 2011;12:28. http://dx.doi.org/10.1186/1745-6215-12-28
133. Ellard DR, Thorogood M, Underwood M, Seale C, Taylor SJ. Whole home exercise intervention for
depression in older care home residents (the OPERA study): a process evaluation. BMC Med
2014;12:1. http://dx.doi.org/10.1186/1741-7015-12-1
134. Garratt AM. Evaluation of the stages of completion and scoring of the Patient Generated Index
(PGI) in patients with rheumatic diseases. Qual Life Res 2015;24:2625–35. http://dx.doi.org/
10.1007/s11136-015-1014-7
135. Ruta DA, Garratt AM, Leng M, Russell IT, MacDonald LM. A new approach to the measurement
of quality of life. The Patient-Generated Index. Med Care 1994;32:1109–26.https://doi.org/
10.1097/00005650-199411000-00004
136. Ruta DA, Garratt AM, Russell IT. Patient centred assessment of quality of life for patients with
four common conditions. Qual Health Care 1999;8:22–9. https://doi.org/10.1136/qshc.8.1.22
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
115
137. Haywood KL, Garratt AM, Dziedzic K, Dawes PT. Patient centered assessment of ankylosing
spondylitis-specific health related quality of life: evaluation of the Patient Generated Index.
J Rheumatol 2003;30:764–73.
138. Patel KK, Veenstra DL, Patrick DL. A review of selected patient-generated outcome measures
and their application in clinical trials. Value Health 2003;6:595–603. https://doi.org/10.1046/
j.1524-4733.2003.65236.x
139. Martin F, Camfield L, Rodham K, Kliempt P, Ruta D. Twelve years’ experience with the Patient
Generated Index (PGI) of quality of life: a graded structured review. Qual Life Res 2007;16:705–15.
http://dx.doi.org/10.1007/s11136-006-9152-6
140. Hush JM, Refshauge KM, Sullivan G, De Souza L, McAuley JH. Do numerical rating scales and the
Roland-Morris Disability Questionnaire capture changes that are meaningful to patients with
persistent back pain? Clin Rehabil 2010;24:648–57. http://dx.doi.org/10.1177/0269215510367975
141. Ong BN, Konstantinou K, Corbett M, Hay E. Patients’ own accounts of sciatica: a qualitative
study. Spine 2011;36:1251–6. http://dx.doi.org/10.1097/BRS.0b013e318204f7a2
142. Kerns RD, Burns JW, Shulman M, Jensen MP, Nielson WR, Czlapinski R, et al. Can we improve
cognitive-behavioral therapy for chronic back pain treatment engagement and adherence?
A controlled trial of tailored versus standard therapy. Health Psychol 2014;33:938–47.
http://dx.doi.org/10.1037/a0034406
143. Dionne CE, Dunn KM, Croft PR, Nachemson AL, Buchbinder R, Walker BF, et al. A consensus
approach toward the standardization of back pain definitions for use in prevalence studies.
Spine (Phila Pa 1976) 2008;33:95–103. https://doi.org/10.1097/BRS.0b013e31815e7f94
144. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN study
reached international consensus on taxonomy, terminology, and definitions of measurement
properties for health-related patient-reported outcomes. J Clin Epidemiol 2010;63:737–45.
http://dx.doi.org/10.1016/j.jclinepi.2010.02.006
145. Stevenson M, Gomersall T, Lloyd Jones M, Rawdin A, Hernández M, Dias S, et al. Percutaneous
vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral
fractures: a systematic review and cost-effectiveness analysis. Health Technol Assess 2014;18(17).
http://dx.doi.org/10.3310/hta18170
146. Curtis L, Burns A. Unit Costs of Health and Social Care 2015. Canterbury: PSSRU, University of
Kent; 2015. URL: www.pssru.ac.uk/project-pages/unit-costs/2015/ (accessed 10 June 2016).
147. NHS Digital. Prescription Cost Analysis: England 2015. 2016. URL: http://content.digital.nhs.uk/
catalogue/PUB20200 (accessed 28 February 2017).
148. Department of Health (DH). NHS Reference Costs 2014 to 2015. London: DH; 2015.
URL: www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015 (accessed
10 June 2016).
149. Curtis L. Unit Costs of Health and Social Care 2013. Canterbury: PSSRU, University of Kent; 2013.
URL: www.pssru.ac.uk/project-pages/unit-costs/2013/ (accessed 28 February 2017).
150. Dr Foster Research Ltd. National Pain Audit – Find a Clinic. London: Dr Foster Research Ltd; 2015.
URL: www.nationalpainaudit.org/findclinic (accessed 9 September 2016).
151. Care Quality Commission. Hospitals. URL: www.cqc.org.uk/content/hospitals (accessed
26 April 2017).
152. Slade SC, Keating JL. Exercise prescription: a case for standardised reporting. Br J Sports Med
2012;46:1110–13. http://dx.doi.org/10.1136/bjsports-2011-090290
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
116
153. Haywood KL, Packham JC, Jordan KP. Assessing fatigue in ankylosing spondylitis: the importance
of frequency and severity. Rheumatology 2014;53:552–6. https://doi.org/10.1093/rheumatology/
ket397
154. Hewlett S, Ambler N, Almeida C, Cliss A, Hammond A, Kitchen K, et al. Self-management of
fatigue in rheumatoid arthritis: a randomised controlled trial of group cognitive-behavioural
therapy. Ann Rheum Dis 2011;70:1060–7.
155. Fairbank JC, Couper J, Davies JB, O’Brien JP. The Oswestry low back pain disability questionnaire.
Physiotherapy 1980;66:271–3.
156. Froud R, Patterson S, Eldridge S, Seale C, Pincus T, Rajendran D, et al. A systematic review and
meta-synthesis of the impact of low back pain on people’s lives. BMC Musculoskelet Disord
2014;15:50. http://dx.doi.org/10.1186/1471-2474-15-50
157. Madan J, Ades AE, Price M, Maitland K, Jemutai J, Revill P, Welton NJ. Strategies for efficient
computation of the expected value of partial perfect information. Med Decis Making
2014;34:327–42. http://dx.doi.org/10.1177/0272989X13514774
158. Strong M, Oakley JE, Brennan A, Breeze P. Estimating the expected value of sample information
using the probabilistic sensitivity analysis sample: a fast, nonparametric regression-based method.
Med Decis Making 2015;35:570–83. http://dx.doi.org/10.1177/0272989X15575286
159. Maas ET, Ostelo RW, Niemisto L, Jousimaa J, Hurri H, Malmivaara A, van Tulder MW.
Radiofrequency denervation for chronic low back pain. Cochrane Database Syst Rev
2015;10:CD008572. http://dx.doi.org/10.1002/14651858.CD008572.pub2
160. Maas E, Juch J, Ostelo R, Groeneweg G, Kallewaard JW, Koes B, et al. Effectiveness and
cost-effectiveness of radiofrequency denervation for chronic low back pain originating from the
facet joints. Pain Practice 2016;16:150.
161. Salman OH, Gad GS, Mohamed AA, Rafae HH, Abdelfatah AM. Randomized, controlled blind
study comparing sacroiliac intra-articular steroid injection to radiofrequency denervation for
sacroiliac joint pain. Egy J Anaesthesia 2016;32:219–25.
162. Schoenfeld D. Statistical considerations for pilot studies. Int J Radiat Oncol Biol Physics
1980;6:371–4. https://doi.org/10.1016/0360-3016(80)90153-4
163. Stallard N. Optimal sample sizes for phase II clinical trials and pilot studies. Stat Med
2012;31:1031–42. https://doi.org/10.1002/sim.4357
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
117

Appendix 1 Patient and public involvement
perspective
One of our lay representatives reflected on his experience of taking part in this study from earlymeetings to its conclusion:
My associate lay coapplicant and I were invited to the first planning meeting when the idea of a
randomised controlled feasibility trial to test the theory that FJIs might be therapeutically beneficial for
people with low back pain.
We had experience this sort of intervention with varying degrees of benefit. We were also known to
the researchers by our involvement in other lower back pain projects. At the first meeting the makeup
of the team was discussed. Then, at subsequent meeting, the necessary expertise was brought
together and the structure of the trial was formulated.
We were fully involved in all discussions and our ‘expertise by experience’ was called on when
discussing the protocol and PPI element of the proposed trial. We tested the use of mobile phones to
relay pain scores to the trial team. We checked all documentation that was used with patients and
asked for justification for use of quality measures and data analysis to achieve the trials goals.
We took part in the consensus meeting when it was discovered that there were no standard
guidelines for the methods of both giving FJIs or what to inject.
We were fully involved in determining the exclusion criteria for the trial and the data collection time
scale. The BUC had to be standardised so that we had a baseline for the treatment. Also it was
necessary to find out what the professionals meant by facet joint pain. If all this was possible and we
were able to bring together many and varied sites around the country so that recruitment and
procedures could be co-ordinated. We could then proceed to a full trial to prove or otherwise that FJIs
were both therapeutically beneficial and cost-effective.
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Appendix 2 Example screening log
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Appendix 3 Case report form
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Appendix 4 Baseline questionnaire
 
 
 
 
 
 
 
 
 
 
 
 
Facet Joint Injection Study 
 
Baseline Questionnaire 
 
 
 
 
 
PLEASE READ THESE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE 
Thank you for agreeing to take part in this study. The answers you give in this questionnaire will 
help us understand your experiences when making a treatment decision for your low back pain.  
Please answer all the questions. Although it may seem that questions are asked more than once, it is 
still important that you answer every one. 
Please follow the instructions for each section carefully.  
 
 
Participant study ID number 
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Section 1 
 
1. Date you are completing this questionnaire: |__|__| |__|__| |__|__| 
             day       month      year 
2. What is your date of birth:   |__|__| |__|__| |__|__|  
3. Gender: Male 1 Female 2 
4. What is your ethnic origin?  (Please tick one) 
1.1.1.1 White 
01  British  
02  Irish  
03  Any other White background, please specify  
1.1.1.2 Mixed 
04  White and Black Caribbean 
05  White and Black African 
06  White and Asian 
07  Any other Mixed background, please specify………………………………..….. 
1.1.1.3 Asian or Asian British 
08  Indian 
09  Pakistani 
10  Bangladeshi 
11  Any other Asian background, please specify . 
1.1.1.4 Black or Black British 
12  Caribbean 
13  African 
14  Any other Black background, please specify .  
1.1.1.5 Chinese or other ethnic group 
15  Chinese 
16  Any other background, please specify .. .. 
 
5. At what age did you leave full time education? or- 
I am still in full-time education (please tick the box)  
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Work Status  
2. Are you currently working?  
 1   Yes, full time  
 2   Yes, part time  
 3   No  (Please go to question 8)  
3. How many hours of paid work do you do per week? .  hours per week 
 
 
4. If you are not currently working which of the following applies to you? 
1  Retired          
2  At home and not looking for paid work (e.g. looking after home, family or others) 
3  Unable to work due to low back pain 
4  Unable to work due to other illness  
5  Unemployed and looking for work        
6  In full time education 
7  Other (Please describe) ______________________________________ 
 
 
 
5.  How satisfied are you with your current health, in relation to your low back pain? 
Very dissatisfied     
Somewhat dissatisfied     
Neither satisfied nor dissatisfied   
Somewhat satisfied      
Very satisfied      
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Section 2 
This section is about your back pain today.  When your back hurts, you may find it difficult to do
some of the things you normally do.  This list contains some sentences that people have used to
describe themselves when they have back pain.  When you read them, you may find that some stand
out because they describe you today.   
As you read the list, think of yourself today.  When you read a sentence that describes you today, place a
cross in the box beside it.  If the sentence does not describe you, then leave the box blank and go on to
the next one.  Remember, only place a cross if you are sure that it describes you today. 
 
1. I stay at home most of the time because of my back.  ..........................................................  
2. I change positions frequently to try and get my back comfortable.  .......................................  
3. I walk more slowly than usual because of my back.  .............................................................  
4. Because of my back, I am not doing any of the jobs that I usually do around the house.  .....  
5. Because of my back, I use a handrail to get upstairs.  ..........................................................  
6. Because of my back, I lie down to rest more often.  ..............................................................  
7. Because of my back, I have to hold on to something to get out of an easy chair.  ...............  
8. Because of my back, I try to get other people to do things for me.  .......................................  
9. I get dressed more slowly than usual because of my back.  .................................................  
10. I only stand up for short periods of time because of my back. ..............................................  
11. Because of my back, I try not to bend or kneel down.  ..........................................................  
12. I find it difficult to get out of a chair because of my back.  .....................................................  
13. My back is painful almost all the time.  .................................................................................  
14. I find it difficult to turn over in bed because of my back.  .......................................................  
15. My appetite is not very good because of my back pain.  .......................................................  
16. I have trouble putting on my socks (or stockings) because of the pain in my back.  ..............  
17. I only walk short distances because of my back pain.  ..........................................................  
18. I sleep less well because of my back.  ..................................................................................  
19. Because of my back pain, I get dressed with help from someone else.  ...............................  
20. I sit down for most of the day because of my back.  .............................................................  
21. I avoid heavy jobs around the house because of my back.  ..................................................  
22. Because of my back pain, I am more irritable and bad tempered with people than usual.  ...  
23. Because of my back, I go upstairs more slowly than usual.  .................................................  
24. I stay in bed most of the time because of my back.  .............................................................  
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Section 3 
This section is about how much your back trouble has been interfering with your daily activities
in recent weeks. 
For the next six questions please circle the number which represents how your back pain has 
made you feel over the last 4 weeks. 
 
1. In the past 4 weeks, how much has your back pain interfered with your daily activities on a scale of 0-
10 where 0 is ‘no interference’ and 10 is ‘unable to carry out any activities at all’? 
             
    ‘no       ‘unable to 
    Interference’         carry out any 
   activities at all’ 
0 1 2 3 4 5 6 7 8 9 10 
 
2. In the past 4 weeks, how much has your back pain changed your ability to take part in recreational, 
social and family activities on a scale of 0-10 where 0 is ‘no change’ and 10 is ‘extreme change’? 
 
    ‘no       ‘extreme 
    change’        change’ 
0 1 2 3 4 5 6 7 8 9 10 
 
3. In the past 4 weeks, how much has your back pain changed your ability to work (including housework) 
on a scale of 0-10 where 0 is ‘no change’ and 10 is ‘extreme change’? 
 
    ‘no       ‘extreme 
    change’        change’ 
0 1 2 3 4 5 6 7 8 9 10 
 
4. In the past 4 weeks, how bad has your worst back pain been on a scale of 0-10 where 0 is ‘no pain’ 
and 10 is ‘as bad as a pain could be’? 
 
    ‘no       ‘as bad as  
    pain’        pain could be’ 
0 1 2 3 4 5 6 7 8 9 10 
 
5. In the past 4 weeks, on average how bad has your back pain been on a scale of 0-10 where 0 is ‘no 
pain’ and 10 is ‘as bad as a pain could be’? 
 
    ‘no       ‘as bad as  
    pain’        pain could be’ 
0 1 2 3 4 5 6 7 8 9 10 
 
6. How would you rate your back pain today on a scale of 0-10 where 0 is ‘no pain’ and 10 is ‘as bad as a 
pain could be’. 
 
    ‘no       ‘as bad as  
    pain’        pain could be’ 
0 1 2 3 4 5 6 7 8 9 10
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Section 4 The following questions are to ask about your general health state at the moment. Under 
each heading, please tick the ONE box that best describes your health TODAY. 
 
 
 
 
 
 
 
 
 
 
 
Note – The EuroQol EQ5D 5L was presented here.  
 
As this is a licenced product we cannot reproduce it within this report 
See: http://www.euroqol.org/eq-5d-products/eq-5d-5l.html 
 
 
 
Section 5 
This questionnaire asks for your views about your health. This information will help keep track
of how you feel and how well you are able to do your usual activities.  
 
For each of the following questions, please place a cross in the one box that best describes your
answer. 
 
 
 
 
 
Note – the Optum Short Form 12 Health survery questionnaire (SF-12) was presented here.  
 
 
 
As this is a licenced product we cannot reproduce it within this report. 
See:  
https://campaign.optum.com/optum-outcomes/what-we-do/health-surveys/sf-12v2-health-survey.html 
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Section 6 
Below are some statements about feelings and thoughts. 
 
Please tick the box that best describes your experience of each over the last 2 weeks 
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We would like to know how you have been feeling in the last few weeks. Please circle a 
number for each statement indicating how often you feel that way. 
  
  Almost never    
Almost 
all the 
time 
1 I feel like a failure 1 2 3 4 5 
2 I get a frightened feeling, as if something awful is about to happen 1 2 3 4 5 
3 I feel guilty 1 2 3 4 5 
4 I can laugh and see the funny side of 
things 
1 2 3 4 5 
5 I am disappointed in myself 1 2 3 4 5 
6 I get a frightened feeling, like butterflies in 
the stomach 
1 2 3 4 5 
7 I feel cheerful 1 2 3 4 5 
8 I blame myself constantly 1 2 3 4 5 
9 I get a sudden feeling of panic 1 2 3 4 5 
10 I look forward with enjoyment to things 1 2 3 4 5 
11 I think about harming myself 1 2 3 4 5 
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Section 7 
Please rate how confident you are that you can do the following things at present, despite the 
pain.  To answer circle one of the numbers on the scale under each item, where 0 = ‘not at all 
confident’ and 6 = ‘completely confident’.  
For example  
 
0 1 2 3 4 5 6 
Not at all      Completely  
confident      confident 
Remember, this questionnaire is not asking whether or not you have been doing these things, 
but rather how confident you are that you can do them at present, despite the pain.   
 
 Not at all confident    
Completely 
Confident 
1. I can enjoy things, despite the pain 0 1 2 3 4 5 6 
2. I can do most of the household chores 
(e.g. tidying-up, washing dishes, etc.), 
despite the pain 
0 1 2 3 4 5 6 
3. I can socialise with my friends or family 
members as often as I used to do, despite 
the pain 
0 1 2 3 4 5 6 
4. I can cope with my pain in most situations 0 1 2 3 4 5 6 
5. I can do some form of work, despite the 
pain. (‘work’ includes housework, paid and 
unpaid work). 
0 1 2 3 4 5 6 
6. I can still do many of the things I enjoy 
doing, such as hobbies or leisure activity, 
despite the pain 
0 1 2 3 4 5 6 
7. I can cope with my pain without medication 0 1 2 3 4 5 6 
8. I can still accomplish most of my goals in 
life, despite the pain 0 1 2 3 4 5 6 
9. I can live a normal lifestyle, despite the 
pain 0 1 2 3 4 5 6 
10. I can gradually become more active, 
despite the pain 0 1 2 3 4 5 6 
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Section 8 
In this section you are asked about your pain in general and how it impacts upon your life and 
how your back pain affects you and how you would like to see it improve. 
 
During the past month, how troublesome have each of the following symptoms been? (Please 
mark  the appropriate box (with a cross ‘x’) on each row for each area that you have pain) 
  No pain experienced 
Not at all 
troublesome 
Slightly 
troublesom
e 
Moderately 
troublesom
e 
Very 
troublesom
e 
Extremely 
troublesom
e 
Head ache             
Neck pain             
Shoulder 
pain             
Elbow pain             
Wrist / hand 
pain             
Chest pain             
Abdominal 
pain             
Upper back 
pain             
Lower back 
pain             
Hip/thigh 
pain             
Knee pain             
Ankle/foot 
pain             
Other pains             
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Now please complete the questionnaire to tell us how your life is currently affected by your back pain and 
how you would like to see it improve.  
PART 1: List Area
In this part we would like you to 
think of 5 most important areas of 
your life affected by your back pain 
and write these in the boxes below
If you cannot think of 5 areas then 
just fill as many boxes as you want. 
Some examples are provided below
Pain; Work; Driving; Sleep; Fatigue; 
Social life; Hobbies; Completing 
tasks; Relationships - with family or 
friends; Feeling depressed; Loss of 
self-esteem; Walking; Slow to do 
things; Travelling; Sexual relations; 
Self-image; Pain; work; recreation 
with family; feeling depressed; loss 
of self esteem; driving; sleep; 
fatigue; housework.
PART 2: Score Areas
Please score each area you listed in Part I.  
The score should show how badly you were 
affected by your back in the areas listed 
today. Give each area a score by circling 
the number.
In the same way, we would like you to rate 
“All other aspects of your life affected by 
your back pain, not already mentioned”. By 
this we mean all other aspects of life 
affected by your back and not included in the 
list you gave.
PART 3: Spend Points
Now imagine that any or all of 
the areas of your life mentioned 
in PART I could be improved. 
You have 10 imaginary points to 
spend to improve any or all of 
these areas.
Give more points to areas you 
would most like to improve and 
less to areas that are not so 
important. You don’t have to 
spend points in every area, but 
don’t spend more than 10 points 
in total.
All other areas of your life 
affected by your back pain, not 
already mentioned.
As bad as 
could 
possibly 
be
As good 
as could 
possibly 
be
Total 
number of 
points that 
you spend 
must add 
up to 10
0     1     2     3     4     5      6          
0     1     2     3     4     5      6          
0     1     2     3     4     5      6          
0     1     2     3     4     5      6          
0     1     2     3     4     5      6          
0     1     2     3     4     5      6          
Total = 10
Please circle one 
number
on each line
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Section 9.  Medication 
 
1. In the last three months, have you USED any prescribed or bought over the counter medication 
because of your back pain? 
  Yes                     No   
 
2. If yes, please fill in the details in the tables below. Paracetamol is given as an example of how we 
would like you to complete the table. Include all back pain related medications. The table is split into 
three sections (Tablets, Gels and Patches). You may find it helpful to look on the packaging of your 
medication for some of the details. If you need to, please continue on the last page of this booklet. 
Medication Usual Dose Number 
of times 
daily 
 
Number of 
days used 
On 
prescription? 
Paracetamol 250mg 
 
2 tablets 
 
2 
 
8 days 
 
No 
     
     
     
     
     
     
 
Pain relief gels 
Medication (name) 
Number of 
times daily 
 
Number of days 
used 
On prescription? 
Ibugel twice 4 days Yes 
    
    
 
Pain relief patches 
Medication (name) 
 
Number used On prescription? 
BuTrans 4 Yes 
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Appendix 5 Three-month follow-up questionnaire
 
 
 
 
 
 
 
Facet Joint Injection Study 
 
Three-Month Follow up Questionnaire 
 
 
 
 
PLEASE READ THESE INSTRUCTIONS BEFORE COMPLETING THE QUESTIONNAIRE 
Thank you for agreeing to take part in this study. The answers you give in this questionnaire will 
help us understand your experiences when making a treatment decision for your low back pain.  
Please answer all the questions. Although it may seem that questions are asked more than once, it is 
still important that you answer every one. 
Please follow the instructions for each section carefully.  
 
 
Participant Study ID number 
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Date you are completing this questionnaire:  |__|__| |__|__| |__|__| 
   day        month      year 
 
 
 
Section 1 
By placing a cross in one box for each question below, please indicate which statement best 
describes your feelings towards the treatment or advice you have received for your back pain 
since you joined the study on dd/mm/yyyy (date of enrolment) . 
 
 
Very dissatisfied     
Somewhat dissatisfied     
Neither satisfied nor dissatisfied   
Somewhat satisfied      
Very satisfied      
 
 
Substantial harm     
Moderate harm     
No benefit      
Moderate benefit     
Substantial benefit     
 
 
Vastly worse      
Much worse      
Slightly worse      
No change      
Slightly better      
Much better      
Completely better     
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 Vastly worse      
Much worse      
Slightly worse      
No change      
Slightly better      
Much better      
Completely better     
 
Very dissatisfied     
Somewhat dissatisfied     
Neither satisfied nor dissatisfied   
Somewhat satisfied      
Very satisfied      
 
Section 2: Your back pain over the past 4 weeks 
 
 
 
  0 1 2 3 4 5 6 7 8 9 10  
                   No pain  Worse pain 
 
No pain experienced     
Not at all troublesome   
Slightly troublesome     
Moderately troublesome    
Very troublesome     
Extremely troublesome    
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Section 3 
This section is about your back pain today.  When your back hurts, you may find it difficult to do
some of the things you normally do.  This list contains some sentences that people have used to
describe themselves when they have back pain.  When you read them, you may find that some stand
out because they describe you today.   
As you read the list, think of yourself today.  When you read a sentence that describes you today,
place a cross in the box beside it.  If the sentence does not describe you, then leave the box blank
and go on to the next one.  Remember, only place a cross if you are sure that it describes you today.
 
1. I stay at home most of the time because of my back.  ..........................................................  
2. I change positions frequently to try and get my back comfortable.  .......................................  
3. I walk more slowly than usual because of my back.  .............................................................  
4. Because of my back, I am not doing any of the jobs that I usually do around the house.  .....  
5. Because of my back, I use a handrail to get upstairs.  ..........................................................  
6. Because of my back, I lie down to rest more often.  ..............................................................  
7. Because of my back, I have to hold on to something to get out of an easy chair.  ...............  
8. Because of my back, I try to get other people to do things for me.  .......................................  
9. I get dressed more slowly than usual because of my back.  .................................................  
10. I only stand up for short periods of time because of my back.  ..............................................  
11. Because of my back, I try not to bend or kneel down.  ..........................................................  
12. I find it difficult to get out of a chair because of my back.  .....................................................  
13. My back is painful almost all the time.  .................................................................................  
14. I find it difficult to turn over in bed because of my back.  .......................................................  
15. My appetite is not very good because of my back pain.  .......................................................  
16. I have trouble putting on my socks (or stockings) because of the pain in my back.  ..............  
17. I only walk short distances because of my back pain.  ..........................................................  
18. I sleep less well because of my back.  ..................................................................................  
19. Because of my back pain, I get dressed with help from someone else.  ...............................  
20. I sit down for most of the day because of my back.  .............................................................  
21. I avoid heavy jobs around the house because of my back.  ..................................................  
22. Because of my back pain, I am more irritable and bad tempered with people than usual.  ...  
23. Because of my back, I go upstairs more slowly than usual.  .................................................  
24. I stay in bed most of the time because of my back.  .............................................................  
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Section 4 
This section is about how much your back trouble has been interfering with your daily activities
in recent weeks. 
For the next six questions please circle the number which represents how your back pain has 
made you feel over the last 4 weeks. 
 
1. In the past 4 weeks, how much has your back pain interfered with your daily activities on a scale of 0-
10 where 0 is ‘no interference’ and 10 is ‘unable to carry out any activities at all’? 
             
    ‘no       ‘unable to 
    Interference’         carry out any 
   activities at all’ 
0 1 2 3 4 5 6 7 8 9 10 
 
2. In the past 4 weeks, how much has your back pain changed your ability to take part in recreational, 
social and family activities on a scale of 0-10 where 0 is ‘no change’ and 10 is ‘extreme change’? 
 
    ‘no       ‘extreme 
    change’        change’ 
0 1 2 3 4 5 6 7 8 9 10 
 
3. In the past 4 weeks, how much has your back pain changed your ability to work (including housework) 
on a scale of 0-10 where 0 is ‘no change’ and 10 is ‘extreme change’? 
 
    ‘no       ‘extreme 
    change’        change’ 
0 1 2 3 4 5 6 7 8 9 10 
 
4. In the past 4 weeks, how bad has your worst back pain been on a scale of 0-10 where 0 is ‘no pain’ 
and 10 is ‘as bad as a pain could be’? 
 
    ‘no       ‘as bad as  
    pain’        pain could be’ 
0 1 2 3 4 5 6 7 8 9 10 
 
5. In the past 4 weeks, on average how bad has your back pain been on a scale of 0-10 where 0 is ‘no 
pain’ and 10 is ‘as bad as a pain could be’? 
 
    ‘no       ‘as bad as  
    pain’        pain could be’ 
0 1 2 3 4 5 6 7 8 9 10 
 
6. How would you rate your back pain today on a scale of 0-10 where 0 is ‘no pain’ and 10 is ‘as bad as a 
pain could be’. 
 
    ‘no       ‘as bad as  
    pain’        pain could be’ 
0 1 2 3 4 5 6 7 8 9 10 
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Section 5 The following questions are to ask about your general health state at the moment. Under 
each heading, please tick the ONE box that best describes your health TODAY. 
 
Note – The EuroQol EQ5D 5L was presented here.  
 
As this is a licenced product we cannot reproduce it within this report 
See: http://www.euroqol.org/eq-5d-products/eq-5d-5l.html 
 
 
 
 
 
 
 
Section 6 
This questionnaire asks for your views about your health. This information will help keep track
of how you feel and how well you are able to do your usual activities.  
 
For each of the following questions, please place a cross in the one box that best describes your
answer. 
 
 
Note – the Optum Short Form 12 Health survery questionnaire (SF-12) was presented here.  
 
 
 
As this is a licenced product we cannot reproduce it within this report. 
See:  
https://campaign.optum.com/optum-outcomes/what-we-do/health-surveys/sf-12v2-health-survey.html 
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Section 7 
Below are some statements about feelings and thoughts. 
 
Please tick the box that best describes your experience of each over the last 2 weeks 
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We would like to know how you have been feeling in the last few weeks. Please circle a 
number for each statement indicating how often you feel that way. 
  
  Almost 
never 
   Almost 
all the 
time 
1 I feel like a failure 1 2 3 4 5 
2 I get a frightened feeling, as if something 
awful is about to happen 
1 2 3 4 5 
3 I feel guilty 1 2 3 4 5 
4 I can laugh and see the funny side of 
things 
1 2 3 4 5 
5 I am disappointed in myself 1 2 3 4 5 
6 I get a frightened feeling, like butterflies in 
the stomach 
1 2 3 4 5 
7 I feel cheerful 1 2 3 4 5 
8 I blame myself constantly 1 2 3 4 5 
9 I get a sudden feeling of panic 1 2 3 4 5 
10 I look forward with enjoyment to things 1 2 3 4 5 
11 I think about harming myself 1 2 3 4 5 
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Section 8 
Please rate how confident you are that you can do the following things at present, despite the 
pain.  To answer circle one of the numbers on the scale under each item, where 0 = ‘not at all 
confident’ and 6 = ‘completely confident’.  
For example  
 
0 1 2 3 4 5 6 
Not at all      Completely  
confident       confident 
Remember, this questionnaire is not asking whether or not you have been doing these things, but 
rather how confident you are that you can do them at present, despite the pain.   
 
 Not at all 
confident 
   Completely 
Confident 
1. I can enjoy things, despite the pain 0 1 2 3 4 5 6 
2. I can do most of the household chores (e.g. 
tidying-up, washing dishes, etc.), despite the 
pain 
0 1 2 3 4 5 6 
3. I can socialise with my friends or family 
members as often as I used to do, despite 
the pain 
0 1 2 3 4 5 6 
4. I can cope with my pain in most situations 0 1 2 3 4 5 6 
5. I can do some form of work, despite the pain. 
(‘work’ includes housework, paid and unpaid 
work). 
0 1 2 3 4 5 6 
6. I can still do many of the things I enjoy doing, 
such as hobbies or leisure activity, despite 
the pain 
0 1 2 3 4 5 6 
7. I can cope with my pain without medication 0 1 2 3 4 5 6 
8. I can still accomplish most of my goals in life, 
despite the pain 0 1 2 3 4 5 6 
9. I can live a normal lifestyle, despite the pain 0 1 2 3 4 5 6 
10. I can gradually become more active, despite 
the pain 0 1 2 3 4 5 6 
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Section 9 
In this section you are asked about your pain in general and how it impacts upon your life and 
how your back pain affects you. 
Now please complete the questionnaire to tell us how your life is currently affected by your back 
pain. 
 
PART 1: List Area
When you completed this 
questionnaire 
3-months ago,
you told us the following areas                              
were the most important areas of 
your life affected by your back pain  
PART 2: Score Areas
Please score each area you listed in part 1. 
The score should show how badly you are 
affected by your back pain today. Give each 
area a score by circling the number.
In the same way, we would like you to rate 
“All other aspects of your life affected by 
your back pain, not already mentioned”. By 
this we mean all other aspects of life 
affected by your back and not included in the 
list you gave. 
We complete
We complete
We complete
We complete
We complete
All other areas of your life 
affected by your back pain, not 
already mentioned.
The worst 
you can 
imagine
Exactly as 
you would 
like to be
0     1     2     3     4     5      6         
0     1     2     3     4     5      6         
0     1     2     3     4     5      6         
0     1     2     3     4     5      6         
0     1     2     3     4     5      6         
0     1     2     3     4     5      6         
Please circle one 
number
on each line
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Section 10 
The following pages contain questions about the expenses you have incurred and the services
you have used since joining the study, related to your back pain, including any help and support
provided by your family and friends. 
Some question will seem more relevant than others, but please try to answer all the questions. If
you are unsure about any answer then please include as much as you can remember.  
Medication 
 
 
  Yes                     No   
 
 
Medication Usual Dose Number 
of times 
daily 
 
Number of 
days used 
On 
prescription? 
Paracetamol 250mg 
 
2 tablets 
 
2 
 
8 days 
 
No 
     
     
     
     
     
 
Pain relief gels 
Medication (name) 
Number of 
times daily 
 
Number of days 
used 
On prescription? 
Ibugel twice 4 days Yes 
    
    
 
Pain relief patches 
Medication (name) 
 
Number used On prescription? 
BuTrans 4 Yes 
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NHS Treatments only (Private treatments are later) 
 Inpatient Care (admitted to hospital overnight) 
 Since joining the study on dd/mm/yyyy (date of enrolment), have you been admitted to 
hospital? (Back pain related only) 
   Yes                     No Go to question 2 below 
 If yes, please provide details of each hospital admission in the table below: 
 
 
Name of hospital 
 
Name/Type of 
ward 
 
Total length of stay  
   nights 
  nights 
   nights 
 
 
 Day Case treatment 
 
2.1 Since joining the study on dd/mm/yyyy (date of enrolment), have you been re-admitted to 
hospital  as a day patient? (Back pain related only) 
Yes                     No  Go to question 3 
 
2.2. If yes, please provide details of each hospital admission in the table below: 
 
 
 
Name of hospital 
 
Name/Type of ward 
 
Total length of stay  
  days 
  days 
   
days 
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 Outpatient Care 
   Since joining the study on dd/mm/yyyy (date of enrolment), have you made any visits to 
hospitals or clinics as an outpatient (for an appointment at a hospital but not admitted, but 
not including treatments as part of the study)? (Back pain related only) 
es                 No  Go to question 4 on next page 
 If yes, please provide details in the table below. If the clinic or specialty is not listed, 
please feel free to write this in. 
 
 
Type of service or clinic 
 
Have you used this service? 
 
(Please circle) 
 
Number 
Consultant (pain clinic, specialist clinic) YES / NO  
Physiotherapist YES / NO  
Radiology :MRI scan YES / NO  
Radiology :CT scan YES / NO  
Radiology :x-ray YES / NO  
Radiology :ultrasound YES / NO  
Blood tests (count all blood tests  
done on one day, as one test) 
YES / NO  
Hospital A&E YES / NO  
Other service 
 
Please provide details .. 
 
Other service 
 
Please provide details .. 
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 Community health and social care 
 
 Since joining the study on dd/mm/yyyy (date of enrolment), have you been in contact 
with any other health or social care professionals in the community? Examples include 
your GP, the practice or community nurse, social worker and home help visitors. (Back 
pain related only and not including services paid for privately) 
   Yes                     No  Go to question 5 on next page 
If yes, please indicate the person you saw and how often you saw them. If the person isn’t listed then 
feel free to write this in. 
 
  Have you used this 
service? 
 
(Please circle) 
 
Number of 
contacts 
GP surgery visit YES / NO  
GP home visit YES / NO  
Practice nurse YES / NO  
District nurse surgery visit YES / NO  
District home nurse YES / NO  
Rehabilitation Specialist YES / NO  
Physiotherapist surgery visit YES / NO  
Physiotherapist home visit YES / NO  
Occupational therapist YES / NO  
Counsellor YES / NO  
Psychologist YES / NO  
Social worker YES / NO  
Other: Please provide 
details below: 
 
YES / NO  
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 Private treatment 
 
 Since joining the study on dd/mm/yyyy (date of enrolment), have you received any 
health care you paid for yourself, or paid for through private insurance? Please do not 
include any treatment paid for by the NHS. (Back pain related only) 
   Yes                     No  Go to question 6 on next page 
 
If yes, please indicate the person you saw and how often you saw them. If the person isn’t listed then 
feel free to write this in. Please also provide an estimate of the total cost of this private health care to 
the nearest pound. 
 
 
  Have you used 
this service? 
 
(Please 
circle) 
 
Number 
of 
contacts  
Total Cost: 
Medical 
Insurance 
Contributio
n  
Total Cost: 
Personal 
Contribution  
Physiotherapist YES / NO  £ £ 
Occupational therapist YES / NO  £ £ 
counsellor YES / NO  £ £ 
Psychologist YES / NO  £ £ 
Radiology :MRI scan YES / NO  £ £ 
Radiology :CT scan YES / NO  £ £ 
Radiology :x-ray YES / NO  £ £ 
Radiology :ultrasound YES / NO  £ £ 
Consultant service YES / NO  £ £ 
Osteopath YES / NO  £ £ 
Chiropractor YES / NO  £ £ 
Acupuncturist  YES / NO  £ £ 
Homeopath YES / NO  £ £ 
Other: Please provide 
details below: 
 
YES / NO  £ £ 
Other: Please provide 
details below: 
 
YES / NO  £ £ 
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 Special Equipment or aids 
 Have you used any special equipment or aids provided by health or social 
services or other providers to help you since you joined the study on 
dd/mm/yyyy (date of enrolment) (e.g. wheelchair, stair handrails)? (Back pain 
related only) 
Yes                     No  Go to question 8   
 If yes, please describe below the equipment or aids provided to you, and any costs 
incurred for their use. 
Description of equipment 
or aid used 
Who provided it? (e.g. 
health services, social 
services, self) 
Cost to you (if 
none, please write 
‘0’) 
  £ 
  £ 
  £ 
  £ 
  £ 
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 Additional Information 
 Since you joined the study on dd/mm/yyyy (date of enrolment) have you  or your 
partner, relatives and friends incurred  any additional costs as a result of your contact with 
health or social care services or your general health state (either planned or 
unplanned)? (Back pain related only) 
 
Yes                     No  Go to question 9 
 
 If yes, please provide details in the following table: 
 
 
 
 
Additional Costs 
 
Have you incurred this form of 
additional cost to attend 
health/social care 
appointments? 
 
Cost to you 
(if none, please 
write ‘0’) 
Cost to 
partner/ 
relatives/ 
friends 
(if none, 
please write 
‘0’) 
Travel costs (e.g. bus fares) 
 
YES / NO £ £ 
Child care costs 
 
YES / NO £ £ 
Cost of help with housework 
 
YES / NO £ £ 
Cost of laundry services 
  
YES / NO £ £ 
Other: Please specify: 
 
... 
 
Other: Please specify: 
... 
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 Time off work 
 
 
 Are you currently working?         Yes                     No   
 If no, please tick main reason 
 
Because of your health    
 
Because you are retired?    
 
For other reasons? (Please specify)   
 
 
Yes                     No  
 
9.4  If yes, please provide details below: 
 
 
 
 
 
 
 
Additional Information 
 
 
If you need more space to answer any of the questions, please continue your answers here. Don’t forget to 
write down the number of the question you are answering so we know where to record the information 
Days lost:  Income lost: £ 
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Appendix 6 Sample size calculation
Facet feasibility study sample size calculations
At the end of the feasibility trial, we will obtain an estimate, θ^ of the unknown treatment difference along
with a 95% CI given by:
θ^ − 1:96
ﬃﬃﬃﬃﬃﬃﬃ
2σ2
n/2
s
, θ^ + 1:96
ﬃﬃﬃﬃﬃﬃﬃ
2σ2
n/2
s0
@
1
A. (4)
We will consider proceeding to the main study if the upper limit exceeds some prescribed target δ.
For a true treatment difference of θ, we have, θ^ ∼ N(θ, 2σ2/(n/2)), so that
pr θ^ + 1:96
ﬃﬃﬃﬃﬃﬃﬃ
2σ2
n/2
s
≥ δ; θ
0
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1
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0
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(5)
Calculation of this expression gives the probability of recommending progression to the main study with
total sample size n when the true treatment effect is θ.
If the true treatment effect is equal to the specified target value, that is, θ = δ, this probability is 1 –Φ
(1.96) = 0.975, so that the probability is 0.975 irrespective of the sample size or choice of δ (this follows
from the definition of a 95% CI). For θ = 0, we get the probability of erroneously proceeding to the main
study when the true effect is zero. Values for a range of values of n and δ are given in Table 33.
These probabilities can be interpreted in a number of ways. The test can be viewed as a test of the null
hypothesis θ = δ conducted at the one-sided 2.5% level. The probabilities in Table 33 then correspond to
the power of this test to detect the alternative θ = 0.
TABLE 33 Probability of deciding to proceed to main study when true treatment effect is 0 for range of sample
size and δ values
δ n= 80 n= 90 n= 100 n= 110 n= 120 n= 130 n= 140
0.20 0.857 0.844 0.831 0.819 0.806 0.794 0.781
0.25 0.800 0.781 0.761 0.742 0.723 0.704 0.685
0.30 0.732 0.704 0.677 0.651 0.624 0.599 0.573
0.35 0.653 0.618 0.583 0.550 0.517 0.486 0.456
0.40 0.568 0.525 0.484 0.445 0.409 0.374 0.342
DOI: 10.3310/hta21300 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 30
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Ellard et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
179
Alternatively, considering a conventional test of the null hypothesis that θ = 0, this approach fixes the
power to detect a difference of size δ to be 97.5% (and does so irrespective of the unknown variance).
The type I error rate is then determined by the sample size (and σ2) and is given by the values in Table 33.
The approach of using a high power and a high type I error rate in pilot studies has been advocated by a
number of authors (e.g. see Schoenfeld162 and Stallard163).
It is proposed to take n to be approximately 130 (150 less about 20% dropout). For a δ of 0.35, this gives
a probability of proceeding to the main study when the true treatment effect is zero of approximately
50%. Equivalently, this decision will be taken provided the treatment effect estimate at the end of this
study is at least positive.
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Appendix 7 Patient enrolment, contact details
and randomisation case report form
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